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I 
ABSTRACT 
             
The loading of therapeutic actives into polymeric nanoparticles represents one of the 
approaches towards drug transport through the blood-brain barrier – the main obstacle to drug 
delivery into the central nervous system. The non-toxic, biocompatible and biodegradable 
polysaccharides chitosan and dextran were modified with permeation-enhancing alkylglyceryl 
pendant chains through reaction with epoxide precursors. The modified polysaccharides were 
characterised by spectroscopic methods (
1
H-, 
13
C-NMR and FT-IR). These polysaccharides 
were further formulated into nanoparticles using three methods, namely: nanoprecipitation, 
solvent displacement via dialysis and electrospraying. The resultant colloidal systems formed 
were characterised using Dynamic Light Scattering, Nanoparticle Tracking Analysis and 
Electrophoretic Mobility Measurements. Dried nanoparticles were further characterised by 
Scanning Electron Microscopy and Atomic Force Microscopy. Formulations of alkylglyceryl-
dextran derivatives were found to be stable at the physiologically relevant pH of 7.4. Over the 
same range of pH values, formulations of alkyglyceryl-chitosans formed aggregates. 
Respectively dependent upon the method of formulation and the pH, nanoparticles from 
poly(lactic acid)-graft-butylglyceryl-modified dextran exhibited diameters in the range 100-400 
nm and zeta potentials of between -15 and -30 mV. The preparation of nanoparticulate 
congeners that incorporated a fluorescent marker molecule (Doxorubicin, Rhodamine B or 
Fluorescein) allowed the studies of the capabilities of nanoparticles to accommodate and release 
a model therapeutic load. Rhodamine B-loaded nanoparticles further allowed the study of the 
uptake of nanoformulations by mouse (bEnd3) brain endothelial cells. The interactions of 
nanoparticles with modelled blood-brain barriers (mouse bEnd3 and human hCMEC/D3) were 
studied by Electric Cell Substrate Impedance Sensing and also by means of the Transwell 
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model. Data from MTT and Presto Blue assays were consistent with the absence of 
nanoparticle-induced cytotoxic effects. An in ovo study that used 3-day chicken embryos 
indicated the absence of whole-organism acute toxicity effects but failed to unmask the 
biodistribution profile of nanoparticles. The results have shown that poly(lactic)-graft-
alkylglyceryl-modified dextran nanoparticles possess some promising features (size, stability, 
loading capacity, and toxicity) that render them candidates for further evaluation as 
biocompatible nanocarriers for drug delivery to the brain. 
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1 
INTRODUCTION AND AIMS 
             
Brain disorders represent almost one third of the total burden of diseases in Europe [1]. 
In the future, the increase of average life expectancy is predicted to result in a growth of 
neurodegenerative diseases in the elderly population, while the current advances in diagnostic 
methods are expected to add to an already long list of known neurodegenerative, 
cerebrovascular, inflammatory and infectious brain ailments [2]. Consequently, the market for 
drugs for central nervous system disorders is estimated to grow by five times, reaching the same 
size to that of the cardiovascular disease market [3]. 
The intravascular route of drug delivery to the brain is preferred over that through other 
routes (e.g. intranasal or intraocular) due to the proximity of the brain parenchymal cells  to 
brain capillaries (20 μm) and also due to the large surface area of the brain vessel network 
(20 m
2
) [4]. Intravenous drug delivery to the brain is generally impeded by the blood brain 
barrier (BBB). The BBB has a role in maintaining the specific environment required for 
neuronal signalling. The presence of tight junctions and efflux proteins, together with processes 
such as selective abluminal transport and the flow of intracerebral fluid, result in a restricted 
entry into the brain of toxins, xenobiotics and endogenous molecules present in the circulatory 
system, which may otherwise compromise the delicate homeostasis of the neuronal 
environment.  
Nanoparticulate drug delivery systems benefit from favourable pharmacokinetic 
characteristics. The therapeutic potential of nanoparticles formulated from biodegradable, 
nontoxic, and non-immunoactive polymers for drug delivery to the brain is currently a very 
active area of research [5-7]. The surface features of nanoparticles can be finely tuned so that 
they can influence the particle distribution into specific tissues and trigger the release of the 
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drug load in appropriate conditions. Nanoparticulate carriers can also prolong the lifetime of a 
drug in the bloodstream. Due to their accessibility, biocompatibility and biodegradability, 
polysaccharides have been extensively studied as promising materials for drug delivery systems 
as they have the added advantage of bearing functional moieties that easily allow their chemical 
modification. In parallel, intracarotidally administered short chain alkylglycerols are known to 
enhance the permeability of drugs through the BBB. 
This project was aimed at the study of the potential of nanoparticulate carriers from 
alkylglyceryl-modified polysaccharides to transport therapeutic agents to the brain[8-10]. More 
specifically, the main objectives of this work were to: 
- prepare and characterise alkylglyceryl-modified chitosan and alkylglyceryl-modified 
dextran; 
- use these alkylglyceryl-modified polysaccharides as support matrixes for nano-sized drug 
carrier systems;  
- explore the potential of  colloidal suspensions of these systems as candidate systems for 
intravascular drug delivery, via an assessment of their stability in simulated physiological 
conditions; 
- employ fluorescent marker molecules to assess the loading capacity and release profiles of 
nano-formulations; 
- assess toxicity, cellular uptake and interaction with a modelled BBB of cell monolayers 
through in vitro studies of the effects of the nano-formulations on mouse or human brain 
endothelial cells; 
- investigate the in ovo biodistribution and associated toxicity of fluorescently labelled 
nanoparticles using chicken embryos. 
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LITERATURE BACKGROUND 
             
2.1. Delivering actives to the brain – why is it so important? 
It is estimated that brain disorders such as anxiety, stroke, dementia, mood disorders or 
psychotic illnesses represent approximately 35 % of the total burden of diseases in Europe and 
affect about one third of the population [1]. For the European Union, the estimated total cost 
related to brain disorders in 2010 was ca. €798 billion. With high average cost per inhabitant of 
€5 550 (ranging from €285 for headache to €30 000 for neuromuscular disorders) [2] this is 
comparable to the cost of cardiovascular diseases, cancer, and diabetes together.  
 
Figure 2.1. Life expectation at birth, UK population. Adopted from [11]. 
 
While more diseases and infections are now being cured successfully compared to the 
past due to advances in modern medicine, the average human lifespan has been growing 
continuously over the last 150 years (Figure 2.1.), reaching ca. 78 years for males and 82 years 
for females in UK (2008 data; [12]). This means a higher chance of experiencing CNS disorders 
[13]. Despite all research efforts, patients suffering from serious neurodegenerative diseases 
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such as brain tumours, HIV encephalopathy, epilepsy, cerebrovascular diseases or 
neurodegenerative disorders outnumber those dying of all types of systemic cancers and heart 
diseases [14]. 
 
2.2. The anatomy and physiology of the blood-brain barrier 
The brain is the emotional and rational control centre of the human body that helps us to 
survive. This organ provides us with the thinking capacity that makes humankind different from 
other organisms on this planet. The most complex structure of the body, the brain consists of 
1 x 10
11
neurons [15], impulse-conducting cells, and about 1 x 10
12
 astrocytes that act as 
supporting cells [16]. 
 
Figure 2.2. Schematic display of the cells in the CNS; adapted from [17]. 
A neuron can have 1 000 - 10 000 synapses, connections between individual neurons, 
where the electrical impulse changes to chemical, with the total number of synapses reaching 
1 x 10
14
 to 5 x 10
14
 in an adult (or even 10
15
 in a new-born, Figure 2.2.). Morphologically, the 
brain is protected by the cranium against mechanical damage. Between the neuronal tissue of 
the brain and bone of the cranium, there are soft layers of neurocranium, so called meninges 
(pia mater, arachnoid and dura mater; Figure2.3.) that provide “buffering” to absorb 
mechanical stress and allow the branched microvasculature to supply the required bloodstream 
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components to the neuronal tissue [18]. At the same time, the circulation of cerebrospinal fluid 
(CSF) provides maintenance for CNS. The CSF is cleared into the blood through arachnoid 
granulations to remove the metabolites from the brain [19]. The brain is separated from the 
internal body environment by the presence of the blood-brain barrier. 
 
Figure. 2.3. Schematic representation of the meninges; adopted from [20]. 
The blood-brain barrier (BBB) provides a morphological structure which strictly divides 
the brain tissue from blood vasculature [21], in order to maintain the delicate homeostatic 
balance of nutrients, ions and signalling molecules required in the brain environment for proper 
neuronal communication [22]. The BBB limits the entry of plasmatic components, red blood 
cells, and leukocytes into the brain. If these cells cross the BBB following an ischemic injury, 
inflammation, Intracerebral haemorrhage or vascular disorder, neurotoxic products are 
generated that can compromise synaptic and neuronal functions [23]. The BBB serves as a 
defence line that protects the brain compartment from the entry of unwanted molecules such as 
blood-borne metabolites, toxins, virions, bacteria and xenobiotics[24]. However, in protecting 
the brain, the BBB does not allow the entry of a large list of CNS-active molecules, including 
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therapeutic peptides, protein based neuropharmaceuticals, and more than 98% of all small drug 
molecules [24, 25]. 
The existence of a barrier between brain and bloodstream was suggested by Ehrlich and 
confirmed by Lewandowski in 1900, when bile acids or ferrocyanide applied intravenously 
could not be found in the brain [26]. In 1909, Goldman showed that a dye, Trypan Blue, could 
cross between the brain and the cerebro-spinal fluid but was excluded from passing between 
these regions and the blood. From this observation Goldman concluded that there was no 
impermeable barrier between brain and spinal cord tissue [27]. Electron microscopy studies 
using horseradish peroxidase have subsequently shown that the BBB is localised at the level of 
tight junctions (TJ) present between adjacent endothelial cells [28, 25]. 
Morphologically, the BBB comprises of neurovascular groups of cooperating adjacent 
cells such as endothelial cells and glial cells [25] (Figure 2.4.). The endothelial cells are 
anchored to the basal lamina [22] with the astrocyte end-feet tightly covering the vessel wall 
and appearing to be critical for the induction and maintenance of the barrier properties of the 
endothelial cells [29].  
Glial cells comprise microglia, macroglia, and oligodendrocytes. Microglia including 
pericytes, which may regulate the BBB [30], and macrophage-like precursor cells [31]. 
Macroglia include astrocytes that support the neurons and enhance the TJ function by providing 
cellular links [22]. 
  LITERATURE BACKGROUND 
7 
 
Figure 2.4. Blood-brain barrier neurovascular unit: capillary endothelial cells are surrounded 
by basal lamina and astrocyte perivascular end feet.  a) detail of an endothelial cell showing a 
tight junction (TJ) and endogenous transporters such as EAAT1–3 (excitatory amino acid 
transporters), GLUT1 (glucose transporter 1), LAT1 (L-system for large neutral amino acids), 
Pgp (P-glycoprotein); adapted from [22]. 
 
The pericytes embrace the brain capillary endothelium intimately. They are a 
morphologically, physiologically, and biochemically heterogeneous class of cells which take 
part in transport processes across the BBB [32]. Pericytes are also thought to regulate the 
proliferation of endothelium via the transforming-growth factor-β (TGF-β) [33]. Moreover, it 
seems that the number of pericytes present at the vasculature corresponds with the level of 
endothelial junction “tightness” [32, 34].  
Astrocytes are adjacent to the endothelial cells and pericytes and are important for TJ 
formation [35, 36]. They enhance the membrane barrier properties as over 99 % of the external 
wall of brain blood vessels is enveloped by astrocyte end-feet. However, individual feet are not 
sealed and astrocytes can communicate via protein exchange through small gaps [37]. 
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Astrocytes support neurons by maintaining homeostasis in the brain via potassium uptake, 
gliotransmitter synthesis and phagocytosis [38]. The neurovascular unit is also comprised of the 
basal lamina, an extracellular matrix that provides a membranous connection between 
endothelial cells, astrocytes and pericytes (Figure 2.4.) [39]. The basal lamina is a 30-40 nm 
thick structure containing collagen type IV, fibronectin, laminin and other extracellular matrix 
proteins, which are likely to be involved in TJ maintenance [40]. 
The main features that contribute to the protective role of a normal BBB are [41]: 
 Tight junctions sealing the intercellular gaps; 
 A reduced rate of pinocytosis from the luminal side; 
 No fenestration of the endothelium; 
 An enzymatic barrier controlling uptake of nutrients; 
 An efflux transporter system such as P-glycoproteins which remove molecules from the 
endothelial cells. 
In some situations the BBB can become compromised, for instance in the case of brain 
tumours [42-44].During inflammation, tumour necrosis factor α (TNF α) can influence BBB 
permeability [45, 46]. Inflammation can also increase the adhesion of lymphocytes to 
endothelium and their penetration through the BBB. The endothelial cells express cell adhesion 
molecules VCAM-1, PECAM-1, and ICAM-1 which attract the cells [47]. Also, in chronic 
conditions the barrier may be further compromised during continuous transendothelial 
migration of inflammatory cells [48]. Cells that have left the bloodstream and are entering the 
brain may be considered in relation to three compartments: the vessel wall, the perivascular 
(Virchow–Robin) space, and the neuropil (last two are separated by the glia limitans). As 
capillaries which do not possess perivascular space, the basement membrane of the vessel wall 
and the basement membrane of the glia limitans could merge into a ‘fused gliovascular 
membrane’ that allows intimate contact of astrocytes with pericytes and endothelial cells [26]. 
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2.2.1. Tight junctions 
The microvascular brain endothelial cells differ from endothelial cells found in other 
tissues because of their increased mitochondrial content, lack of fenestrations, low pinocytic 
activity and presence of tight junctions (TJ) (Figure 2.5.) [49-51]. The tight junction network in 
the BBB is a complex structure of transmembrane proteins that includes junctional adhesion 
proteins and cytoplasmatic proteins [52, 53], Figure 2.5. 
 
Figure 2.5. Schematic representation of a BBB tight junction. Junctional proteins such as 
occludins, claudins, ZO-1, JAMs, catenins and E-cadherin (all linked to actin, part of the cell 
cytoskeleton) are involved in the formation of the tight junction; adapted from [54]. 
 
The transmembrane proteins are linked to the cytoskeletal proteins present in 
cytoplasma (spektrin, actin) via zonulaoccludens proteins (ZO-1, ZO-2, ZO- 3 [18]); catenins 
and E-adherin are also involved in the formation of the TJ [49], though it appears that occludin 
plays a critical role in establishing the barrier properties of the BBB [18]. If occludin is down-
regulated by various brain disorders, the BBB becomes more permeable [55]. Gap junctions that 
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provide cell-to-cell signalling connections [56] have also been discovered, but their role in BBB 
function is not yet known [57].  
 
2.2.2. Blood-brain barrier transport activity 
The blood-brain barrier does not serve as a passive and rigid defence facility but acts as 
a dynamic interface that has a high metabolic activity. Active transport processes requires 
energy that is supplied by the high number of mitochondria present in the endothelial cells [58]. 
Drug efflux transporters such as P-glycoprotein, Multidrug Resistance Proteins or Organic 
Anion Transporting Polypeptides are expressed at the endothelial cell or astrocyte end-feet 
levels. These transporters are key elements in a molecular machinery that confers special 
permeability properties to the BBB, and their combined actions can result in a rapid efflux of 
xenobiotics from the brain [29]. Multidrug Resistance Proteins (MRP) belong to the family of 
ATP-binding Cassette (ABC) transporters, which are multidomain integral membrane proteins 
present in all mammalian species and that utilise the energy of ATP hydrolysis to translocate 
solutes across cellular membranes [29, 51, 59]. 
 
Figure 2.6. Schematic representation of transport mechanisms across the BBB; adapted from 
[22]. 
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Potential transport mechanisms of various molecules across the blood-brain barrier are 
represented in Figure 2.6. Tight junctions restrict water-soluble molecules (a), while small lipid-
soluble substances can diffuse through the membranes of the endothelial cells (b). Various 
transporters present at the BBB level are subject to competition from endogenous substrates like  
glucose, amino acids, purine bases, nucleosides, choline and other substances as xenobiotics (c); 
P-glycoprotein is an example of an efflux protein that removes molecules from the cytoplasm of 
the endothelial cells and returns them into the lumen of the blood vessels. Specific proteins, 
such as insulin or transferrin, can be taken up by receptor specific endocytosis followed by 
transcytosis across the endothelial cells (d), while cationic particles can interact with the 
negative charges present on the membranes of endothelial cells via adsorptive-mediated 
endocytosis and transcytosis (e) [22]. 
 
2.3. Drug delivery to the brain 
The majority of the CNS-related research efforts at the beginning of this millennium 
were devoted to CNS drug discovery. Only a small portion or research was directed to CNS 
drug delivery. This imbalance led to the current situation where huge resources have been used 
for the development of numerous CNS actives that, despite perfect hits with intracellular targets, 
were in most cases not able to cross the BBB [60].  
The methods devised to overcome the BBB can be divided into invasive and non-
invasive. The invasive methods include intra-cerebroventricular injection, convection-enhanced 
diffusion [61], the use of intra-cerebral implants [62], high frequency focused ultrasound [61, 
63] and vasoactive agents [64]. Hyperosmotic tight junction opening caused by mannitol or 
arabinose [63] can also be used to increase permeability through the BBB, as can bradykinin 
analogues, such as RMP-7 (also known as lobradamil) [65, 66] and short-chain alkylglycerols 
[9, 67]. Less invasive approaches include chemical modification (lipidisation) of molecules (e.g. 
morphine-heroin [68]), targeting natural receptors with antibodies (OX26 monoclonal antibody 
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against transferrin receptor [69]), or employing colloidal nano-sized carriers that can also 
enhance the favourable pharmacokinetic characteristics of actives [70].  
 
2.3.1. Invasive routes 
Methods that result in a non-selective opening of the BBB or that lead to the direct 
application of drugs, colloidal systems or implants into the brain are normally classified as 
invasive. These methodologies involve direct intracranial surgery followed by convection 
enhanced delivery [71] or by placement of implants [72], application of focused ultrasound [73] 
(Figure 2.7.) or use of microwaves [74, 75]. Other methods include hyperosmotic disruption by 
polyol solutions [65], application of bradykinin-anologue RMP-7 [66], application of 
alkylglycerols [10] or sodium caprate [76] and some other experimental approaches [77, 78]. 
Also, it was shown that a GSM phone signal influenced the permeability of the BBB in rats 
[79]. 
 
Figure 2.7. Experimental setup for the application of 1 MHz ultrasound in 30 s cycles; adopted 
from [73]. 
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2.3.1.1. Intracerebral injections, infusions and implants 
 Active pharmaceutical ingredients can be delivered into the brain by intra-cerebro-
ventricular infusion or intra-cerebral implants [80]. A drug can be directly injected into the brain 
in the form of solution (Convection Enhanced Brain Drug Delivery) [81], in the form of a 
colloidal system such as a liposomal formulation [71, 82], or in the form of an implant 
containing a slow releasing drug [64] such as PLGA microparticles loaded with Paclitaxel [72]. 
These methods are highly invasive procedures that require neurosurgery and special equipment, 
and carry a high risk. If for instance an injected volume or a solid implant is rapidly introduced 
into brain tissue, it may damage that area of the brain [64]. In addition, once actives are 
introduced using such a method, the diffusion rate in brain parenchyma has been found to be 
very poor [83]. 
 
2.3.1.2. Hyperosmotic disruption  
BBB permeability can also be manipulated by intracarotidal arterial infusion of 
hyperosmotic solutions such as those of some polyols (mannitol and arabinose) [64, 65, 84]; 
oral administration of sugar was also claimed to increase the delivery to the brain of co-
administered drug molecules [64]. This effect has been explained by the osmotic stress that 
induces a variety of cyto-skeletal changes that ultimately contribute to the opening of the barrier 
[85]; the mechanism of action is a reversible “shrinkage“ of endothelial cells by draining water 
from the cells thus lowering the transepithelial electric resistance of the endothelium. This has 
been shown to lead to an increased permeability of paracellular markers, such as sucrose and 
inulin, through both a brain endothelial cell layer model and in animal studies [86]. However, 
this effect appears to be non-selective for tumour tissues (e.g. mannitol was found to provide a 
relative high accumulation of cytotoxic drugs in a tumour-free brain tissue [87]).  
Recent clinical studies suggested that BBB disruption by intra-arterial hyperosmotic 
mannitol can enhance the penetration of anticancer drugs and prolong survival in patients with 
malignant brain tumours [88]. However, despite successful application in some clinical centres, 
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the method has not been widely spread because the procedure is difficult, invasive, and there is 
a risk of post-treatment neurotoxicity developing [63].  
 
2.3.1.3. Blood-brain barrier modulating agents 
Molecules such as bradykinin or its analogue (RMP-7) [66, 89], sodium caprate [76] or 
alkylglycerols [10]were found to exhibit modulation of the blood-brain barrier.  
Alkylglycerols were shown to increase the amount of co-distributed drugs in the brain 
following intra-carotidal administration [9, 10, 67, 90-95]. 
 
R-butyl, pentyl, hexyl
1-O-alkylmonoglycerol
1-O-alkyldiglycerol
 
Figure 2.8. Chemical structures of the alkylglycerols studied by Erdlenbruch et al. [95]. 
 
1-O-Alkylglycerols (mostly with 16 and 18 carbon atom chains) are naturally found in 
human haematopoietic organs (bone marrow), in human milk and (in abundance) in shark liver 
oil [96, 97]. In terms of biological activity, 1-O-alkylglycerols were found to exhibit antitumour 
effects – interestingly, sharks have a very low incidence of cancer [96, 98, 99]. Also, 
supplementation with 1-O-alkylglycerols in tumour-bearing rats promoted gain in body weight, 
a reduction of tumour weight, and maintained glycemia and liver glycogen content to values 
similar to control healthy rats [97]. Alkylglycerols can also influence the basic fibroblast 
Growth Factor-stimulated endothelial cell proliferation [100], and amplify biosynthesis of 
platelet-activating factor in monocyte cell lines produced by mammalian sperm (which makes 
alkylglycerols important activators of sperm motility) [101]. Other biological actions of 
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alkylglycerols include antibacterial [102], and antifungal [103]; they were also used in the 
prophylaxis of radiation side effects associated to cancer treatment [104]. Submicron vesicules 
for drug delivery (300-800 nm; algosomes) were formulated by hydrating a film consisting of a 
mixture 1-O-alkylglycerols, cholesterol and dicetyl phosphate [105].  
As mentioned previously, mono- and di-alkylglycerols have been reported to temporary 
open the BBB when administered intracarotidally [9, 91, 106]. The delivery of methotrexate to 
brain was increased 2 to 230 fold into ipsilateral hemisphere compared to the control, however, 
only intracarotidal administration of alkylglycerols seems to be efficient, while the intravenous 
application did not show any positive results [10]. The alkylglycerols, given to the carotid artery 
were shown to increase brain uptake of antineoplastic agents as cisplatin and methotrexate and 
the antibiotics vancomycin and gentamycin in rats drugs by C6 glioma bearing [92] and RG2 
implanted tumours [90] rats when co-administered into the right internal carotid. The effect was 
pronounced in the ipsilateral hemisphere, as expected, and in the same range for tumorous and 
tumour-free tissue [92]. 
1-O-pentylglycerol induced the extravasation of fluorescein, albumin and methotrexate 
in the ipsilateral brain and to the tumour by enhancing paracellular permeability of tight 
junctions. The effect of 1-O-pentylglycerol was lower than that of hyperosmotic mannitol, and 
much higher than the effect of bradykinin but, in contrast to mannitol, it did not enhance BBB 
permeability in the contralateral brain hemisphere or the cerebellum and brain stem [8]. In vivo 
Near Infrared Time-Domain Optical Imaging showed that delivery of fluorescent molecules 
after application of hexyldiglycerol was still detectable after 24 hours after application (Figure 
2.9.) [91]. The effect and duration of alkylglycerol-induced BBB-opening was more rapid and 
localized to the site of injection, with less in vivo toxicity [8], offering a safer alternative of 
BBB disruption to using hyperosmotic mannitol [63].  
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Figure 2.9. In vivo Near Infrared Time-Domain Optical Imaging. Normalised fluorescence 
intensity of fluorescent tracer in mouse brain after application of helxyldiglycerol: 6 (a), 9 (b), 
24 (c) and 72 (d) hours after alkylglycerol mediated BBB opening followed by intracarodial 
injection of marker. Adapted from [91]. 
 
The effect of alkylglycerols on the BBB was described as the result of their interaction 
with the endothelial cell membranes, when the lipid bilayer was disorganised and fluidified in a 
manner that facilitated trans-endothelial incorporation and diffusion of the drug molecules [67]. 
Marigny et al. explained this effect of endothelial modulation through the alteration of lipid 
signalling of phospholipase C conducted via diacylglycerol signalling pathway [94]. 
Sodium caprate was found to open the BBB in a reversible manner; experiments using 
it showed a greater flux of tracer compared to hyperosmotic opening by mannitol, and had twice 
the effect of the intracarotidal infusion of bradykinin and a comparable effect to alkylglycerols. 
However, its toxicity and the risk of possible brain oedemas were raised as important 
disadvantages [76].  
Natural peptides such as bradykinin or its analogue RMP-7 [66, 89] were shown to 
increase the delivery of chemotherapeutic agents to tumour tissue in the brain, however the 
increase was limited to two-fold when compared to the control [65].  
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2.3.1.4. Rare experimental methods  
Some CNS-active drugs can also modify the permeability of the BBB for other 
substances; cholinomimetic arecolines have been reported to induce changes in penetration of 
drugs through the BBB [78]. A rather invasive method to disrupt the BBB involves the 
parenteral administration of purified cell wall fragments of eubacteria such as Streptococcus 
pneumoniae [77]. A major limitation is however related to the non-specificity of the approach, 
which leads to the entry of non-invited molecules into the brain [64] (this applies to all non-
specific methods of BBB opening when, even with a minimal disruption of the BBB, the 
circulating neurotoxins, hormones and ions can enter into the neural tissues and unbalance the 
internal brain homeostasis or induce cell damage [107]).  
 
2.3.2. Non-invasive routes 
 These methods do not access the brain parenchyma directly nor disrupt the BBB in a 
non-selective way. They include chemical drug delivery systems (prodrugs) [68] and targeted 
drug delivery platforms [69] and colloidal drug delivery systems [6, 108-111].  
 
2.3.2.1. Prodrugs  
Lipid solubility of a drug is one of the key factors in regulating its passive diffusion into 
the brain [64], so a facile transport of a passive molecule has been associated with an increase in 
its lipophilicity. Most drugs used to treat CNS diseases are small molecules ranging between 
150 and 500 Da and express the log octanol/water partition coefficient between 0.5 and 6.0 
[112]. In contrast, molecules that have permanent charges or are polar or highly branched and 
contain rotating bonds have been found to exhibit a lower BBB penetration [68].  
The prodrug approach for brain delivery involves the administration of a drug that has 
had its lipophilicity increased through a chemical modification, so it becomes more able to 
penetrate the BBB. The prodrug is then converted within the brain into its active form [113]. 
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This ‘lipid penetration’ approach can be classically illustrated with a series of related 
compounds such as morphine, codeine and heroin [64] Morphine shows a relatively low brain 
uptake, but by replacing one of hydroxyl groups with methoxy (to obtain codeine) the lipid 
solubility is increased, and significantly increases in turn the brain uptake (Figure 2.10). Further 
lipidisation by adding two acetyl groups to the molecule of morphine to form heroin increases 
the brain uptake significantly. Inside the brain, heroin is rapidly metabolised to 6-acetyl-
morphine and then to morphine. Morphine, being a more polar molecule than heroin, becomes 
locked inside the brain as it cannot diffuse back into the blood through the BBB [114].  
A B C  
Figure. 2.10. Structures of A - morphine, B - codeine, and C - heroin 
The advantage of the lock-in mechanism is that an active metabolite can retain 
significant concentrations of parent compound in blood stream. A drug can be simply attached 
to a vector, which may simply increase the lipid solubility of the drug or may render the drug 
acceptable for BBB transport system. The linkage between drug and vector should be labile 
once the drug has penetrated into the brain, such as an ester bond [112]. This extension of the 
prodrug principle has been termed as chemical delivery [68]. However, despite advantages this 
approach has also several limitations; lipidisation of molecules generally increases the 
distribution volume, especially plasma protein binding, which affects all pharmacokinetic 
parameters. While increased lipophilicity can improve diffusion transport across the BBB, it 
also may affect the uptake in other tissues [64]. 
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2.3.2.2. Colloidal drug delivery systems 
More recent approaches that have been considered for drug delivery to the brain employ 
colloidal systems such as nanoparticles and liposomes [6, 109-111]. Nanoparticles are colloidal 
particles consisting of macromolecular substances that vary in size from 10 nm to 1000 nm [41, 
115]. Other drug delivery devices in the submicron range are liposomes [116], exosomes [117], 
solid lipid nanoparticles [118], polymeric micelles [119] and dendrimers [120]. 
Colloidal drug delivery systems can potentially possess outstanding advantages [121]: 
1) the passage through the smallest capillary vessels due to their small size 2) the penetration of 
the cells and tissues and targeted delivery to organs such as liver, spleen or lung; 3) controlled-
release properties due to the biodegradability, pH, ion and/or temperature sensibility 4) 
improved stability of drugs and reduced toxic side effects. An ideal colloidal drug delivery 
system is expected to possess specific features such as being non-toxic, non-immunogenic, 
biodegradable and biocompatible, and also being stable in the blood thus ensuring a prolonged 
circulation time. In case of brain drug delivery the colloidal drug delivery system is expected to 
express BBB targeting or BBB penetrating moieties and to carry therapeutic molecules [36, 
108]. 
 
2.3.2.3.Nanoparticles 
 There are several approaches considered in order to enhance nanoparticle crossing the 
BBB. One of the well-studied methods involves coating nanoparticles with Polysorbate 80. It 
was shown that nanoparticles from poly(butylcyanoacrylate) (PBCA), coated with Polysorbate 
80 delivered drugs into the brain [5, 109, 110, 122, 123]. Several interpretations of the 
mechanism of nanoparticle translocation across the BBB were suggested [122], such as: an 
increased flux of nanoparticles due to the concentration gradient; inhibition of P-glycoprotein 
by Polysorbate 80; a general toxic effect of nanoparticles on the endothelial cells [6]; 
endocytosis of nanoparticles; or, most probable, the apolipoproteins present in the blood were 
adsorbed onto these nanoparticles due to their coating with surfactant [124, 125]. Since the 
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Polysorbate 80 coated nanoparticles were shown to adsorb apolipoproteins A-I, E and B from 
blood, the following scenario was suggested [110]: after injection, the coated nanoparticles 
adsorb apolipoproteins A-I, E and B from the blood; in case of apolipoproteins E and B, the 
particles could mimic lipoprotein particles and would be taken up by the brain endothelial cells 
that express numerous endothelial receptors for apolipoprotein endocytosis, so in this case 
nanoparticles behave as ‘Trojan Horses’ [126]. This whole hypothesis is supported by finding 
that a covalent attachment of apolipoproteins A-I, E and B to drug loperamide makes the drug 
active in the brain while the free drug was found to exhibit no effect [64, 110, 127]. Polysorbate 
80 was applied on other kind of nanoparticles; poly(lactic-co-glycolic acid) PLGA nanoparticles 
coated with Polysorbate 80 were found to perform best during in vivo studies that compared 
various nanoparticles coatings for brain drug delivery applications (Figure 2.11.)[128].  
 
Figure 2.11. Nanoparticles from PLGA loaded with Fluorescein and taken up into the brain in 
vivo. The influence of surfactant coating: a) no nanoparticles; b) no coating; c) chitosan; d) 
Polysorbate 80; e) Poloxamer 188. Adapted from [128]. 
Other attempts to employ colloidal drug delivery systems for drug delivery to the brain 
include alkylglyceryl-chitosan based nanoparticles [129], poly(ε-caprolactone)-poly(ethylene 
glycol) nanoparticles [130], poly(acrylamide)-poly(ethylene glycol) nanoparticles [131] or 
liposomal formulations [132, 133] and those modified with cell permeating protein TAT [134].  
  
  LITERATURE BACKGROUND 
21 
2.3.2.4. Liposomes and solid lipid nanoparticles 
Bilayer phospholipid systems, called liposomes, were first described in 1965 [135]. 
They are small artificial vesicles of usually spherical shape that can be produced from non-toxic 
natural phospholipids and cholesterols [116]. Drug molecules can be either entrapped in the 
aqueous space or intercalated within the lipid bilayer of liposomes, depending on the 
physiochemical characteristic of the drug (Figure 2.12.). 
  
Figure 2.12. Liposomal drug delivery systems: a) drug entrapped into the phospholipid bilayer; 
b) drug entrapped into the core; c) combination of drugs; d) long circulating liposomes, e) 
liposomes containing nucleic acid, f) triggered release liposomes, g) ligand-targeted liposomes; 
adopted from [136]. 
 
The properties of liposomes vary with lipid composition, size, surface charge and 
method of preparation. Liposomes are classified by the number of layers into unilamellar or 
multilamellar systems [136]. Early liposomes were designed as carriers that hold the drug inside 
their hydrophilic core or within the hydrophobic phospholipid bilayer coat. Using 
monosialoganglioside in the structure of the liposomal bilayer (”Stealth” liposomes; Trademark 
of Sequss Pharmaceuticals Inc, Menlo Park, CA [137]) has been shown to contribute to the 
avoidance of the Reticulo-endothelial system (RES). A similar effect of extending the 
circulation time of liposomes was also obtained by incorporating distearoylphosphatidylcholine 
in the liposomal bilayer for the delivery of Daunorubicine (DaunoXome by NexStar Inc, San 
Dimas, CA) or by employing hydrophilic poly(ethylene glycol) (PEG) chains [138, 139].  
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Liposomes have been employed in brain drug delivery in various applications, such as 
for targeting neutrophils and monocytes to facilitate the transport of serotonin over the BBB 
[140], by conjugation with antibodies [133], or using convection-enhanced delivery to transport 
contrast agents for magnetic resonance imaging in the brain of primates [83, 141]. The 
liposomes were found as a potentially promising tool for brain drug delivery [36, 140, 142, 
143]. 
Solid lipid nanoparticles are colloidal drug delivery systems with a mean size between 
100 and 400 nm, with a matrix composed of lipids being solid at room and body temperatures, 
dispersed in an aqueous surfactant solution [144]. The solid lipid nanoparticles consist of 
triglycerides (e.g. trimyristin, tripalmitin), hard fat molecules (e.g. glyceryl stearate, cetyl 
palmitate, decanoic acid) and emulsifiers (e.g. soy or egg lecithin, phosphatidylcholine or 
Poloxamers) [145, 146]. Solid lipid nanoparticles recently gained attention for brain drug 
delivery purposes [118]. Some of the long circulating formulations are established on the 
marked as PEG modified solid lipid nanoparticles containing Doxorubicin (Doxil brand name, 
Trademark of Sequss Pharmaceuticals Inc, Menlo Park, CA [137]). 
ACCEPTED MANUSCRIPT 
2.4. Challenges faced by colloidal systems aimed at drug 
 delivery to the brain 
When administered intravenously, colloidal systems face several challenges in the body; 
being removed by the Reticulo Endothelial System (RES, based in lungs, spleen, liver and 
lymphatic nodes), being filtered in the kidneys, or reacting with the immune system are among 
the most important [147]. Even after managing to overcome the general difficulties faced in the 
bloodstream, a drug delivery system can still be stopped by the Blood Brain Barrier from 
entering the internal brain compartment [122]. The RES which is responsible for the “first pass 
effect” [148], is a part of the immune system occurring in blood providing natural defence for 
organism, consists of phagocytotic cells (monocytes and macrophages, Kupfer cells and 
histiocytes) in various tissues (in lymph nodes, in liver, spleen and lungs). RES can remove 
  LITERATURE BACKGROUND 
23 
malfunctioning or damaged circulating cells as erythrocytes and lymphocytes, but also invading 
bacteria, toxins, xenobiotics and nanoparticles [41]. The phagocytotic process is modulated by 
opsonisation – a process, which is described as adsorption of proteins (immunoglobulins and 
antibodies, namely C3 and C5 components of complement, fibronectin, C-reactive protein and 
tuftsin) on the surface of cells or nanoparticles, making these objects more recognisable for the 
RES [149].  
The strategy of avoiding RES consists mainly of surface modifications of nanoparticles 
[150], however in the 1980’s and 1990’s placebo pre-dosing of empty nanocarriers was 
employed to saturate the RES phagocyting capacity [151]. Moreover, attempts at RES 
moderation were performed by transient destruction of macrophages in the liver by 
administration of gadolinium chloride [152] or clodronate entrapped inside liposomes [153]. 
Such approaches, despite success in experimental models, found no justification in clinical 
practise due to impairing the natural defensive system of the body [150]. The PEG corona at the 
surface of PLA nanoparticles was shown to reduce non-specific interaction with blood elements 
[154]. Similar results were obtained with poly(acryl amide), polyvinylpyrrolidone, 
poly(acryloyl morpholine) [155]. Also, employment of polysaccharides as dextran [156, 157] or 
hyaluronic acid [158] was investigated as a protection against protein adsorption and possible 
avoidance of RES uptake. Furthermore, surface modification with PEG chains can be combined 
with targeting moieties, e.g. nanoparticles from hydrophobic poly(lactic acid) (PLA) crosslinked 
with PEG attached to monoclonal antibody against transferrin receptor MAb OX26 [159].  
Once the Drug Delivery System is designed to overcome the RES, the challenge of 
reaching the brain parenchyma remains the primary task [41]. After the nanoparticles overcome 
last 20-30 nm of BBB, they became diluted in Cerebrospinal fluid (CSF, 5 litres of blood to 150 
mL of CSF) which is the maintenance liquid for the brain. It keeps the homeostasis, ions and 
nutrients in balance necessary for precise function of neurons [3]. The pressure of CSF can drift 
nanoparticles back to blood as CSF flows from ventricles, where it is produced, across cisterna 
and through arachnoidal villi to blood microvasculature due to higher pressure than blood [19]. 
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The turnover of total volume of CSF is 3–4 times per day and it can be considered as one 
mechanism of NPs clearance from the brain [41]. 
2.5. Polymeric materials for nanoparticle preparation 
Polymers employed in the preparation of nanoparticles have to be non-toxic, non-
immunogenic, biodegradable and biocompatible [108]. Such features can be exhibited by both 
natural and synthetic polymers [160, 110]. Materials such as dextran, chitosan and poly(lactic 
acid) - which have been selected for this study due to their adequate properties for the 
application considered - will be described below in more detail.  
2.5.1. Chitosan 
Polysaccharides, a heterogeneous group of polymers with a wide range of molecular 
weights and varying reactive groups and chemical composition [161], can be sourced from 
various origins e.g., algal, such as alginate [162]; microbial, such as dextran [163]; from plants, 
such as pectin or guar gum or pullulan [164]; or from animals chitosan [165], hyaluronan [166] 
and chondroitin [167]. 
Chitosan (CS) can be obtained from the deacetylation of chitin, a naturally occurring 
(mainly in marine crustaceans) and biocompatible polysaccharide [165]. Chemically, chitosan 
comprises of a 2-acetamido-2-deoxy-β-D-glucan (1→4) linked to 2-amino-2-deoxy-β-D-glucan 
(Figure 2.13.). 
 
Figure 2.13. Schematic presentation of chitosan nanoparticles cross-linked with TPP. Adopted 
from [436].  
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Chitosan has been investigated as a biopolymer suitable for drug delivery and 
biomedical applications [165, 168], as well as for cosmetics, food industry and agriculture 
[169]. Nanoparticles from chitosan can be prepared by covalent crosslinking with 
glutyraldehyde however this approach is associated with increased toxicity [161, 170]. Chitosan 
bears positive charges in acidic environments due to the amino groups, which can be protonated 
and generate electrostatic complexes with polyanions to create nanoparticles (Figure 2.13). The 
counter ions employed for ionotropic crosslinking can be Sodium Tripolyphosphate (TPP) [171-
175], Dextran Sulphate (DEX-S) [176-181] or BSA-conjugated Dextran [182]. Moreover, 
chitosan can be conjugated or modified chemically with other polymers to produce 
nanoparticles (e.g nanoparticles prepared by linking CS with PLGA [183] or with PLA [184-
187] or with PEG [188]). In some cases, chitosan was used to coat nanoparticles from various 
materials such as PLGA [128, 189]. 
Chitosan is considered a good candidate for brain drug delivery systems as it has been 
suggested it can open tight junctions [190]. Also, nanoparticles from modified chitosan have 
been studied for drug delivery to the brain (such as alkylglyceryl chitosan croslinked with TPP 
[129, 173], trimethylchitosan-PLGA conjugate for Coenzyme Q10 delivery [191]; chitosan-
based nanoparticles were also studied for intranasal delivery of dopamine [192], venlafaxine 
[193], rivastigmine [194] or estradiol [195].  
In many cases, nanoparticles prepared from chitosan were found to exhibit suitable 
features for drug delivery under preparation conditions (i.e. acidic pH), however the transfer of 
nanoparticles to physiological pH has been shown to be accompanied by increase in 
nanoparticle size and agglomeration [173, 196, 197]. Perhaps it is for this reason that many 
reports do not state the dimensions of nanoparticles at neutral pH. Also there exists controversy 
about the non-toxicity of chitosan on one hand [129, 196, 198] versus reports about the toxicity 
of nanoparticles from chitosan on the other [199, 200]. Due to the toxicity some authors 
suggest, chitosan should not be used in parenteral applications but only in per oral formulations 
[201]. 
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2.5.2. Dextran 
Dextran is an extracellular polysaccharide produced by bacteria of Leuconostoc, 
Streptoccocus Lactobacillus, Rhizopus species [202, 203] (Figure 2.14.). The polymer consists 
of main α (1->6) glucan polysaccharide backbone with side branching chains α (1->3). 
Approximate degree of branching was estimated about 5 % [203].  
In 1861 Pasteur observed the formation of dextran in wine; its name was given by 
Scheibler, in 1874, who demonstrated that dextran is a carbohydrate with a positive optical 
rotation [204]. It was found latter, in 1941, that the Leuconostoc extracts had the ability to 
synthesise dextran [203], and the enzyme responsible for the biosynthesis of dextran was 
identified as Dextransucrase (1,6--D-glucan-6--glucosyl transferase, EC. 2.4.1.5). Dextran 
can be easily degraded by the enzyme Dextranase (o-1,6-D-glucan-6-glucanohydrolase, 
E.C.3.2.1.11.) [205].  
 
 
Figure 2.14. Chemical structure of dextran.  
 
Dextran was recognised as a useful polymer in medicinal applications when Gronwall 
and Ingelman used dextran in 1947 to cure shock in their patients [206, 207]. Since then, it has 
been employed as a plasma-expander in emergency cases when there was not enough quantity 
of blood available [208, 209]; more recently, dextran was approved by FDA as a plasma volume 
substitute [210]. The molecular weight of natural dextran ranges from 12 kDa to 600 000 kDa 
[211], however for medicinal purposes lower molecular weight fragments are used [212]. The 
first production was established with Leuconostoc mesenteroides strand 7E, however in 1951 
the production was switched to strand B-512F (isolated from a bottle of infected root beer), 
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[213]. Interestingly, Dextran caused reversible red blood cells aggregation in concentrations 
above 2g/100 mL of blood and in range of high molecular weights (70 kDa - 28 000 kDa) [214]. 
Although the optimal properties were found in Dextran Mw < 25 kDa, Dextran 40 was selected 
with respect to renal excretion of small molecules [215]. Dextran was linked to haemoglobin to 
serve as plasma expander and oxygen transporter as well. This construct was causing 
hyperaggregation however such phenomenon was not found harmful and the aggregation was a 
reversible process [216].  
 
Figure 2.15. Organisation of modified dextran chains on the surface of silica particles. Adapted 
from [217]. 
Dextran was also investigated for use in various drug delivery systems: Dextran based 
polymethacrylate derivatives were found as biocompatible in vivo [218]. Polyvinyl co-polymers 
of Dextran were formulated by nanoprecipitation into nanoparticles in range of diameters 100-
200 nm [219]. Dextran, as a polysaccharide coating, provided prolonged circulation times to 
nanoparticles from PBCA when compared to uncoated nanoparticles [220]. Moreover, 
nanoparticles with corona from Dextran of various molecular weights attached to the core of 
PBCA polymer were investigated for interaction with plasma proteins. The study revealed that 
certain composition of dextran chains (associated to high molecular weight) on the surface of 
nanoparticles was activating complement component C3 to C3b more than low molecular 
weight Dextran (Figure 2.15.) [221]. Apparently, long chains were bound to the surface of 
PBCA nanoparticles in form of “loops” and “trains” whereas short chains appeared to be in 
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“brush-like” formation, leaving poor accessibility of OH groups. Moreover, a similar study 
compared dextran and PEO in activity towards restricting opsonisation of particles by blood 
proteins [222]. It was found that a specifically side-on grafted dextran onto the nanoparticle 
surface was as active as PEO in preventing fibrinogen adsorption.  
In vivo experiments showed the capability of dextran and heparin surface coverage to 
prolong the circulation of poly(methylmethacrylate) (PMMA) nanoparticles: both 
polysaccharides on the surface of nanoparticles provided long circulation times (still detectable 
after 48 hours) however bare PMMA nanoparticles were found to have a half-life of only 3 min. 
Indeed, the dextran or heparin modifications of PMMA nanoparticles appeared as weak 
complement activators when compared to crosslinked dextran (Sephadex) or bare PMMA 
nanoparticles [223]. Also, dextran was investigated as protection against protein adsorption and 
possible avoidance of RES uptake [156, 157]. Controversially, several studies showed no 
capability to reduce protein adsorption (BSA and fibrinogen) by dextran or PEO when grafted 
onto polydimethylsiloxane surfaces [224]. Furthermore, in a different study the dextran was 
found less active than PEO in repelling BSA when grafted onto a silica surface [217]. BSA was 
selected as a model protein in studies mentioned above, because it can take part in classical C3 
complement activation pathway by binding in complex BSA/anti BSA to erythrocytes [225].  
 
2.5.3. Poly(lactic acid) 
Poly(lactic acid) acid (PLA) is known as a material with good biocompatibility and 
biodegradability [226, 227], though a drawback of this polymer could be the lack of moieties 
that would allow easy functionalisation. A modification of PLA can take part at the carboxylic 
end [228], or another promising approach could be radical grafting. Grafted PLA could be then 
substituted with an active [229-231] or cross-linked with another polymer [232]. 
Poly(lactic acid) can be prepared by ring opening polymerisation of lactide [233] 
(Figure 2.16.). Since the monomer is a chiral molecule, the product may be obtained as L, D or 
in a meso form [234]. Degradation of PLA occurs by autocatalytic cleavage of the ester bonds 
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and can further continue to Krebs´ cycle, where it can be finally degraded to water and CO2 
[235]. When used for nanoparticle preparation, the PLA-based products are reported to be stable 
both in fridge (4°C) and at room temperature (20°C) for weeks. However, at body temperature 
their decomposition occurs in days [236]; the process is size dependent as structures larger than 
10 μm took longer time to decompose in human body as particles of this size cannot be 
phagocytosed [237].  
-H2O
Ring opening
polymerisation
Lactic acid
Poly(lactic acid)
Lactide  
Figure 2.16. Preparation of poly(lactic acid) by ring opening polymerisation [233]. 
PLA has been known to form small size nanoparticles with a low polydispersity index 
[238], with many applications in drug delivery being investigated [239-244]. Methods for 
preparing PLA-based nanoparticles include nanoprecipitation (a key technique described by 
Fessi [245]), emulsification-evaporation process [246] and solvent displacement process via 
dialysis (discussed in Chapter 2.6. [247]). 
Following intravenous application, nanoparticles of bare PLA have been found to be 
rapidly removed from the blood stream by macrophages by phagocytosis; the blood half-lives 
were between 2 and 3 min [248]. To avoid this, hydrophilic coatings by covalent binding of 
poly(ethylene glycol) (PEG) have been used, and were found to reduce opsonisation and 
phagocytosis [64, 249, 250]. PLA-PEG copolymers were used in combination with chitosan 
films for buccal delivery of insulin [246]. Connecting PLA to dextran yielded copolymers that 
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could be formulated into nanoparticles exhibiting core-shell properties [220, 251-254]. As a 
biocompatible polymer, PLA has been also investigated for use in implants [255] or as tissue 
scaffolds [256]. 
 
2.6. Methods for preparation of nanoparticles 
 Nanoparticles can be prepared from various types of polymers. The main methods to 
prepared nanoparticles from prefabricated biodegradable polymers include: nanoprecipitation; 
solvent displacement via dialysis; emulsification; electrospraying; and electrostatic 
complexation. Other methods include salting [257, 258], supercritical fluid technology [259, 
260] and desolvation method [261, 262]. Nanoparticles can be prepared also by polymerisation 
of monomers, e.g. emulsion polymerisation in water, a method that requires a poorly water-
soluble monomer, water soluble initiator and a surfactant [263-265].The removal of the 
surfactant is sometimes a difficult step in the preparation process, therefore surfactant-free 
polymerisation is receiving more attention [266, 267]. Other polymerisation methods include 
mini-emulsion polymerisation [268], interfacial polymerisation [269] and controlled/living 
polymerisation [270]. When required, drug loading into/onto nanoparticles can be accomplished 
by absorption, adsorption, or encapsulation [271]. 
 
2.6.1. Nanoprecipitation 
 An easy and rapid way to obtain small nanoparticles is the interfacial solvent 
displacement, also known as nanoprecipitation and described by Fessi [245]. A polymer (plus a 
drug or other molecule to be loaded) dissolved in a low boiling point solvent (usually acetone, 
though other organic solvents can be used as well) is added dropwise to a non-solvent which is 
miscible with the solvent. This operation usually takes place at room temperature under 
moderate stirring. The mechanism of nanoparticle formation via nanoprecipitation can be 
imagined as the nucleation of small aggregates of macromolecules followed by aggregation of 
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these nuclei. The process stops at the moment of reaching the colloidal stability [310]. Solvent 
diffuses deep into the non-solvent, leaving the polymer and drug in form of a nanoparticle 
(Figure 2.17.). The rest of solvent is evaporated under reduced pressure, and the nanoparticles 
can be separated by centrifugation [272]. The size of the resulting nanoparticles can be 
influenced by the choice of solvent/non-solvent system, namely by the miscibility of the two 
phases and the interaction parameter χ expressing the affinity of solvent and non-solvent [276], 
the concentration, the viscosity and the dielectric constant), by the dropping rate of the solvent, 
the speed of stirring, or the presence and concentration of a surfactant in the non-solvent phase 
(polyvinyl alcohol, Poloxamer 188, Polysorbate 80) [273].  
 
Figure 2.17. Ternary phase diagram of PCL in solvent/non-solvent system: the region of 
insolubility A, the area of flocculation BII, the area of nanoprecipitation BI and they are of 
dissolution of PCL BIII. Adopted from [310] 
Nanoprecipitation is used widely to produce nanoparticles from polyesters (poly(lactic 
acid) [245], dextran-polylactide copolymers [163, 251], poly(lactic-co-glycolic acid)), cellulose 
derivatives [274], cyanoacrylates [275] or poly (ε-caprolactone) [276]. Due to the nature of 
solvent/non solvent system, the method is suitable for entrapment of hydrophobic drugs, 
however it can be been modified to entrap hydrophilic molecules as well [276]. 
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2.6.2. Solvent displacement via dialysis 
 In the dialysis method, the polymer is dissolved in an organic solvent and placed inside 
a dialysing tube. Dialysis is performed against environment, which is miscible with the solvent 
but it acts as a non-solvent for the polymer. The displacement of the solvent inside the 
membrane is followed by progressive rearrangement of the polymer chains as a result of an 
increasingly limited solubility and ultimately by the formation of nanoparticles (Figure 2.18.). 
Though the mechanism has not been fully elucidated yet, it may be similar to nanoprecipitation 
[263]. Detailed investigations suggested that the formation of nanoparticles could be divided 
into three steps: (1) aggregation – individual polymeric chains start binding to each other in 
solution; (2) formation of polymeric particles; (3) solidification of nanoparticles [277]. 
 
Figure 2.18. Schematic representation of the solvent displacement (dialysis) method 
  
The dialysis is a suitable method for preparation of nanoparticles from various polymers 
including PLA or PLGA and is very useful for copolymers that are soluble only in solvents with 
high boiling point (e.g. dimethyl sulfoxide, dimethylformamide or dimethylacetamide). 
Nanoparticles from PLA [277], PLGA-PEG [278], PLA-DEX [252], PCL[279], poly(N-
isopropylacrylamide)-graft-poly(ethylene oxide) [280] were prepared via dialysing method.  
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2.6.3. Emulsification-evaporation and double emulsification 
 Emulsification allows encapsulation of lipophilic substances [281, 282] and involves 
two phases: organic and aqueous. For the nanoencapsulation of a lipophilic active, the organic 
phase contains the polymer, the active and an organic solvent (which is partially miscible with 
water). This organic medium acts as a solvent for the different components of the organic phase. 
The aqueous phase comprises of the aqueous dispersion with a stabilizing agent while the 
dilution phase is usually water [282]. Ethyl acetate is the organic solvent of choice, though 
propylene carbonate, benzyl alcohol and dichloromethane can also be used. Suitable polymers 
are polyesters (especially PLA and PLGA) or their copolymers (such as PLA-PEG) [283]. 
Polyvinyl alcohol (PVA) is usually employed as a surfactant in the water phase [242]. The 
mechanism of formation comprises of two steps: emulsification and evaporation. The size of the 
particles is determined by the first step [284]. The theory indicates that each emulsion droplet 
produces several nanocapsules and that these are formed by the combination of polymer 
precipitation and interfacial phenomena during solvent diffusion [285]. The solvent is 
evaporated after this step. 
Double emulsions are “emulsions of emulsions”, and allow encapsulation of both 
hydrophilic and lipophilic substances [282]. These systems can be either water-oil-water 
emulsion (w/o/w) or oil-water-oil emulsion (o/w/o) [281]. Double emulsions are usually 
prepared in a two-step emulsification process using two surfactants: a hydrophobic one 
designed to stabilize the interface of the w/o internal emulsion and a hydrophilic one to stabilize 
the external interface of the oil globules for w/o/w emulsions. The mechanisms of formation of 
nanoparticles are associated with both nanoprecipitation and emulsification-diffusion principles 
[286]. During a typical procedure of double emulsification, the primary emulsion is formed by 
ultrasound and the w/o surfactant stabilizes the interface of the w/o internal emulsion. The 
second emulsion is also formed by ultrasound and nanocapsule dispersion is stabilized by the 
addition of the stabilizing agent. Finally, the solvents are removed by evaporation or extraction 
by vacuum, leaving hardened nanocapsules in an aqueous medium (Figure 2.19.) [282]. 
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Figure 2.19 . Schematic representation of the double emulsion/evaporation method.  
 
 A study using poly(caprolactone) as a model polymer investigated the influence of the 
preparation method (nanoprecipitation and emulsion evaporation) in terms of characteristics of 
the resulting colloidal system. It was discovered that the nanoprecipitation produced smaller 
nanoparticles than emulsification. Moreover, zeta potential and drug release from nanoparticles 
was influenced by the method [273].  
 
2.6.4. Electrospraying 
 Electrohydrodynamic atomisation (or electrospraying) is a method, which uses electric 
forces for producing nanoparticles via fluid atomisation [287, 288]. Compared with traditional 
emulsion fabrication techniques, electrospraying has the potential to reduce denaturation of 
proteins, and it can afford tight regulation over particle size distribution and morphology [289]. 
In the process of electrospraying, the liquid at the outlet of a nozzle is subjected to an electrical 
shear stress by the high electric potential of the nozzle (Figure 2.20.). A cone shape of the spray 
is preferred, when the droplets can be extremely small, down to the nanometre range.  
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Figure 2.20. Schematic representation of the electrospraying method 
The charge and size of the droplets can be controlled by adjusting the flow rate and 
voltage applied to the nozzle [287]. Electrospraying in the cone-jet mode can be described in 
three stages: the acceleration of the liquid in the liquid cone; the breakup of the jet into droplets; 
and the development of the spray after droplet formation [290]. The resulting size distribution of 
the droplets can be nearly monodisperse. The fact that the droplets are electrically charged 
facilitates control of their motion in the electric field. Charged droplets are self-dispersing in 
space incurring no droplet coagulation.  
 The smallest nanoparticles so far obtained by electrospraying method (the setup was 
equipped with neutralisation chamber with a radioactive source) were from sucrose (4 nm 
diameter [291]). There were prepared several formulations for drug delivery purposes via the 
electrospraying method: PCL microparticles loaded with Paclitaxel [292], PLGA nanoparticles 
(250 nm) loaded with Paclitaxel [293], PLA microparticles containing Paclitaxel [294] 
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2.6.5. Electrostatic complexation 
 The method of electrostatic complexation (also known as ionotropic gelation) employs 
attractive forces of counter ions to crosslink molecules – pectin with magnesium chloride [295] 
or chitosan with counter-ions as TPP (Figure 2.13) [296, 297, 173], dextran sulphate [178, 298] 
or hyaluronan [299]. The chitosan derivatives are dissolved in a weak acid and added to the 
counter-ion which is dissolved in aqueous phase where the crosslinking takes part. The 
molecule to be entrapped should bear a charge to take part directly in the structure of 
nanoparticles. The release of such molecule from nanoparticles is usually low due to the 
electrostatic forces, as in case of release of Evans Blue dye from chitosan nanoparticles 
crosslinked by sodium tripolyphosphate [173].  
 
2.7. Methods for nanoparticle characterisation   
 The most important physical characteristics of nanoparticles are size, shape and zeta 
potential. The size and shape of nanoparticles can be visualised directly using scanning electron 
microscopy (SEM), transmission electron microscopy (TEM) and atomic force microscopy 
(AFM) [300]. Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) can be 
used to determine the particle diameter by analysing particle Brownian motion in a controlled 
environment [301, 302]; these methods measure the hydrodynamic diameter in solution. Other 
methods employed to determine the size of nanoparticles include Analytic centrifugation [303-
305] and Scanning ion occlusion spectroscopy (SIOS) [306, 307]. The zeta potential of 
nanoparticles gives an indication of the stability of a particular colloidal system. Zeta potential 
is usually calculated from electrophoretic mobility (EPM), which is behaviour of nanoparticles 
under electric field [308-310]. The current chapter briefly reviews the relevant techniques for 
characterising nanoparticles employed in this experimental study.  
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2.7.1. Dynamic light scattering 
Particles, emulsions and molecules in suspension move in solution due to the 
bombardment of the solvent molecules – thermodynamic phenomenon called Brownian motion. 
When a laser illuminates the particles, the intensity of the scattered light fluctuates in a mode 
that is dependent on the size of the particle. The smaller particles are moving faster than the 
large ones. Analysis of the fluctuations of intensity delivers the velocity of the Brownian 
motion; the size of the particle can be calculated using Einstein-Stokes equation [301]:  
  
  
    
 
where d is the hydrodynamic diameter (in m), k is the Boltzmann constant(J K
−1
), η is the 
solvent viscosity(kg s
−1
 m
−1
) and T is the absolute temperature (K). The Brownian motion is 
followed as a function of time by irradiating the particles with a laser beam and collecting the 
scattered light. At certain angle the diffusion of nanoparticles causes rapid changes in intensity 
signal (Figure 2.21. A). 
A) B)  
Figure 2.21. Schematic representation of: A) the DLS method (scattering angle 90°);  B) non-
random intensity signal in a “random” set of data (from [311]). 
 
Figure 2.22. Typical correlation function obtained by DLS, represented as correlation 
coefficient over time. 
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The correlation of the signal to the time is a statistical technique employed to measure 
the degree of non-randomness in a “random” set of data (Figure 2.21. B). The correlation 
coefficient is typically normalised to 1 and develops as a function of time [311]. The endpoint 
time of the plateau and the decay curve gradient can give an indication of parameters such as 
particle size and polydispersity (Figure 2.22.). The cumulant fit of the correlation curve is the 
analysis method recommended by the International Standards Organisation [311]. The 
hydrodynamic size is calculated by this method as an average value (Z-average), which is 
weighted by the scattering intensity of the signal of the particle. While the cumulant algorithm 
and the Z-average are useful for describing general solution characteristics, for multimodal 
solutions consisting of multiple particle size groups the Z-average value can be misleading 
(Figure 2.23.) [312]. For multimodal solutions, it is more appropriate to fit the correlation curve 
to a multiple exponential form, using common algorithms such as CONTIN or non-negative 
least squares [311]. 
 
Figure 2.23. Example of DLS results for a polydisperse sample; adapted from [312]. 
 
 
 Dynamic Light Scattering is a well-established, rapid and reproducible method that can 
be successfully employed to determine the size of nanoparticles in uniform samples (when 
polydispersity index is low). However, in many cases samples exhibit greater polydispersity 
indexes so the size distribution of such samples determined by DLS is likely to be not entirely 
accurate (Figure 2.24.) and in all cases, the results should be confirmed by another analytical 
method such as nanoparticle tracking analysis, Atomic force microscopy or Scanning electron 
microscopy. However, it may be possible that results will be different as each method is based 
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on a different principle, but by combining several methods a more accurate representation of the 
true nature of the sample can be obtained [301, 313].  
 
Figure 2.24. Intensity distribution of poly(lactic acid) nanoparticles as measured by a Malvern 
Nano Zetasizer instrument. The z-average diameter [nm] is displayed on a logarithmic scale.  
 
2.7.2. Nanoparticle tracking analysis 
Nanoparticle tracking analysis was developed by Carr et al. who commercialised the 
method under the Nanosight brand in 2003 [314]. The method allows real time visualization and 
analysis of nanosized structures in liquids, where the Brownian motion of individual 
nanoparticles is visualized by laser and tracked/captured (30 fps) by a CCD camera mounted on 
a microscope (Figure 2.25.). 
 
Figure 2.25. Schematic representation of the Nanoparticle Tracking Analysis method [315]. 
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The software analyses the trajectory of each single particle in time and the diameter is 
calculated from the Einstein-Stokes equation [302]:  
  
  
    
 
where d is the hydrodynamic diameter (in m), k is the Boltzmann constant(J K
−1
), η is 
the solvent viscosity(kg s
−1
 m
−1
) and T is the absolute temperature (K). This formula can be 
adjusted to obtain the coordinates of a particle in 2D system, as follows: 
 
(   )  
    
   
 
 
where T is the temperature, t is the time (s), k is Boltzmann constant, η is the viscosity 
of the medium and r is the hydrodynamic radius (m) [301]. 
As the particle size distribution of a sample presented by NTA is based on 
measurements of individual particles, the result describes the sample from a different 
perspective compared to DLS (where the result is expressed as intensity weighted Z-average 
distribution). Moreover, the different intensities of particles can be seen and total number of 
particles in sample can be estimated as well (Figure 2.26.). The instrument (Nanosight LM 14) 
usually uses a single mode diode laser (usually 635 nm or 638 nm, less than 35 mW); the 
sample cell volume is ca. 250 μL; the magnification of the microscope is 100 x [302].  
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Figure 2.26. 3D projection of nanoparticle distribution. Colour coding is a representation of 
the ability to distinguish different nanoparticle populations based on size and intensity [315]. 
NTA seems more suitable for polydisperse samples (usually organic samples, Figure 
2.26.) than DLS. The NTA method relies on calculations based on movements of individual 
particles unlike DLS method which fits the data of correlation function to theoretical curves. It 
is beneficial to employ both methods in parallel to obtain a more realistic picture about a 
biological sample [301, 302, 316, 317].  
 
2.7.3. Microscopic methods 
 Nanoparticles are too small to be visualised using normal optical techniques, however 
this becomes possible by using a beam of electrons (SEM, TEM) or by indirectly imaging by 
Atomic force microscopy (AFM). These methods allow visualisation of samples in vacuo 
(SEM, TEM) however modifications of traditional SEM (Environmental SEM) and AFM 
instruments can operate in liquids under certain conditions. 
Scanning electron microscopy. The SEM technique was developed in early 1948 by 
Oatley [318]. A Scanning electron microscope employs a beam of electrons to visualise the 
surface of a solid sample; the electrons are emitted from a Tungsten cathode (2700 K) and 
accelerated by an electric field (1-50 kV). The electron beam is scanning the surface line by line 
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by adjustment of the deflection coils (Figure 2.27). Detectors collect X-rays, backscattered 
electrons, and secondary electrons which are emitted by the sample and convert them into a 
signal that is sent to a CRT collector, which produces the final image. Data is collected over an 
area of the surface of the sample, and a two-dimensional image is generated. Magnification 
ranges from 20X to approximately 30,000X. 
 
Figure 2.27. Schematic representation of a Scanning Electron Microscope; adopted from [318]. 
The sample for traditional SEM should exhibit conductive features in order to interfere 
with the electron beam. All metals are conductive and require no preparation before being used 
however non-metal samples need to bear a conductive layer. The coating is provided by gold in 
a sputter coater. The sample is placed in a vacuum under argon atmosphere. An electric field 
causes an electron to be removed from the argon, making the atoms positively charged. The 
argon ions then become attracted to a negatively charged gold foil. The argon ions knock gold 
atoms from the surface of the gold foil. These gold atoms fall and settle onto the surface of the 
sample producing a thin gold coating [319]. 
Environmental SEM. The environmental SEM (ESEM) technique allows visualisation 
of samples without coating, or in a wet state [320]. The water molecules in vapour take part in 
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secondary electron detection [321]. Recent developments have led to an imaging mode known 
as “wet-STEM”, which allows observations directly in liquid phase. The idea behind was to 
perform SEM in transmission mode in an environmental SEM [318]. 
 
Transmission electron microscopy. Transmission Electron Microscopy (TEM) was 
developed in 1930’s by Ruska, who received a Nobel Prize for his efforts in 1986 [322]. TEM 
operates on the same principle as a light microscope. Instead of light the TEM employs a beam 
of electrons which is transmitted through the sample. The electrons interact with the sample as 
they pass through the sample (not more than 100 nm thick) and the non-scattered electrons hit a 
fluorescent screen. The final image, after a magnification, can be directly visualised, or captured 
on a camera. 
 
Atomic force microscopy. Atomic force microscopy (AFM), described for the first 
time in 1986 by Binning and his group [324], belongs to a group of scanning probing 
microscopy techniques. AFM can measure local properties of a sample such as height, friction, 
or magnetism. The method employs a probe, a very thin needle at the end of a cantilever which 
can monitor the surface of a sample. The changes in position of the cantilever are magnified by 
a laser beam (Figure 2.28.) [325]. 
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Figure 2.28. A: Schematic representation of the AFM technique. B: Detail images of an AFM 
tip; Adopted from[323].  
 
AFM operates by measuring force between a probe and the sample. The probe is a sharp 
tip, which can be 3-6 μm tall pyramid with 15-40 nm radius. The lateral resolution of AFM is 
low (~30 nm) due to the convolution, the vertical resolution can be up to 0.1 nm [324]. The 
cantilever reflects off a laser beam which creates an optical lever. The reflected laser beam hits 
a four segment photo-detector. The differences between the segments of photo-detector indicate 
the position of the laser spot on the detector and thus the angular deflections of the cantilever 
[326]. 
AFM can operate in contact (the cantilever touching the surface) or in non-contact 
(cantilever oscillates 5-15 nm over the surface) modes. AFM is very sensitive to the 
intermolecular forces present between the tip and the studied surface; in contact mode the 
interactions between the probe and sample is repulsive. The drift of the tip across the sample 
(caused by normal force) creates a substantial friction force, which can damage the sample if the 
force is not controlled properly. In the non-contact mode the forces between the tip and the 
sample are repulsive or attractive and depend on the distance [327]. The forces taking part are 
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weak van der Waals forces or Coulomb and dipole interactions. The changes of forces induce 
changes in the oscillation pattern of the cantilever. In order to achieve a precise image, the probe 
needs to be brought in small proximity of the surface of the sample, the tip can slightly touch 
the surface to become semi-contact (tapping mode) AFM which is a beneficial method for 
biological samples [323, 327] or rather in combination with other analytic size determining 
techniques [328]. 
 
2.7.4. Scanning ion occlusion spectroscopy 
Scanning Ion Occlusion Spectroscopy (SIOS) is technique that employs a permeable 
elastic membrane that has an adjustable pore [306, 307, 329]. As the sample passes through the 
pore, there is a linear relationship between the particle volume and electric resistance across the 
pore [330] (Figure 2.29.). The diameter of nanoparticles is defined according the linear 
calibration with particles of known sizes. The device demonstrated reliability in comparison 
with other methods in range 200 -1000 nm [331]. 
 
Figure 2.29. Schematic representation of the Scanning Ion Occlusion Spectroscopy, technique; 
adopted from [330] 
. 
The pore is precision manufactured into polyurethane membrane. This produces an 
approximately conically shaped pore with a size that is dependent on the puncturing process. 
The membrane containing this pore is then sandwiched in a fluid cell in the SIOS device and 
stretched onto four jaws, which provide stretch in two dimensions in the horizontal plane. 
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Macroscopic stretching of these jaws produces nanoscopic changes in the pore size (Figure 
2.30.). The fluid cell incorporates electrodes, which are used to apply an electric field and to 
monitor the current produced in the electrolyte solution contained in the fluid cell. A change in 
the pore size is then detected as a change in the base current level, while the passage of 
suspended particles through the pore is detected as a momentary drop in the measured current (a 
‘blockade’). A count of these blockades in a measured time gives the particle count rate [331]. 
Scanning Ion Occlusion Spectroscopy instruments - commercialised under the Izon 
brand) is able to measure the diameter and zeta potential of individual particles [332, 333] 
(Figure 2.30.). The flow of nanoparticles through the pores is influenced by various forces: 
hydrodynamic, electro-osmotic and electrophoretic. Individual forces can be distinguished and 
thus the electrophoretic mobility can be derived through single particle movement as well.  
 
Figure 2.30. Scanning Ion Occlusion Spectroscopy combined with zeta potential measurements: 
A) particle in transit through the pore B) individual particle measurement` adapted from [332]. 
 
2.7.5. Zeta potential measurements 
Zeta potential is a measure of the electrokinetic potential in a colloidal system. As an 
application of the DVLO theory the Zeta potential is an indicator of the stability of a dispersed 
system against aggregation [334]. The environment surrounding the particle exists as two 
layers; an inner region (Stern layer, Figure 2.31.) where the ions are strongly bound and an 
outer (diffuse) region where the ions are looser. When a particle moves in a liquid environment, 
ions within the Stern layer are associated and move as well; however ions in diffuse layer do not 
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travel with the particle. The electric potential at this boundary, also called the surface of 
hydrodynamic shear, is defined as the zeta potential. Particles with a high zeta potential of the 
same charge, will repel each other. Conventionally a high zeta potential is considered in 
absolute sense (-30mV and +30mV). The high value indicates stability of the dispersive system 
against aggregation. Additionally, in some cases the system can be stable not because of charge 
related repulsion forces but because of steric conformation on the surface of the particles, e.g. 
PEG chains [246, 335, 336] or polysaccharides [309]. 
 
Figure 2.31. Schematic representation of the diffuse layer and the charge variability in the 
space around individual nanoparticles. Adapted from [337]. 
Laser Doppler electrophoresis is also known as laser Doppler velocimetry. An electric 
field is applied across a sample in solution, causing charged particles to migrate toward the 
poles of opposite charge. Light scattered from these particles will be Doppler or frequency 
shifted, with the magnitude of the Doppler shift being dependent upon the particle surface 
charge. A laser beam is passed through the sample in the capillary cell undergoing 
electrophoresis and the scattered light from the moving particles is frequency shifted: 
        (
 
 
)     
     frequency shift (Hz) 
  V the particle velocity (cm.s
-1
) 
  λ laser wavelength (nm) 
    scattering angle (o) 
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Figure 2.32. Longitudinal section in a Malvern folded-capillary cuvette [337]. 
 
Henry’s function for aqueous media with moderate electrolyte concentration has a value 
of 1.5 (Smoluchowski approximation) when the particles are larger than 0.2 µm and the 
electrolyte concentration is higher than 10
-3
 M. For small particles with low dielectric constant 
and in non-aqueous solutions, F(ka) is 1 (Huckel approximation) [334]. Zeta potential is related 
to the electrophoretic mobility, according to Henry’s equation: 
 
  
     (  )
   
 
Ue  electrophoretic mobility (cm. s
-1
) 
Z zeta potential (mV) 
Ε dielectric constant  
   viscosity (Pa.s) 
F(ka) Henry’s function 
 
2.8. In vitro models of the blood-brain barrier 
 Blood-brain barrier models can be based on primary brain cells, such as the model 
designed by Nakagawa et al. which consisted of rat endothelial cells, pericytes and astrocytes 
[338], or with porcine primary cells [339]. As the acquisition of primary cells can be sometimes 
difficult, using manipulated cell lines is in many cases considered an acceptable alternative. 
Monocultures of immortalised endothelial cells of different origin, such as porcine [340], 
human (hCMEC/D3 [341, 342]), or murine (bEnd3 [129, 343]) were previously shown to be 
sufficient to mimic the barrier function of the BBB. However, to make the model more robust, 
some researchers recommend the combination of endothelial cells with astrocytes [344] 
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(employed in Transwell setup Figure 2.33.) and also the addition of pericytes to strengthen the 
tight junctions [49, 345]. 
 
 
Figure 2.33. Schematic representation of a blood-brain barrier model; adopted from[344]. 
 
 Advanced BBB models can simulate the flow of cell media to mimic blood circulation 
and also simulate the change in the concentration of the applied active as well as induce a shear 
stress into the model, as in case of models based on porcine [346] or human models [347, 348]. 
An indicator of the BBB properties can be measurement of transendothelial electrical resistance 
(TEER). The high values indicate better barrier properties (mouse endothelial cells approx. 
800 Ω [129], human endothelial cells approx. 1800 Ω in mono-culture [49]); the co-cultures of 
endothelia cells with astrocytes usually perform better than mono-cultures [345].  
 
Figure 2.34. Scheme of electric cell to substrate impedance sensing (ECIS): (a) 8 well plate 
with electrodes, (b) empty electrode, (c) electrode with cells; adopted from [349]. 
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TEER can be measured either within the Transwell setup [49, 350, 351] or in 
independent experiments with cells planted on electrodes [129]. The latter, known as electric 
cell to substrate impedance sensing (ECIS), can signalise changes in the cell populations as 
attachment, movement or change of shape [349, 352]. The principle can be found in relation 
between the electrical current and resistance, in Ohm’s law (Figure 2.34). 
 
2.9. In ovo model for toxicity and biostribution studies 
Mammalian models are frequently used for preclinical in vivo evaluation of new drug 
delivery systems (rat [128, 353]; mouse [354-356]; rabbit [357, 358] macaque [357, 359], cat 
[360], dog [361, 362], calf [363], pig [364, 365]), however such models tend to be costly and 
add an administrative burden in terms of legal and ethical implications. The alternatives to 
mammalian models can be provided by zebrafish Danio rerio [366, 367] or even simpler 
organisms such as Drosophila [368]. These models cannot substitute mammal models however 
such simple options bridge the gap between in vitro and in vivo testing. One of the approaches 
includes employment of chicken embryos [369-371].  
The low cost and the simplicity and rapidity of setting up an in ovo model make chick 
embryos (Figure 2.35.) interesting candidates that could be used to establish an intermediate 
step between in vitro cellular tests and preclinical mammalian in vivo models, especially for 
studies related organism toxicity [371]. The transparency of embryos allows easy monitoring of 
the fate of the administered fluorescently labelled nanoparticles and can provide an early 
indication of the effect of nanoparticles at the organism level. Although chick embryos are not 
yet widely used for the evaluation of new drug carriers, the US Food and Drug Administration 
(FDA) has already approved products pre-clinically evaluated with chick embryos [371]. 
Indeed, FDA guidance for industry from 2006 regarding the development of products for the 
treatment of chronic cutaneous ulcer and burn wounds, considered the chicken chorio-allantoin 
membrane (CAM) model as an alternative for preclinical testing [371]. CAM of chicken embryo 
was used as in vivo models for photodynamic therapy. This method has been successfully used 
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for the treatment of choroidal neovascularization in age-related macular degeneration [372] or to 
test compound toxicity [373], or for material construct biocompatibility [374], wound healing 
[375] or anticancer agents [371] were also tested using this model. Nanoparticulate behaviour in 
embryotic blood vessels of CAM was investigated for the first time by Clancy, who employed a 
perfusion method combined with fluorescence correlation microscopy [376].  
 
Figure 2.35 Image of chicken embryo (Adopted from [377]). 
 
Depending on the stage of development the chicken embryo has functioning cardio-
circulation system and an immunity system with B and T lymphocytes, toxicity of drugs could 
be easily evaluated in terms of embryo death or adverse effects on the CAM. Two approaches 
for such embryo studies have been thus far developed: an “in ovo” method, where the embryos 
are left inside the eggshell during their development and also for the duration of the assay, and 
an “ex ovo” method, where the embryos are actually cultivated in recipients simulating the 
eggshell. The approach ultimately depends on the age of the embryo at the beginning of the 
experiment and on the nature of the intervention [371]. 
 
Table 2.1. Classification of embryo damage caused by photodynamic therapy, (Adopted from 
Lange [372]). 
Damage 
scale 
  Criterion 
0 No damage 
1 Partial closure of capillaries < 10 μm 
2 Closure of capillary system, partial closure of blood vessels of diameter < 30 μm 
3 Closure of vessels < 30 μm and partial closure of higher order vessels 
4 Total closure of capillaries < 70 μm and partial closure of large vessels 
5 Total occlusion of vessels in the irradiated area 
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 A special scale that can be used for toxicity studies employing embryonal model was 
developed by Lange et al [372] (Table 2.1.). The scale helps with the assessment of various 
stages of damage to the embryo (Lange was interested in particular in the anti-neoangiogenesis 
induced by photo-dynamic therapy). Chicken embryos were also used in toxicity studies of 
porphyrin loaded PLGA nanoparticles [370]. 
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3 
CHEMICAL MODIFICATIONS 
OF POLYSACCHARIDES 
            
Selected polysaccharides were modified by covalent attachment of alkylglyceryl 
pendant chains to the available hydroxyl groups. This was achieved by treatment of 
polysaccharides (chitosan and dextran) with a range of alkyloxiranes (n-pentyloxymethyl 
oxirane, OX5, and n-octyloxymetyloxirane, OX8, were synthesised in house, while n-
butoxymethyloxirane, OX4, was sourced commercially). A series of alkylglyceryl modified 
polysaccharides: butylglyceryl chitosan (CS-OX4), pentylglyceryl chitosan (CS-OX5), 
octylglyceryl chitosan (CS-OX8), butylglyceryl dextran (DEX-OX4) and octylglyceryl dextran 
(DEX-OX8), were prepared following the above method. Further covalent binding of 
alkylglyceryl-modified dextran to poly(lactic acid) was achieved using carbodiimide chemistry 
to yield poly(lactic acid)-graft-butylglyceryl dextran (PLA-DEX-OX4) and poly(lactic acid)-
graft-octylglyceryl dextran (PLA-DEX-OX8). The possibility of increasing number of reactive 
groups in the molecule of poly(lactic acid) (to attach more alkylglyceryl dextran molecules) was 
attempted via free radical grafting.  
 
3.1. Materials and instrumentation 
Epibromohydrin, 1-octanol, sodium hydride (60 % w/w suspension in mineral oil), 
chitosan (low MW, degree of deacetylation 75-85 %), dextran from Leuconostoc (MW 6 kDa), 
dimethyl sulfoxide (DMSO, anhydrous, ≥ 99.9 %), butyloxymethyloxirane (OX4, 95 %), 4-
(dimethylamino)pyridine (DMAP, puriss. > 99 %), Zn(BF4)2, potassium tert-butoxide (t-BuOK; 
reagent grade > 97 %), carbonyldiimidazole (CDI, reagent grade), benzoyl peroxide (BPO), 
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toluene (anhydrous, 99.8 %), and maleic anhydride (MA, puriss., ≥ 99 %) were obtained from 
Sigma Aldrich UK. Dicyclohexylcarbodiimide (DCC, ≥ 99 %,) was obtained from Fluka. 
Tetrahydrofuran (THF anhydrous, ≥ 99.9 % stabilised by 250 ppm BHT), hydrazine 
monohydrate, 4-(4-nitrobenzyl)pyridine, tetraethylenepentamine, and non-anhydrous solvents 
were obtained from Fisher Scientific, UK. Poly(lactic acid) with free carboxyl group (PLA, 
MW 15 kDa) was obtained from Purac, Netherlands. n-Pentyloxymethyloxirane (OX5) was a 
gift from Dr. Molnár. All reagents were used as obtained. 
Solvent removal under reduced pressure was performed using a Büchi Rotovapor R-200 
powered with a Sogevac Saskia PIZ 100 vacuum pump equipped with a liquid nitrogen trap. 
When required, solvents were degassed using three freeze-thawing cycles. Sonication was 
performed using a Grant ultrasonic bath XB3 (Farnell, UK). Thin Layer Chromatography silica 
gel plates F254 were obtained from Merck, UK. Dialysis was performed using Visking 
membrane tubing (Medicell International Ltd, UK) with cut-off either 12-14 kDa or 3 kDa in a 
discontinuous system (10.0 L deionised water. exchanged 3 times/day). Low speed 
centrifugation was performed using a Jouan B4i centrifuge equipped with a S40 rotor (4 000 
rpm; 15 minutes, unless otherwise specified). 
The products were characterised by 
1
H- and 
13
C-NMR spectroscopy using a JEOL 
Eclipse 400+ instrument (Jeol, UK; 400 MHz for 
1
H- and 100 MHz for 
13
C-NMR); samples 
were dissolved in either CDCl3, D2O or DMSO-d6 employing 0.2 % TMS as a reference The 
spectra were processed using the JEOL Delta v 5.0.2 software. FT-IR spectra were recorded 
using a Nicolet 6700 instrument (Thermo Scientific, UK) equipped with an ATR Smart Orbitt 
accessory with diamond crystal, at 128 scans and 4 cm
-1 
data spacing. The analysis of spectra 
was performed using the Omnic Specta 8.0 software. The molecular weight of alkylglyceryl-
dextran derivatives was estimated using a GPC Shimadzu (PL-GPC 120) system equipped with 
3 serial PL-aquagel-OH columns (8 µm particle size; 20, 40 and 60 Å pore type, respectively) 
and a refractive index detector, under thermostatted conditions (30 °C). A phosphate buffer 
(pH=7; prepared from 0.2M NaNO3 and 0.01M NaH2PO4) was run as eluent at a flow rate of 1.0 
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mL/min. The calibration was performed with pullulan standards (Shodex Denko) of MW 
0.6 × 104, 1 × 104, 2.17 × 104, 4.88 × 104 and 11.3 × 104, 21 × 104, 36.6 × 104, 80.5 × 104 g/mol. 
Static light scattering (SLS) measurements were performed to estimate the molecular weight of 
alkylglyceryl-dextran derivatives. A Malvern Zetasizer Nano instrument with scattering angle 
173° (backscatter) or 90° powered by Malvern software was employed to perform the SLS 
analysis; toluene was used as an internal scattering standard. Samples were dissolved in 
ultrapure water and double filtered via 200 nm filter polyethersulfone membranes (GD/X) from 
Whatman, UK. 
 
3.2. Methods 
3.2.1. Synthesis of n-alkyloxymethyloxiranes  
The synthesis of n-alkyloxymethyloxiranes was carried out according to a literature 
procedure [378] that was further optimized in-house [111]; the preparation of n-
octyloxymethyloxirane (OX8) is exemplified below (Figure 3.1.). Briefly, epibromohydrin 
(11.0 mL; d = 1.601 g/mL, 129 mmol; working extremely carefully due to its toxicity) was 
added to anhydrous THF, (80.0 mL) containing sodium hydride (60 % w/v dispersion in mineral 
oil; 6.0 g, 150 mmol) under continuous magnetic stirring in a round bottom flask placed in an 
ice bath. n-Octanol (19.5 mL, 0.827 g/mL, 150 mmol) was added dropwise. The reaction was 
performed under nitrogen atmosphere and was monitored by TLC (silica as stationary phase and 
DCM as mobile phase). The compounds were visualised by spraying with a solution of 4-(4-
nitrobenzyl) pyridine (2% w/v in acetone) and subsequent heating the plate to 100 °C following 
by immersion into a solution of Tetraethylpentylamine (10% w/v in acetone) to observe the 
development of purple spots (epoxide containing compounds). After approx. 3 hours the 
reaction mixture was poured into iced water and extracted with diethyl ether (3 x 70.0 mL) to 
afford a crude liquid product (yields 65  83 %), which were purified by vacuum distillation 
(0.177 kPa; bp 120-121°C). The pure n-octyloxymethyloxirane was a colourless liquid (total 
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yield 23 – 49 %). The structural confirmation analysis was carried out using FT-IR and 1H- 
NMR. 
y=3, pentanol
y=6, octanol
y=3, pentyloxymethylorirane
y=6, octyloxymethyloxirane
THF
NaH
 
Figure. 3.1. Preparation of n-alkyloxymethyloxirane derivatives. 
 
3.2.2. Synthesis of alkylglyceryl-modified chitosan derivatives 
The modifications of chitosan were performed according to a three-step protocol 
established in-house [111], the free amino groups were protected by phthaloylation (which also 
yielded solubility in polar organic solvents such as DMSO and DMF) prior to selectively 
reacting the saccharidic hydroxyl functionalities with n-alkyloxymethyloxiranes (OX4, OX5, 
and OX8) in alkaline conditions followed then by deprotection of the amino groups using 
hydrazine. The experimental details are presented below.  
 
Synthesis of phthaloyl-chitosan (CS-PH). A solution of chitosan (2.0 g, 2.92 mmol) 
dissolved in anhydrous DMF (100 mL) was added dropwise to solution of phthalic anhydride 
(5.4 g, 35.00 mmol) in DMF (50 mL), and the reaction mixture was refluxed (152 °C) for 18 
hours under nitrogen atmosphere with continuous magnetic stirring (Figure 3.2.). The reaction 
mixture was then poured into ice-water (ca. 1.0 L). The precipitate obtained was collected by 
filtration and washed with ethanol and diethylether, and further purified overnight by Soxhlet 
extraction with ethanol. Drying in a desiccator over P2O5 afforded phthaloyl-chitosan (CS-PH) 
as a beige compound (yields 43 - 85 %) and characterised by FT-IR and
1
H-NMR spectroscopy.  
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DMF
136°C
Chitosan Phthaloylchitosan
 
Figure 3.2. Preparation of alkylglyceryl-modified chitosans - the phthaloylation step. 
 
General method for the preparation of alkylglyceryl-modified phthaloyl-chitosans 
(CS-PH-OX4; CS-PH-OX5; CS-PH-OX8). Phthaloyl-chitosan (1.0 g; 3.66 mmol) was 
dissolved in anhydrous DMF (100 mL) under a nitrogen atmosphere and the mixture was being 
added dropwise to a solution of potassium tert-butoxide (1.6 g; 14.64 mmol) dissolved in 
anhydrous THF (10 % w/v).  After stirring the mixture for 30 min at room temperature, a 
solution of an alkyloxirane (n-butyloxymethyloxirane OX4, n-pentyloxymethyloxirane OX5, n-
octyloxymethyloxirane OX8), dissolved in anhydrous DMF (50 % v/v, 14.64 mmol) was added 
dropwise (ca. 30 min, Figure 3.3.).  The reaction mixture was stirred overnight at room 
temperature, then the solution was poured into ice-water (500 mL) and the solvents were 
removed at low pressure using a rotary evaporator. The brown solid residue was resuspended in 
water and dialyzed against deionised water for 4 days. Freeze drying of the dialyzed solution 
afforded the final products (CS-PH-OX4; CS-PH-OX5; CS-PH-OX8) as light brown powder 
(yields 55  71 %), which were characterised by FTIR and1H-NMR spectroscopy. 
y=6, PH-CS-OX8
y=3, PH-CS-OX5
y=2, PH-CS-OX4
x=6, OX8
x=3, OX5
x=2, OX4
tBuOK
DMF
R=
Phthaloylchitosan Alkyloxirane Phthaloylalkylglycerylchitosan  
Figure 3.3. Preparation of alkylglycery-modified chitosans–the reaction between protected 
chitosan and oxiranes. 
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General procedure for the removal of phthaloyl groups leading to the preparation 
of alkylglyceryl-modified chitosans (CS-OX4, CS-OX5, CS-OX8).Alkylglyceryl-modified 
phthaloyl-chitosan (eitherCS-PH-OX4, CS-PH-OX5 or CS-PH-OX8 (0.25 mmol)) was 
suspended in a solution of hydrazine monohydrate (0.7 mL; d= 1.032; 14.00 mmol) and water 
(3.0 mL), which was refluxed for 15 hours (Figure 3.4.). After cooling, the reaction mixture was 
diluted with water (10.0 mL) and the solvents were removed under reduced pressure. The solid 
residue was dialysed in water for 4 days and finally freeze dried to afford alkylglyceryl-
modified phthaloyl-chitosans (CS-OX4; CS-OX5; CS-OX8) as beige powder (yields 44 - 64 %), 
further characterised by FT-IR, 
1
H-NMR spectroscopy analysis. 
y=6, PH-CS-OX8
y=3, PH-CS-OX5
y=2, PH-CS-OX4
R=
y=6, CS-OX8
y=3, CS-OX5
y=2, CS-OX4
R=
N2H4
H2O
100°C
 
Figure 3.4. Preparation of alkylglyceryl-modified chitosans – the deprotection step. 
 
3.2.3. Synthesis of alkylglyceryl-modified dextran derivatives 
Dextran was modified by attaching alkylglyceryl side chains to the hydroxyl groups via 
a two-step reaction that involved the transformation of saccharidic hydroxyl groups into more 
reactive alcoholates using a strong base (either potassium tert-butoxide, pyridine or DMAP) 
followed by reaction with n-alkyloxymethyloxirane (n-butyloxymethyloxirane OX4 or n-
octyoxymethyloxirane OX8), as described below (Figure 3.5.). An alternative route 
investigating zinc tetrafluoroborate hydrate as a catalyst in aqueous environment was tested as 
well. 
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Method A) in organic environment. Dextran (1.00 g; 6.10 mmol) was dissolved in 
anhydrous DMSO (200 mL). The base (potassium tert-butoxide; 1.36 g; 12.20 mmol and 2.72 
g; 22.40 mmol; pyridine 0.96 g; 12.20 mmol; and DMAP 1.49 g; 12.20 mmol) dissolved in 
anhydrous THF (50 mL) was then added dropwise into the DMSO solution of Dextran, and the 
mixture was allowed to react for 2 hours under continuous stirring, followed by the dropwise 
addition of a solution of oxirane (OX4 - 63 mmol; 9.0 mL; d=0.91, or OX8 - 63 mmol; 12.6 
mL) in DMSO (20.0 mL; Figure 3.5.). The reaction mixture was stirred for 48 hours at room 
temperature (25 °C) then poured into a dialyzing membrane (MWCO 3 kDa) and dialysed 
extensively against deionised water (10.0 L; exchanged 3x per day) for three days. The content 
of the dialysing membrane (approx. 400 mL) was then washed three times with diethylether (3 
× 150 mL) in a separation funnel to remove water-insoluble impurities. After removing the 
traces of volatile solvents in a rotoevaporator under reduced pressure (25°C) the aqueous layer 
was lyophilised affording alkylglyceryl-modified dextrans (butylglyceryldextran DEX-OX4 and 
octylglyceryldextran DEX-OX8) as a slightly brown powder. The yields were in range 52-73 %.  
The final products were characterised with FTIR, 
1
H - and 
13
C – NMR spectroscopy. (The 
spectra and characterisation are in APPENDIX I and II.) 
route A) 
t-BuOK
or DMAP
or Pyridine
route B)
Zn(BF4)2
R= H   or
n= 3;  DEX-OX4
n= 7;  DEX-OX8
n= 3; OX4
n= 7; OX8  
Figure 3.5.Synthesis of alkylglyceryl-modified dextrans. 
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Method B) in aqueous environment. In this method the aqueous system was 
employed: Dextran (1.0 g, 6.10 mmol) was dissolved in water (50 mL) with pH 1 adjusted by 
concentrated hydrochloric acid. Zinc tetrafluoroborate hydrate Zn(BF4)2 (2.92 g, 12.20 mmol) 
was added and stirred for 2 hours. Subsequently butyloxirane (OX4 63 mmol, 9.0 mL, d=0.91) 
was dropwise added to the aqueous solution and stirred overnight. After 14 hours the reaction 
was stopped and the reaction mixture was submerged for dialysis for 72 hours and lyophilised. 
The yields were in range 55-81 %. The structural confirmation analysis was carried out by FT-
IR (ATR), 
1
H- and 
13
C-NMR spectroscopy; the molecular weight of products was estimated by 
GPC against pullulan standards (range of MW: 0.6 × 104, 1 × 104, 2.17 × 104, 4.88 × 104 and 
11.3 × 104, 21 × 104, 36.6 × 104, 80.5 × 104 g/mol) in a phosphate buffer in pH 7 (APPENDIX 
V).  
The absolute molecular weight of alkylglyceryl-modified dextrans was also measured 
by Static Light Scattering using a Malvern Zetasizer Nano instrument, with toluene as an 
internal scattering standard. The aqueous polymer solutions (concentration range 1.0 - 0.0001 
mg/mL) were used to construct a Debye plot of concentrations. These attempts were not 
successful due to the polydisperisty of the samples.  
 
3.2.4. Synthesis of poly(lactic acid)-graft-alkylglyceryl modified  
  dextran 
Alkylglyceryl modified dextran derivatives were attached to poly(lactic acid) using 
carbodiimide zero length cross-linkers. Such modifications were conducted in ratio to react one 
molecule of poly(lactic acid) to one molecule of alkylglyceryl-dextran. Furthermore, attempts 
were carried out to attach more molecules of alkylglyceryl-modified dextran to one molecule of 
poly(lactic acid). For that reason it was necessary to introduce more reactive groups into the 
polymeric backbone of poly(lactic acid). The groups were provided by maleic anhydride which 
was grafted via free radical mechanism to the poly(lactic acid). As these attempts exhibited low 
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degrees of grafting and the steps of further binding the alkylglyceryl-dextran were not 
continued.   
3.2.4.1. Synthesis using zero length cross-linkers  
The covalent attachment between poly(lactic acid) (PLA) and alkylglyceryl-dextrans 
(DEX-OX4 and DEX-OX8) was achieved using zero length cross-linkers such as N,N'-
dicyclohexylcarbodiimide (DCC) [278, 379] or N,N’-carbodiimidazole (CDI) [252, 380].  
Method A) using DCC 
R= H or
n=3; DEX-OX4
n=7; DEX-OX8
PLA
DCC
n=3; PLA-DEX-OX4
n=7; PLA-DEX-OX8
 
Figure 3.6. Attachment of poly(lactic acid) to alkylglyceryldextran via DCC. 
 
The reaction was carried out following Choi’s procedure [379]. Briefly, DCC (0.045 g, 
0.20 mmol) dissolved in DMSO (10 mL) was added to a PLA solution (1.750 g, 0.11 mmol) in 
100 mL DMSO under stirring in a round bottom flask that was previously degassed and purged 
with nitrogen and equipped by a magnetic stirrer bar. After stirring for 30 min, this solution was 
added to an alkylglyceryl-dextran solution (DEX-OX4, 0.700 g, 2.20 mmol, DEX-OX8, 0.850 
g, 2.20 mmol) in DMSO (100 mL) to which 4-(dimethylamino)pyridine (DMAP, 0.026 g, 0.22 
mmol) was previously added. The reaction was continued with stirring and under nitrogen at 
room temperature (25 °C) for 24 hr. The reaction mixture was then filtered to remove any by-
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product (dicyclohexylurea) and dialyzed (MWCO 12 kDa) against deionised water for 48 h 
followed by freeze drying. The resulting off-white powder was washed with acetone to remove 
any un-reacted PLA, dried under vacuum at room temperature and then washed with water to 
remove un-reacted alkylglyceryl-dextran and finally freeze-dried again. The structures of 
copolymers (PLA-DEX-OX4 and PLA-DEX-OX8) were confirmed by 
1
H- and 
13
C- NMR and 
FT-IR analysis. (The spectra and characterisation are in APPENDIX III and IV.) The yields 
were in range 33-56%. 
Method B) using CDI 
CDI
PLA activated PLA
 
Figure 3.7. Activation of poly(lactic acid) with CDI in chloroform. 
R= H or
activated PLA
n=3; DEX-OX4
n=7; DEX-OX8
n=3; PLA-DEX-OX4
n=7; PLA-DEX-OX8
 
Figure 3.8. Attachment of activated poly(lactic acid) to alkylglyceryldextran in DMSO. 
 This preparation was carried out by a modification of Nagahama’s procedure [252], as 
follows. The reaction apparatus was degassed and purged with nitrogen, then poly(lactic acid) 
(PLA, 0.50 g, 0.033 mmol) dissolved in anhydrous chloroform (7.0 mL) was added dropwise to 
the carbodiimidazole solution (CDI, 0.11 g, 0.66 mmol) in anhydrous chloroform (5.0 mL). The 
                                                               CHEMICAL MODIFICATIONS OF POLYSACCHARIDES 
63 
reaction mixture was stirred for 6 h at room temperature under nitrogen, and then washed with a 
large amount of ethanol (10 mL) to remove the excess CDI and imidazole. The resultant 
precipitate was collected by centrifugation and dried overnight in vacuo (25 °C). The presence 
of the imidazoyl group in the CDI-activated PLA (yield 82-90%), obtained as white crystalline 
powder, was confirmed by 
1
H-NMR spectroscopy. In the second step alkylglyceryl-dextran 
(DEX-OX4 0.20 g, 0.66 mmol, DEX-OX8, 0.24 g, 0.66 mmol) and 4-(dimethylamino)pyridine 
(DMAP, 0.08 g, 0.60 mmol) were dissolved in anhydrous DMSO (50 mL) separately, CDI-
activated PLA (0.40 g, 0.027 mmol) was dissolved in anhydrous DMSO (50 mL) and dropwise 
added to the DEX-OX & DMAP solution. The reaction mixture was stirred at room temperature 
for 24 h under nitrogen, then the reaction was stopped by adding conc. HCl (150 μL) to 
neutralize any DMAP and imidazole. The reaction mixture was dialysed against deionised water 
for 48 h then freeze-dried. The solid residue was washed with acetone to remove un-reacted 
PLA and with water to remove un-reacted alkylglyceryl-dextran. The purified products (yields 
68-81%) were freeze-dried and analysed by FT-IR, 
1
H- and 
13
C-NMR spectroscopy.  
 
3.2.4.2. Modification of poly(lactic acid) using maleic anhydride  
Poly(lactic acid) (PLA) was modified with maleic anhydride via free radical grafting in 
order to gain more reactive groups in the molecule for further modification with alkylglyceryl-
dextran. Poly(lactic acid) (PLA, 0.10 g, 0.008 mmol) and maleic anhydride (MA, 0.10 g, 1.020 
mmol) were dissolved in degassed anhydrous toluene (10 mL), followed by the addition of 
benzoyl peroxide (BPO) in various ratios (2.5 to 20 % w/w, relative to PLA). The reaction 
mixture was kept stirring at 100 °C for 12 h, under nitrogen flow. The product was separated 
and purified by precipitation in ethanol, then dried under vacuum at room temperature (yields 
52-74%). The characterisation was performed by FT-IR, 
1
H-NMR spectroscopy. The degree of 
grafting of maleic anhydride units to poly(lactic acid) backbone was low therefore the 
subsequent step of synthetizing alkylglyceryl-dextran derivatives was discontinued. 
                                                               CHEMICAL MODIFICATIONS OF POLYSACCHARIDES 
64 
BPO
MA
MPLA
PLA
 
Figure 3.9.Reaction scheme of grafting maleic anhydride onto the backbone of poly(lactic acid) 
in the presence of radical initiators (Adopted from [229]). 
 
3.3. Results and discussion 
3.3.1. Synthesis of n-alkyloxymethyloxiranes  
n-Octyloxymethyloxirane (OX8) was prepared by a nucleophilic substitution reaction 
between epibromohydrin and primary alcohol following a method described in the literature 
[381, 382] and optimised in-house [111]. The purification of the crude product was achieved by 
vacuum distillation (yields 23 – 49 %). The final products appeared as colourless liquids with 
specific odour (b.p. 128 °C; 105 kPa) 
The product structure was confirmed by FT-IR (ATR mode) and 
1
H-NMR spectroscopy 
and was found in agreement with previously published data [111]. The broad band 
corresponding to the O-H stretching vibration present in the FTIR spectra of the alcohol (3400 
cm
-1
) disappeared completely in the spectra of the final product, indicating that the hydroxyl 
group was transformed into an ether group which was confirmed by vibration C-O-C 
(1107cm
1
). The 
1
H-NMR showed characteristic alkyl peaks at 0.90, 1.24 and 1.55 ppm (in ratio 
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approx. 3:10:2) for the octyl group of the OX8 (Figure 3.10.). The results matched earlier 
obtained characterisation data [111].  
 
Figure 3.10. 
1
H-NMR of n-octyloxymethyloxirane (OX8) with structure (numbers indicate 
groups of protons, letters individual protons). 
 
3.3.2. Synthesis of alkylglyceryl modified chitosan derivatives 
Preparation of phthaloyl-chitosan. Phthaloyl chitosan (CS-PH) was prepared from 
commercially available low molecular weight chitosan (Sigma; DDA 75-85 %) by treatment 
with phthalic anhydride in DMF. The product (phthaloylated chitosan) was soluble in polar 
organic solvents such as DMSO and DMF due to changes in inter- and intra-molecular 
hydrogen bonding [111, 383]. The infrared spectra of CS-PH displayed a broad band at 3460 
cm
-1
, indicative of OH stretching vibrations, and a C=O band at 1711 cm
-1
 typical of anhydrides 
and signal for aromatic ring (721 cm
-1
). 
1
H-NMR spectra consisted of pyranose signal (3.0-5.1 
ppm) and aromatic ring signal (7.4-7.9 ppm, Figure 3.11.). The product was obtained as a beige 
compound (yields 43 - 85 %). The characterisation data were identical with previous description 
in original source [111]. 
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Figure 3.11.
1
H-NMR spectrum of phthaloyl-chitosan (CS-PH). 
 
Synthesis of alkylglyceryl-modified phthaloyl-chitosan derivatives. The 
phthaloylated alkylglyceryl-modified chitosan derivatives were prepared by treatment of 
phthaloyl chitosan with alkyloxiranes via a nucleophilic substitution reaction (Figure 3.3.). The 
products were obtained as light brown powders (yields 55-71%). 
The FTIR spectrum of all the phthaloylated alkylglyceryl-modified chitosan derivatives 
contained absorption bands characteristic for both CS-PH and alkylglycerols. Absorption bands 
at approx. 3070, 2950, 2900 cm
-1
, the C-H stretching vibrations, belong to the alkylglycerols, 
signals at approx. 1770, 1710 cm
-1
 were characteristic C=O adsorption bands for the carbonyl 
groups of the N-phthalimido group and approx. 1660, 1560 cm
-1
 vibrations were the amido 
groups of chitosan. In 
1
H-NMR spectra, signals appearing at approx.0.8 and 1.7 ppm 
(characteristic chemical shifts for alkyl hydrogen atoms), were indicative of the presence of 
alkylglyceryl chains. NMR signals due to the hydrogens of the polysaccharidic units of chitosan 
appeared between 2.8 - 4.3 ppm, and were partially overlapped by the broad D2O signal. The 
presence of the phthaloyl group was confirmed by the signals appearing at 7.1 - 7.9 ppm 
(Figure 3.12.). The characterisation data were found in agreement with original source [111]. 
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Figure 3.12. 
1
H-NMR spectrum of phthaloyl-alkylglyceryl modified chitosan (CS-PH-OX4). 
 
Preparation of alkylglyceryl modified chitosan CS-OX4, CS-OX5, CS-OX8. 
Removal of the phthaloyl groups from CS-PH-OX4, CS-PH-OX5 and CS-PH-OX8 was carried 
out with hydrazine monohydrate in water at 100°C for 15 hours [111]. The products were 
purified by dialysis and after freeze-drying were recovered as white-off powders. 
The FT-IR spectra of the resulting alkylglyceryl-modified chitosan derivatives exhibited 
the expected amino group band around 1630 cm
-1
, while the bands corresponding to the 
phthalimido groups (approx 1700 cm
-1
) disappeared. The removal of the phthaloyl groups was 
also confirmed by 
1
H-NMR, as the signals for phthalimido groups (7.1 - 7.9 ppm) disappeared 
whereas the signals attributed to alkyl chains (0.8, 1.2 and 1.4 ppm) and to the aminoglycosidic 
ring (2.8-4.3 ppm) were confirmed. The characterisation data are in agreement with previously 
published source [111]. 
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Figure 3.13. 
1
H-NMR spectrum of alkyl-modified chitosan (CS-OX4). 
 
The degree of substitution of the primary hydroxyl group (Table 3.1.) was calculated 
from the relative intensities of the signals assigned to the long alkyl CH3 group (Hy; 0.8 ppm) 
and to the CH3 group of the acetylated chitosan (HCH3), as illustrated in Equation 3.2. The 
degree of deacetylation (DDA, Equation 3.1) was also determined from the 
1
H-NMR spectra, by 
calculating the ratio of the integral of peak at 4.9 ppm (attributed to the C1 protons) and integral 
of peak at 2.1 ppm (terminate CH3 group of deacetylated chitosan unit). The degree of 
substitution obtained for derivatives CS-OX4, CS-OX5 and CS-OX8 are shown in Table 3.1. 
The characterisation data are in agreement with previously published source [111]. 
   ( )   (
  
         
)      
 DDA (%)  degree of deacetylation 
 Hb  integral of the 4.9 ppm signal assigned to the CH1 proton of chitosan  
 CH3  integral of the 2.1 ppm signal assigned to the CH3 proton of chitosan 
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  ( )   
        
   
 
 DS (%)  degree of substitution 
 HCH3  integral of the 2.1 ppm signal assigned to the CH3 proton of chitosan 
 Hy  integral of the 0.8 ppm signal assigned to the terminal methyl of  
   alkylglyceryl group 
 
Table 3.1. Degree of substitution of alkylglyceryl-chitosan derivatives. 
 Degree of substitution 
[%] 
Butylglyceryl-chitosan (CS-OX4) 88 
Pentylglyceryl-chitosan (CS-OX5) 32 
Octylglyceryl-chitosan (CS-OX8) 14 
 
  
3.3.3. Synthesis of alkylglyceryl-modified dextran derivatives 
The modification of dextran with alkylglyceryl chains was carried out via a nucleophilic 
substitution reaction involving the attack of the hydroxyl groups (transformed into alcoholates) 
to the oxirane ring, following a similar procedure published on chitosan [173, 381]. A number 
of different bases have been employed for this purpose (Table 3.2.). 
Table 3.2. List of bases employed for the attachment of alkylglyceryl moieties. 
 pKa [water] 
potassium tert-butoxide 17.0 
Dimethylaminopyridine 9.2 
Pyridine 5.2 
 
Using the potassium tert-butoxide (tBuOK) afforded higher degree of substitution 
compared to other basic catalysts such as DMAP; pyridine as base was unsuccessful (Table3.). 
The degree of substitution was found to increase as the excess ratio of both base and oxirane 
increased. Moreover, four times an excess ratio of (DEX: tBuOK: OX4 - 1:4:4) resulted in 
higher than if the amounts were only doubled (1:2:2). The amount of oxirane employed was the 
same as the base (or catalyst). 
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Attempts to modify dextran with butylglyceryl chains by employing Zn(BF4)2 as a 
catalyst in aqueous media (pH 1) - as suggested by [180, 384] – resulted in a low degree of 
substitution (Table 3.4). The OX4 exhibited a limited solubility in water (2 % v/v) [385]) so it is 
likely that the solubility of the oxiranes influences the reaction. The literature also mentioned 
using aqueous systems employing NaOH as a base however such approach can be limited by 
solubility of the epoxy compounds [156, 386]. 
Table 3.3. Optimisation of base/catalyst for synthesis of DEX-OX4. 
DEX->DEX-OX4 
reaction 
Mw 
[g/mol] 
Ratio to 
Dextran 
Duration 
[hours] 
Solvent 
Degree of 
Substitutio
n [%] 
 
Base 
DMAP 122 2 24 DMSO 2.1-6.6 
Pyridine 79 2 24 DMSO 0 
t-buOK 112 
2 24 DMSO 0 - 12.0 
4 48 DMSO 19.1 – 75.3 
Catalyst Zn(BF4)2 161 3 24 
H20/ HCl  
pH1 
0 - 1.8 
 
The modification of dextran was confirmed by FT-IR spectroscopy (Figure 3.14.) 
mainly by changes in the fingerprint area. Introduction of alkylglyceryl chains resulted in the 
formation of a new secondary alcohol in the glyceryl pendant, however the increase of hydroxyl 
groups in whole macromolecule did not happen as a hydroxyl group on C2 was transformed to 
new ether bond. The main bands in the IR spectra of dextran can be assigned as follows [387]: 
bands present in the range 400–700 cm-1 are due to skeletal vibrations, (C–C–C), (C–C–O), (C–
O) and (C–C), with a relative intensity as a function of water content. The bands present at 537 
and 550 cm
-1
 were assigned to the (C–C–O) bending vibration. The spectral range 1000–1200 
cm
-1
 has been suggested to be dominated by contributions from, (C– C) and (C–O) stretching 
vibration. The band centred at 1127 cm
-1
 could be assigned to (C–O–C). The vibrational band at 
1012 cm
-1
 in the spectrum was assigned to the (C–O) vibration. It has been suggested that the 
absorption bands in spectral range between 1200 cm
-1
 and 1500 cm
-1
 may be caused mainly by 
(CH) deformation vibrations and (COH) bending vibrations. The spectrum shows one mode 
around 1273 cm
-1
 assigned to the (C–O) stretching mode in the ring. The band at 1343 cm-1is 
supposed to be the (O–C–H) vibration and 1539 cm-1 can be assigned as (CH2) group vibration. 
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The bands present at 2913 cm
-1
 and 3215 cm
-1
 were assigned as (C–H) and (O–H) stretching 
vibrations, respectively. 
 
Figure 3.14: FT-IR spectra of butylglyceryl dextran DEX-OX4. 
In the 
1
H-NMR spectrum of  butylglyceryl-modified dextran, the signal of the anomeric 
(C
1
) proton (4.67 ppm) was well separated from the signals of the other protons on 
glucopyranosyl ring (3.2–3.7 ppm), in agreement with values reported in the literature [387-
389]. The multiplet at 4.96 ppm represents the protons from hydroxyl groups of dextran [388]. 
The NMR spectroscopy of the novel products revealed peaks at 0.86 ppm, 1.29 ppm and 1.45 
ppm which were indicative of the presence of the alkyl group (Figure 3.15; The spectra and 
characterisation are in APPENDIX I and II.) 
 
Figure 3.15. 
1
H-NMR spectrum of DEX-OX4. 
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The degree of substitution with alkylglyceryl chains (expressed as percentage of 
substituted saccharide units bearing alkylglyceryl group -e.g. 100 % means each glucopyranose 
unit is substituted with one alkylglycerol) ranged from 0.7 to 75.1 % for DEX-OX4, and 
between 16.5 and 38.2 for DEX-OX8 depending on amount of base employed in the reaction. 
The degree of substitution found in DEX-OX4 and DEX-OX8 was calculated (Equation 3.3.) 
from the ratio of peak integrals corresponding to the alkyl chain end CH3 group (C4’ group in 
case of DEX-OX4 at 0.86 ppm) and to the anomeric C1group proton of the glucopyranose ring 
(4.67 ppm).  
  [ ]  
 
   ∫   
∫  
       
 
The degree of substitution was found to be dependent on the type of catalyst, the solvent 
used and the excess of reactants It can be assumed that only the hydroxyl group at 
C2participated in the reaction, as the reactivity of the hydroxyl groups in dextran towards 
alkylation agents was determined as decreasing in the order C2>C4>C3[380, 390-392] (likely 
due to the proximity to the anomeric C1 carbon [203]) and the calculated degree of substitution 
(using Equation 3.3.) never exceeded 100 %. 
The molecular weight of modified dextrans (DEX-OX4 and DEX-OX8) were analysed 
by GPC (Figure 3.16.) and compared to the molecular weight of the starting material, following 
a conventional calibration performed using pullulan standards (APPENDIX V). It appeared that 
the molecular weight of the modified dextrans decreased compared to the starting material 
which may indicate the cleavage of glycosidic bonds between individual glucopyranose units in 
strong alkaline conditions. This is in contrast with literature data regarding the stability of 
dextran in alkaline conditions [393]. The decrease of molecular weight can be associated to 
impurities presented in starting material however those could be removed during reaction 
process (dextran was not purified prior to reactions). Another reason may be the change of 
conformation of the product after attaching the alkylglyceryl moieties which could depend on 
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the degree of substitution (Table 3.4.). The different shape of molecule possibly could change 
the interaction with the stationary phase of the GPC column [394]. 
 
Figure 3.16. GPC chromatogram of butylglyceryl-modified dextran (DEX-OX4). 
While molecular weights (MW) of natural dextrans are in the range of 9 - 500 million 
Dalton [395], the values from producers may differ significantly [396]. Indeed, the starting 
material employed in this study (Dextran from Leuconostoc spp. obtained from Sigma) was 
reported by the manufacturer as having a nominal Mw 6000 whereas the molecular weight 
determined by GPC was 10 477 (Table 3.4). 
Table 3.4. Molecular weight of alkylglyceryl-modified dextran derivatives , as determined by 
GPC. 
Compound Mn MW PDI DS [%] 
DEX (Sigma, MW ~6000) 9363 10477 1.12 0 
DEX-OX4 6863 7743 1.13 36.12 
DEX-OX8 9092 10157 1.12 16.58 
 
Another possibility of determining the molecular weight of polysaccharides is by using 
static light scattering [397], however this method is normally limited to low dispersity samples 
as it is based on scattering intensity of a molecule in various concentrations. Our attempts to 
analyse the synthesized alkylglyceryl-dextrans using this method were not successful 
(measurements of samples in different concentrations indicated various dimensions of the 
molecule), likely due to the rather high polydispersity of the samples (0.854; obtained by 
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Dynamic Light Scattering measurements of size of the molecule), such a value is normally 
unsuitable for cumulant analysis. 
 
3.3.4. Synthesis of poly(lactic acid) -graft- alkylglyceryl-modified 
 dextran 
 This section discusses the attachment of alkylglyceryl-modified dextran derivatives 
(DEX-OXn) to poly(lactic acid) (PLA) in order to gain a copolymer which can be formulated 
into nanoparticles. Two approaches were investigated. One approach employed the terminal 
carboxyl group of PLA to bind to a hydroxyl group of one molecule of DEX-OXn. Another 
approach explored binding more DEX-OXn molecules to one molecule of PLA. For that 
purpose it was attempted to increase the number of reactive groups in the PLA molecule. 
Despite partial success in grafting of PLA the attempts were discontinued due to low grafting 
degrees of the products. 
 
3.3.4.1. Synthesis using zero lenght crosslinkers  
The poly(lactic acid) was attached to alkylglyceryl-dextran via carbodiimide chemistry. 
A number of alternatives involving the use of anhydrous organic solvents and zero-length cross-
linkers such as carboiimides [252, 278, 379, 398] were considered. Two candidates were 
examined: dicyclohexyl carbodiimide (DCC) and carbodiimidazole (CDI). The use of DCC was 
reported by Bhat [399] for attaching 4-azidobenzoic acid to dextran; however, one drawback in 
using any carbodiimide in a one-step reaction is that it may introduce intramolecular 
crosslinking between the hydroxyl groups in the modified dextran, especially if the carbodimide 
and base are in excess and the carboxyl groups were already consumed [400]. A solution for this 
problem could be to isolate and purify the intermediate (namely the activated PLA by CDI), 
before reacting it subsequently with alkylglyceryl dextran; this would avoid intramolecular 
crosslinking and would result in more defined modified products. Moreover, using DCC results 
in the formation of toxic dicyclohexylurea as a byproduct that needs to be removed from the 
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solution containing the final product; a better alternative would involve the use of CDI, which 
generates nontoxic CO2 and imidazole byproducts [395]. On the other hand, if CDI activated 
PLA was not isolated in the first step, the intramolecular crosslinking of hydroxyl groups of 
dextran would occur in presence of DMAP as well. 
The reactions were carried out in anhydrous conditions. Purification of products 
included washing of products with water (removed water soluble un-reacted DEX-OX) and 
acetone (removed un-reacted PLA). After drying in a desiccator the final products were 
obtained as off-white powders (DCC route yielded 33-56 % and CDI route yielded 68-81 % 
respectively). The products were characterised by FT-IR and NMR spectroscopies which 
confirmed identical results from both synthetic routes. The FT-IR spectra of the products 
showed a significant band at 1751 cm
-1
 , which can be attributed to C=O stretching vibration of 
PLA, while the broad band at 3352 cm
-1
 represents OH stretching vibrations of DEX-OX 
derivatives (Figure 3.17).  
 
Figure 3.17. Comparison of dextran derivatives FT-IR spectra; dextran (DEX - bottom), 
butylglyceryl dextran (DEX-OX4 - middle) and poly(lactic acid)-graft-butylglyceryldextran 
copolymer (PLA-DEX-OX4-top). 
1
H-NMR spectra of PLA-DEX-OX4 exhibited peaks for both the butylglyceryl-
modified dextran DEX-OX4 (0.87 ppm terminal CH3 of pendent alkylglyceryl; 3.22-5.14 ppm 
glucopyranose ring) in addition to the peaks for poly(lactic acid) (1.44 ppm for CH3 of PLA, 
5.19 ppm CH of PLA). The PLA-DEX-OX8 exhibited similar spectra; DEX-OX8 part of the 
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molecule (0.87 ppm for end CH3 of pendent alkylglyceryl; 3.00-4.92 ppm glucopyranose ring) 
in addition to poly(lactic acid) (1.35 ppm for CH3 of PLA, 5.20 ppm CH of PLA, Figure 3.19). 
(The spectra and characterisation are in APPENDIX III and IV.) The products from CDI route 
only were employed in further formulations. 
A conjugate of poly(lactic acid) and commercial dextran (PLA-DEX) was prepared via 
the CDI route, 
1
H-NMR confirmed peaks for both dextran (3.2 ppm – 5.2 ppm) and poly(lactic 
acid) (1.3ppm and 5.3 ppm). This polymer was used for formulation of nanoparticles which 
served as a control to alkylglyceryl-modification containing nanoparticles. The degree of 
grafting (DG) was expressed as a ratio of PLA and DEX-OXn (defining number of PLA units 
per 100 glucopyranose units of DEX-OXn, according de Jong et al., who used the formula for 
PLA-DEX conjugate [401], Table 3.5). The DG for was calculated using 
1
H-NMR spectra. 
   
 
 ∫  
∫  
      
 
a integration of protons of CH3 group of PLA (at 1.31 ppm) 
C
1
 integration of the anomeric proton of DEX-OXn (at 5.17 – 4.39 ppm) 
 
 
Table 3.5. Degree of grafting of products. Expressed as number of units of PLA per 100 units of 
dextran derivative. 
  
Derivative 
Degree of grafting 
[range] 
PLA-DEX 130-142 
PLA-DEX-OX4 108-120 
PLA-DEX-OX8 88-112 
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Figure 3.18: 
1
H NMR spectra of PLA-DEX-OX4, groups of protons are assigned by numbers 
(dextran part of the molecule) or by letters (PLA).  
 
3.3.4.2. Modification of poly(lactic acid) with maleic anhydride 
A second approach to link alkylglyceryldextran to poly(lactic acid) (PLA) considered 
the possibility of increasing the degree of grafting by modifying PLA with maleic anhydride 
(MA) ‘anchors’ [402] (instead of employing the only one carboxyl group of PLA) followed by a 
carbodiimide-type reaction of the potential carboxylic moieties with alkylglyceryldextran. Free 
radical initiator benzoylperoxide (BPO) was employed to generate ternary radicals at the 
C
2
carbon atom of PLA. Such a radical attacked a double bond of maleic anhydride (Figure 
3.20.). The reaction took place in anhydrous conditions and the product was purified by 
precipitation from ethanol (yields 52-74%). 
                                                               CHEMICAL MODIFICATIONS OF POLYSACCHARIDES 
78 
 
Figure 3.19. Peak assignment of poly(lactic acid) grafted with maleic anhydride  
The degree of grafting with maleic anhydride (DG) was calculated from the 
1
H- NMR 
spectra as a ratio of peak integrals using the signals at 5.1 ppm (assigned to the CH proton in 
poly(lactic acid)) and at 3.8 ppm (assigned to the CH2 protons in maleic anhydride), as described 
in the literature [403]. The degree of grafting was in the range 0.81-2.21 % (expressed as 
percentage of lactic acid units modified with maleic anhydride) – which is in accordance with 
literature (ca. 1-3 % [402], [229]) and this was found to be dependent on the amount of initiator 
(Table 3.6.). However, even when relatively high amounts of initiator were used (up to 20 % 
w/w relative to PLA), the degree of grafting was not increased to a level comparable to natural 
polysaccharides (to serve as a structure to attach multiple molecules of alkylglyceryl dextran 
derivatives to one molecule of poly(lactic acid) via the carbodiimide approach described in 
chapter 3.3.4). 
Table 3.6. Degree of grafting of maleic anhydride onto poly(lactic acid)  
BPO content relative  
to PLA [% w/w] 
Degree of grafting 
[%] 
5  0.81 
10  2.10 
20  2.21 
 
Among the researchers attempting the radical grafting of PLA with MA, the Xufeng 
group reported 1.61-3.16 % [402] and Jun Pan acquired 1.86-2.68 % [229]. A decrease of the 
                                                               CHEMICAL MODIFICATIONS OF POLYSACCHARIDES 
79 
MW of poly(lactic acid) caused by scission from high contents of acidic maleic anhydride was 
also reported in the literature [229, 230, 402], while the low degree of grafting obtained was 
explained by the low activity of BPO [229]. However, employing a different initiator, dicumyl 
peroxide, led to an even lower degree of grafting, 0.5 % [404]).  
The low degree of grafting led to discontinuation of subsequent attaching of 
alkylglyceryldextran derivatives to carboxyl groups of modified poly(lactic acid). 
 
3.4. Conclusions  
Chitosan and dextran were selected as polysaccharides of choice due to their 
biocompatibility, lack of toxicity, biodegradability and presence of easily modifiable functional 
groups such as amino and hydroxyl. The functionalisation of these polysaccharides with 
alkylglyceryl moieties was aimed at providing blood-brain barrier permeating features (as 
expected from the alkylglycerol behaviour reported in the literature) to the modified polymers.  
The n-alkylmethyloxiranes employed for the modification of chitosan and dextran were 
prepared (where not available commercially) in moderate yield (n-octylmethyloxirane ca. 23 – 
49 %) by the nucleophilic substitution of epibromohydrin with the corresponding alcohol. 
Alkylglyceryl-modified chitosan derivatives were synthesised in three successive steps: 
the treatment of commercial chitosan with phthalic anhydride yielding phthaloylchitosan (which 
protects the amino groups while increasing the solubility in organic solvents) was followed by 
treatment with either n-butyloxymethyloxirane, n-pentyloxymethyloxirane or n-
octyloxymethyloxirane to afford the corresponding alkylglyceryl-phtaloyl chitosans, which 
were finally deprotected by removing the phthaloyl groups by treatment with hydrazine (12-39 
%, overall yield). The products (butylglycerylchitosan CS-OX4, pentylglycerylchitosan CS-
OX5 and octylglycerylchitosan CS-OX8, respectively) were analysed by spectroscopic methods 
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(FT-IR,
 1
H-NMR), when the degree of substitution with alkylglyceryl chains was determined as 
being in the range 14 - 88 % (as determined from proton spectra).  
Alkylglyceryl-modified dextran derivatives were prepared by reacting commercially 
available dextran with n-alkyloxymethyloxiranes in the presence of a strong base (such as 
potassium tert-butoxide) in anhydrous DMSO. The products were purified by dialysis and 
freeze-drying, affording butyglyceryl-dextran and octylglyceryl-dextran (yields 35-80 %), 
which were identified by NMR and FT-IR. The degree of substitution was in the range of 1.2-84 
%, as determined by 
1
H-NMR spectroscopy. Using a different base in environment of DMSO 
(such as 4-(dimethylamino)pyridine or pyridine) or employing Zn(BF4)2 as a catalyst in an 
aqueous system did not afford higher degrees of substitution compared to using potassium tert-
butoxide. The synthesised alkylglyceryl-dextran derivatives were analysed by Gel Permeation 
Chromatography against pullulan standards, and the results indicated a decrease in the 
molecular weight of the products (average MW 6.07 kDa for butylglyceryl-dextran DEX-OX4 
and MW 9.73 kDa for octylglyceryl-dextran DEX-OX8) compared to the starting material (MW 
10.7 kDa, dextran from Sigma, nominative MW 6 kDa). However the reaction conditions were 
not expected to break the bonds between the polysaccharide units therefore the results could 
represent different interaction of materials with the separation column (related to the degree of 
substitution), rather than expressing any change of molecular weight. 
The alkylglyceryl-dextran derivatives further reacted with poly(lactic acid) in the 
presence of carbodiimide zero-length crosslinkers (such as dicyclohexylcarbodiimide (DCC) 
and carbonyldiimidazole (CDI)) to afford a graft co-polymer that can be formulated into 
nanoparticles (normal dextran is water soluble and does not self-aggregate into nanoparticles, 
nor possesses any hydrophobic moieties or permanent charges that could be used for ionic 
crosslinking). Both CDI and DCC afforded successful binding of both polymers as confirmed 
by spectroscopic methods. However, using CDI in Nagahama’s two step procedure, that 
involves isolating the activated poly(lactic acid), appears to exclude the possibility of internal 
cross-linking between the hydroxyl groups of the alkylglyceryl-modified dextran potentially 
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caused by an excess of carbodiimide to yield alkylglyceryl-dextran-graft-poly(lactic acid) 
derivatives. The degree of grafting was calculated using 
1
H-NMR spectroscopy (degree of 
grafting of butylglyceryl-dextran-graft-poly(lactic acid) was in range 88-102 and octylglyceryl-
dextran-graft-poly(lactic acid) was in range 109-120 units of poly(lactic acid) per 100 units of 
modified dextran).  
 A possibility of attaching multiple alkylglyceyl-dextran molecules to one molecule of 
poly(lactic acid) was exploited by increasing number of reactive groups in poly(lactic acid) 
molecule by free radical grafting. Poly(lactic acid) was grafted with maleic anhydride via a free-
radical reaction in the presence of benzoyl peroxide as an initiator; the degree of grafting was 
low (0.8-2.2 %). Due to limited success in the grafting step the subsequent modification with 
alkylglyceryl-dextran was not continued. 
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4 
PREPARATION AND CHARACTERISATION OF 
POLYSACCHARIDE NANOPARTICLES 
             
4.1. Materials and instrumentation 
Trehalose, sodium tripolyphosphate (TPP), chitosan, dextran, Evans Blue, Rhodamine 
B, dextran sulphate, fluorescein, polyvinylalcohol (PVA) were purchased from Sigma Aldrich. 
Poloxamer 188 (P188) and Poloxamer 407 (P407) were obtained from BASF. Poly(lactic acid) 
(PLA) was received from Purac and doxorubicin hydrochloride was obtained from LGM 
Pharma, USA. Chitosan oligomer (o-CS, Mw 700 Da) was sourced from the stock previously 
synthesised in-house. Solvents such as DMSO, acetone, acetic acid were obtained from Fisher 
Scientific. Cellulose nitrate membrane filters (0.2 µm) were obtained from Whatman, UK.  
Dialysis was performed employing dialyzing Visking tubing MWCO 12-14 kDa or 3 
kDa, Medicell International Ltd, UK; the container with deionised water (10.0 L) was 
exchanged 3 times a day. The purified water was obtained from PURELAB Optima lab system. 
Ultracentrifugation was performed using a X3 Ultracentrifuge (Beckman Coulter Ltd. UK) with 
Ti 70.1 rotor at 20 °C in vacuo (40 000 rpm, 30 min). Pre-centrifugation was performed with an 
Eppendorf MiniSpin centrifuge equipped with a F-45-12-11 rotor (Eppendorph UK). Freeze 
drying of aqueous samples was performed using a Modulyod Freeze Dryer equipment attached 
to an EDWARDS RV3 vacuum pump. Organic solvents were removed under reduced pressure 
using a Büchi Rotovapor R-200 and a Sogevac Saskia PIZ 100 vacuum pump equipped with a 
liquid nitrogen trap. Sonication was performed using a Grant ultrasonic bath XB3 from Farnell, 
UK. The high voltage power supply PSIFC30R04.0-22; Glassman High Voltage Inc, USA was 
used for electrospraying experiments fed by a syringe pump Alladin 300; World Precision 
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instruments, USA. A combined linear shaking thermostatted bath Grant OLS 200, Farnell, UK, 
was used for dye release studies. An Lambda 650 Ultra Violet/Visible Spectrometer from 
Perkin Elmer was used for UV/VIS spectroscopy measurements (Perkin Elmer UV Lab 
software). 
Dynamic Light Scattering (DLS) was used to determine the hydrodynamic diameter of 
nanoparticles - a Malvern Zetasizer Nano ZS instrument from Malvern, UK, equipped with a 
633 nm He-Ne laser (173° back scattering angle detection) was used for this purpose. Samples 
were analysed in triplicates in polycarbonate disposable clear cuvettes at 25 °C following an 
equilibration time of 2 min; the equipment was powered by Zetasizer software v. 6.01 software. 
Results of cumulative analysis were expressed as Z-average mean (Z-av.), the polydispersity 
index (PDI) was also determined. Zeta potential (ZP) was determined from electrophoretic 
mobility (EPM) measurements, which were performed with the same instrument. Samples were 
measured in polycarbonate disposable clear zetasizing cuvettes (software analysis employed 
Smoluchowski model, Henry’s function f(ka) = 1.5). The titrations of colloidal systems were 
carried out to assess the Z-av, and ZP in conditions of various pH; the experiments employed 
MTP-2 (Multi Purpose Titrator-2, Malvern, UK) equipped with a solvent degasser. The sample 
(10 mL) was titrated automatically with aqueous NaOH solutions (5 mM and 50 mM) from pH 
3 to pH 8, and with aqueous HCl solutions (5 and 50 mM) from pH 8 to pH 2. All solutions 
were filtered via 0.2 μm PES filters (Whatman) prior to use. Nanoparticle Tracking Analysis 
(NTA) was performed using a Nanosight instrument equipped with a thermostatted LM-14 unit 
with 532 nm green laser at 25 °C. The image capture (length 60 s) was achieved using a CCD 
Marlin camera; the instrument was powered by NTA 2.2 analytical software. 
The morphology of nanoparticles was investigated by Scanning Electron Microscopy. 
Nanoparticles recovered from freeze drying were redispersed in ultrapure water, then a droplet 
was placed onto a metallic stub and dried in a nitrogen flow. As organic samples need to be 
covered by a thin conductive alloy layer, the nanoparticles were coated with golden alloy in 
argon atmosphere (current 20 mA, pressure 10
-3
 Pa, 5 min) using a Quorum coater Q150RES 
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sputtering equipment from Quorum Technologies Ltd., UK. The samples were investigated 
using a JEOL-JSM-6060LV SEM Microscope (high vacuum, voltage 15 kV, working distance 
11 mm, spot size 40) from Jeol, Japan. The shape of dried nanoparticles was also investigated 
using AFM: nanoparticles were dispersed in ultrapure water, and one drop of the suspension 
was placed on a mica surface and dried in a nitrogen flow. The deposits were then investigated 
with a MultiMode/NanoScope IV Scanning Probe Microscope (Digital Instruments, USA) and 
in tapping mode in air under ambient conditions (T = 23 °C, RH = 21%) using the J-scanner 
(max. xy = 200 mm) using Si cantilevers with integrated tips (t = 3.5–4.5 mm, l = 115–135 mm, 
w = 30–40 mm, f = 200–400 kHz, k = 20–80 N m-1, R o 10 nm; Model: RTESP, Veeco 
Instruments, France) and an RMS amplitude of 0.8 V was used. The results were analysed using 
a Nanoscope Veeco v 710 software from Digital Instruments, USA.  
The statistical analysis was performed using OriginPro 7 software from OriginLab, 
USA by one-way analysis of variance (ANOVA) followed by post hoc Tukey test (p values 
were set at level 0.05 unless stated otherwise). Measurements are presented as mean ± standard 
deviation unless stated otherwise. 
 
4.2. Methods 
4.2.1. Nanoparticles formulated from alkylglyceryl-modified   
chitosan derivatives 
Nanoparticles from chitosan (CS) and alkylglyceryl-modified chitosan (CS-OXn) 
derivatives were prepared by ionotropic gelation using counterions such as sodium 
tripolyphosphate (TPP) or dextran sulphate (DEX-S). Alkylglyceryl-modified chitosan 
derivatives were also employed for coating PLA core nanoparticles in the presence of various 
surfactants. As previous studies [129, 173] indicated nanoparticles formulated with TPP could 
have low stability at physiological pH, the possibility of using DEX-S as a different cross-
linking agent to provide more stable structures was investigated here.  
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4.2.1.1. Nanoparticles formulated from alkylglyceryl-modified chitosan crosslinked 
 with sodium tripolyphosphate 
Solutions of either CS or CS-OXn (n = 4, 5, 8; 0.28% w/v) were prepared by dissolving 
the corresponding polysaccharide in acetic acid (AcOH, 0.35 % v/v) overnight under stirring. 
All solutions were filtered (0.2 μm PES) prior to use. Typically, 14 mL of TPP solution (0.063 
% w/v) was added dropwise by means of a peristaltic pump over 30 minutes into 35 mL of 
polysaccharide solution, under moderate stirring, in a 55 mL plastic container. The solutions 
were then mixed for an additional 30 minutes. 
4 Na+  
Figure 4.1. The chemical structure of Evans Blue. 
For the preparation of fluorescently-labelled nanoparticles, an Evans Blue (Figure 4.1.) 
solution (0.01 % w/v) in HPLC water was added to the polysaccharide solution (0.28 % w/v, 
prepared as described above) and stirred for 30 minutes before the dropwise addition of TPP. 
The formulations were then centrifuged (4 000 RPM; 15 min) using a Jouan B4 centrifuge to 
remove the large aggregates; the supernatant was separated and the hydrodynamic diameter 
(DLS, NTA), zeta potential (ZP) and polydisperisty (DLS) of nanoparticles were measured in 
the preparation media (pH 3-4).  
The nanoparticles were then isolated by ultracentrifugation (rotor 70.1 Ti, 40 000 RPM 
for 30 min, at 20 °C) washed with water and lyophylised. Dialysis was also investigated as an 
alternative purification method (3 days; 10.0 L of deionised water exchanged 3 times per day), 
followed by lyophilisation. Nanoparticles were characterised again after redispersion in PBS 
(pH 7.4, saline 0.9%). 
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The loading of Evans Blue into the nanoparticles was determined by UV/Vis 
spectrophotometry (λ=640 nm, APPENDIX VI). The lyophilised pellets of nanoparticles were 
dissolved in acetic acid (55 %) in concentration 1 mg/ mL. The obtained absorbance was used to 
acquire the concentration of Evans Blue in the sample according the calibration curve in 55 % 
acetic acid. The loading is expressed as ratio of mass of the dye in respect to mass of the whole 
pellet (% w/w). 
 
4.2.1.2. Nanoparticles formulated from alkylglyceryl-modified chitosan by ionic 
 crosslinking with dextran sulphate 
 
Butylglycerol-modified chitosan (CS-OX4) was dissolved (0.15 % w/v) overnight in 
acetic acid (0.32 %, v/v, 25 mL) in a conical flask under vigorous stirring. Dextran sulphate 
(DEX-S) was dissolved in A) water (25 mL) or B) in acetic acid (0.32 %, 25 mL) in various 
concentration ratios (CS-OX4 : DEX-S = 1:5; 1:10; 1:20). The solution of CS-OX4 was added 
dropwise using a peristaltic pump to the DEX-S solution, under vigorous stirring. After 
completing the addition, the mixture was allowed to stir for an additional 30 minutes.  
For labelling the nanoparticles with Evans Blue, the dye was dissolved in the DEX-S 
phase (25 mL) in 0.1 % (w/v) concentration prior to the dropwise addition to the CS-OX4 
solution. The dispersion was centrifuged (3 000 RPM; 3 min, Eppendorph MiniSpin) prior to 
characterization by DLS to determine the hydrodynamic diameter and polydispersity and by 
EPM to determine zeta potential in the preparation medias well. Further isolation and 
purification of nanoparticles were performed by ultracentrifugation followed by freeze-drying 
the pellet. The redispersion of the pellet in PBS (pH 7.4, saline 0.9 %) was carried out in the 
sonic bath for 15 min.  
The loading of Evans Blue into the nanoparticles was determined by UV/Vis 
spectrophotometry (λ=640 nm). The lyophilised pellets of nanoparticles were dissolved in acetic 
acid (55 %) in concentration 1 mg/ mL. The obtained absorbance was used to determine the 
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concentration of Evans Blue in the sample according the calibration curve. The loading is 
expressed as ratio of mass of the dye in respect to mass of the whole pellet (% w/w). 
Nanoparticles from CS-OX crosslinked with both TPP and DEX-S were investigated for 
their stability to various pH conditions by titration with NaOH solution. An automatic MTP-2 
titrator equipped with a degasser and a flow-cell were employed for measuring the 
hydrodynamic diameter and zeta potential as a function of pH using a Malvern Zetasizer nano 
ZS instrument. The pH was varied from pH 3.0 to 8.0 by using NaOH solutions (0.05 M and 
0.005 M). 
 
4.2.1.3. Nanoparticles from poly(lactic acid) coated with akylglyceryl- 
 modified chitosan 
 
Nanoparticles from poly(lactic acid) (PLA) were prepared by nanoprecipitation [245]. 
Briefly, PLA was dissolved in acetone (5 mL, 10.0 mg/mL) and the solution was added 
dropwise into deionised water (25 mL) under stirring (all solutions were filtered using 0.2 µm 
cellulose nitrate membrane filters prior to use). The mixture was stirred for an additional 30 
min, and the residual acetone was removed under reduced pressure. The final concentration of 
nanoparticles was adjusted (25 mL, 2.0 mg/mL) with ultrapure water. The formulations were 
freeze-dried after characterisation by DLS and EPM. 
Nanoparticles prepared from PLA were dispersed in water (2.0 mg/mL) with surfactants 
(Poloxamer 407 (P407); Poloxamer 188 (P188); polyvinyl alcohol (PVA); 0.1 mL; 1.0 mg/mL 
or 10.0 mg/mL). The mixture was incubated with 100 µL butylglyceryl chitosan (CS-OX4; DS 
85.0 %; dissolved in 0.35 % w/v acetic acid) solution (15.0 mg/mL) for 5 minutes under 
stirring. The samples (1.5 mL) were centrifuged (3 000 RPM; 3 min, Eppendorph MiniSpin) to 
remove possible aggregates and the supernatant was characterised by DLS and EPM for 
hydrodynamic diameter and zeta potential, respectively. 
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Redispersion of PLA nanoparticles coated with butylglyceryl-modified 
chitosan in the presence of surfactants. A crude suspension of butylglyceryl chitosan (CS-
OX4) coated PLA nanoparticles was centrifuged (1.4 mL, 7 500 RPM; 10 min) on a trehalose 
bed (0.1 mL; 0.7 g/mL) and the pellet was transferred into an Eppendorf tube. After the addition 
of 1.5 mL of water, the tube was vortexed for 30 sec and sonicated for 5 minutes to redisperse 
the nanoparticles. The sample was centrifuged at low speed (3 000 RPM, 3 min, Eppendorph 
MiniSpin) to remove potential non-dispersed aggregates and the supernatant containing the CS-
OX4-coated PLA nanoparticles, redispersed in water, was analysed to measure the size and zeta 
potential with Malvern Zetasizer Nano ZS. 
pH titrations of PLA nanoparticles coated with butylglycerylchitosan.10 mg of PLA 
nanoparticles coated with CS-OX4 was redispersed in water (10 mL, 1.0 mg/mL). The 
suspension was employed in a closed circuit of Zeta sizing cuvette which was connected to 
Malvern Zetasizer ZS attached to a titrator (MTP-2 from Malvern Instruments). The titration 
started acidic (adjusted by 0.05 M HCl), from pH approx. 4.0 was increased to pH 8.5 using 
0.05 M and 0.005 M NaOH as a titrant. Zeta potential and size of nanoparticles were measured 
after pH increment of about 0.3.  
 
4.2.2. Nanoparticles formulated alkylglyceryl-modified dextran
 derivatives 
 Alkylglyceryl-modified dextran derivatives were formulated into nanoparticles by 
complexation with chitosan (chapter 4.2.2.1.) and by nanoprecipitation with poly(lactic acid) 
(chapter 4.2.2.2.). The nanoparticles from copolymers of alkylglyceryl-modified dextran and 
poly(lactic acid) were formulated via dialysis method, nanoprecipitation and electrospraying 
(chapter 4.2.2.3.). 
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4.2.2.1. Nanoparticles formulated from alkylglyceryl-modified dextran  
 and chitosan oligomer 
Nanoparticles were prepared from a combination of alkylglyceryl-modified dextran 
(butylglyceryl dextran DEX-OX4 was chosen as a model candidate) and chitosan oligomer (o-
CS, MW ca. 700) in the presence of Poloxamer 407 (P 407). To a solution of DEX-OX4 (0.1 % 
w/v, 15 mL) and P 407 (varying concentrations 0.1 - 0.6 % w/v) in HPLC water, a solution of 
chitosan (0.02 % w/v, 5 mL) in acetic acid (0.063 % v/v) was added dropwise with stirring. The 
mixture was stirred for further 30 minutes at room temperature, the nanoparticles were isolated 
by ultracentrifugation (40 000 RPM; rotor 70.1 Ti, 10 min) into a trehalose bed; after discarding 
the supernatant the pellet was redispersed in water within an ultrasonic bath (Gant XB2). 
 . HCl
 
Figure 4.2. The structure of Doxorubicin hydrochloride. 
Doxorubicin-loaded nanoparticles from butylglyceryl-modified dextran and 
chitosan. Doxorubicin is an anthracycline antibiotic used as an anticancer agent [405] and was 
supplied as a hydrochloride salt. To remove the hydrochloride the drug was dissolved in water 
(50 mg/ 1.0 mL) and triethylamine was added (0.1 mL); Doxorubicin free base was extracted 
(3 x) with chloroform using a separating funnel, the combined organic layers were dried over 
magnesium sulphate and the organic solvent was removed in a roto-evaporator to afford the free 
base (yield 68%). Doxorubicin free base (1.0 mg), butylglyceryl-modified dextran (DEX-OX4, 
15 mg) and Poloxamer 407 (15.0 mg) were dispersed in water (15.0 mL) by sonication (30 
min). The nanoparticles were formed after the dropwise addition of chitosan (3.0 mg) dissolved 
in acetic acid (0.03 %, 3.0 ml). Drug loading was determined (as %, w/w) by measuring the 
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non-entrapped drug in the supernatant after via fluorescent method (excitation 480 nm, emission 
590 nm, Optima Fluorimeter) after removing the nanoparticles by ultra-centrifugation (40 000 
RPM, 30 min, rotor 70,1 Ti). A calibration curve (APPENDIX VII) was constructed and 
employed for this purpose.  
 
4.2.2.2. Nanoparticles formulated from poly(lactic acid) and akylglyceryl-modified 
 dextran 
Nanoparticles were obtained by nanoprecipitation of PLA into a DEX-OX4 solution, as 
follows: a PLA solution of acetone (5.0 mg/mL) was added dropwise to a solution of DEX-OX4 
(varying concentrations: 0.07, 0.47, 1.00; 1.40, and 5.00 mg/mL) in water (15 mL) under 
stirring, which was then continued for an additional one hour; the remaining organic solvent 
was removed in vacuo in a rotary evaporator. The nanoparticles were isolated by centrifugation 
(10 000 RPM; 15 min) using an Eppendorph MiniSpin centrifuge and then were resuspended in 
HPLC water prior to the further analysis. The entrapment of (normally water-soluble) 
butylglyceryl dextran (DEX-OX4) in the nanoparticles was verified by FT-IR analysis (ATR 
mode) of the centrifuged (10 000 rpm; 10 min; Eppendorph MiniSpin) and then freeze-dried 
nanoparticles. The pellet of nanoparticles was analysed after first and after additional three 
redispersion-centrifugation-lyophilisation cycles and in the presence of both polymers (PLA and 
DEX-OX4). 
 
4.2.2.3. Nanoparticles formulated from poly(lactic acid)-graft-alkylglyceryl-
 modified dextrans 
Three methods were employed to formulate nanoparticles from poly(lactic acid)-graft-
alkylglyceryl-modified dextran (PLA-DEX-OX4): the solvent displacement (via dialysis), the 
nanoprecipitation and the electrospraying.  
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A. Solvent displacement method (via dialysis).PLA-DEX-OX4 (either 0.5; 1.0; 3.0; or 5.0 
mg/mL) was dissolved in DMSO (10.0 mL), the solution was filtered through a 0.2 μm filter 
(PP membrane) and then dialysed (MWCO 12 000 Da) against deionised water for 72 h (10.0 L; 
exchanged 3 times per day) to remove the DMSO (nanoparticles from PLA-DEX and PLA-
DEX-OX8 were prepared from concentration 1.0 mg/mL). After 48 h, the content of the 
dialyzing tubing was freeze-dried and the solid material was redispersed as nanoparticles in PBS 
(0.9 % NaCl; pH 7.4) or in ultrapure water (conductivity 18 MΩ; pH 7.0). The suspension was 
centrifuged at low speed (3 000 RPM; 5 min, Eppendorph MiniSpin) to remove any potential 
large aggregates formed, then the nanoparticles were analysed by DLS, NTA and EPM.  
B. Nanoprecipitation method. PLA-DEX-OX4 was dissolved in DMSO (3.0 mL, 
concentration 5, 10, 20 mg/ mL), the solution was filtered via a 0.2 μm filter (PP membrane, 
Whatman) and added dropwise into ultrapure water (30.0 mL) under vigorous stirring, which 
was continued for an additional 30 min after addition. The dispersion was then centrifuged 
(3 000 RPM; 5 min; Eppendorph MiniSpin) and the supernatant containing nanoparticles was 
either dialysed (Medicell, MWCO 12 kDa) for 72 h against deionised water (10.0 L; exchanged 
3 times per day), or ultracentrifuged (40 000 RPM, 30 min, rotor 70,1 Ti). Finally, the products 
of purification were freeze-dried to obtain a white-off powder, which was redispersed in PBS 
(pH 7.4; 0.9 % saline) or in ultrapure water (conductivity 18 MΩ, pH 7.0). The suspension was 
centrifuged at low speed (3 000 RPM; 5 min, Eppendorph MiniSpin) to remove any aggregates, 
then the supernatants containing nanoparticles were analysed by DLS, NTA and EPM. 
C. Electrospraying method. Nanoparticles from PLA-DEX-OX4 were prepared using the 
setup presented in Table 4.1. A solution (1.0 mL) of PLA-DEX-OX4 in DMSO (5 % w/v) was 
injected with a syringe pump (Alladin 300; World Precision instruments, USA) into a needle 
which was connected to the high voltage generator (PSIFC30R04.0-22; Glassman High Voltage 
Inc) and the sprayed material was collected onto water surface (a circular dish containing water, 
143.1 cm
2
; 50 mL). The purification of the resulting dispersion was performed either via 
ultracentrifugation (Beckman, Rotor 70.1 Ti; 40 000 RPM; 30 min; 20 °C) or via dialysis (for 3 
 PREPARATION AND CHARACTERISATION OF POLYSACCHARIDE NANOPARTICLES 
92 
 
days, 10.0 L of deionised water exchanged 3 x per day) and freeze-drying. The nanoparticles 
were then redispersed in ultrapure water or PBS (pH 7.4; 0.9 % saline) and the suspension was 
centrifuged at low speed (3 000 RPM, 3 min) to remove any potential aggregates prior to being 
analysed by DLS, EPM and NTA.  
Table 4.1. Electrospraying method - experimental conditions. 
Electrospraying of polymeric solutions took place under specific conditions 
Mixture 
5 % w/v PLA-DEX-OX4 in DMSO 
1 % w/v dye (Rhodamine B Base or Doxorubicin Base) 
Flow rate 15 µL/min 
Needle inner diameter 380 µm 
Air gap distance 20 cm 
Electric field 18 kV 
Volume of ultrapure water for 
nanoparticle collection 
50 mL 
Surface area of ultrapure water 
collecting the nanoparticles 
143.14 cm
2
 
Injecting time (to allow passage of 
1 mL of solution) 
67 minutes 
 
pH stability. Zeta potential was acquired from electrophoretic mobility measurements 
using a Malvern Zetasizer Nano ZS instrument. The zeta potential was assessed in range of pH 
by the Zetasizer instrument equipped with a flow cell and an MTP-2 automatic titrator. The 
suspensions of PLA-DEX-OX4 nanoparticles redispersed in ultrapure water (10.0 mg; 10.0 mL; 
pH 8, as adjusted with 0.005 M NaOH) were titrated with HCl 0.05 M from. pH 8 to pH 2, 
while measuring the diameter and zeta potential of nanoparticles (at 0.3 pH increment).  
Purification and redispersion. For each of the three methods, yields after 
purification processes (as mentioned above) were determined. One route was performed via 
ultra-centrifugation (40 000 RPM, 30 min, 20°C, Beckman 70.1 Ti rotor). Alternatively, the 
dialysis (10.0 L, exchanged 3 x daily for 3 days) was employed as a purification method. The 
yields were determined as ratio of starting material to final product in per cent. 
Loading and release of fluorescent molecules. Fluorescent dyes such as 
Fluorescein, Rhodamine B or Doxorubicin have been employed as markers and model actives to 
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study drug loading and nanoparticle-cell interactions. All three model molecules were used for 
loading by solvent displacement via dialysis and nanoprecipitation; Rhodamine B and 
Doxorubicin were used for electrospraying experiments. In the encapsulation experiments the 
dyes were added (10 % w/w in respect to the polymer) to the organic phase (DMSO). 
Doxorubicin was supplied as a hydrochloride salt therefore the hydrochloride group was 
removed by treatment with triethylamine [253] as described in section 4.2.2.1.Drug loading was 
determined spectrophotometrically (Rhodamine B 318 nm; FITC 493 nm; Doxorubicin 478 nm, 
APPENDIX VIII) as follows: the nanoparticles were separated by ultracentrifugation (40 000 
RPM, 30 min, 20°C, Beckman, rotor 70.1 Ti) and the pellets freeze-dried. The pellets were 
weighted and dissolved in DMSO to determine the amount of the dye in the pellet by UV/Vis 
spectroscopy. The obtained results are plotted against the calibration curves of the fluorescent 
molecules in DMSO. The corresponding calibration curves are presented in APPENDIX IX. 
For the release studies the freeze-dried nanoparticles from PLA-DEX-OX4 were 
redispersed (1.0 mg/mL) in PBS (15 mL, pH 7.4, saline 0.9 %) and distributed in 1.0 mL 
aliquots into 15 Eppendorph tubes, which were placed in a thermostatted shaking water (37 °C). 
Tubes were individually removed at pre-determined time points and centrifuged (13 000 RPM; 
15 min; Eppendorph MiniSpin). Three aliquots (0.1 mL each) were removed from the 
supernatant and placed into a 96 well-plate which was kept in the freezer (-20 °C) until all 
samples were collected; the plate was then equilibrated at room temperature (25 °C) and 
subsequently analysed using an Optima fluorimeter. The release profiles of dyes in PBS were 
based on calibration curves of the fluorescent molecules in PBS (APPENDIX IX).  
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4.3. Results and discussion 
 A series of nanoparticulate formulations were prepared from the materials considered in 
this study (Table 4.2.), either on their own or in combination with poly(lactic acid): 
(alkylglyceryl chitosan derivatives CS-OX4, CS-OX5, CS-OX8; alkylglyceryl dextran derive 
DEX-OX4 and poly(lactic acid)-graft-alkylglyceryl dextran PLA-DEX-OX4 and PLA-DEX-
OX8) using various methods (ionotropic crosslinking, nanoprecipitation, solvent displacement, 
and electrospraying). Nanoparticles were characterised in terms of hydrodynamic diameter and 
zeta potential in simulated physiologically-relevant conditions; promising nanoformulations 
were studied for their loading and release properties using fluorescent actives and markers.  
Table 4.2. Alkylglyceryl-modified materials and methods for nanoparticle formulation. 
Material Method to form nanoparticles 
Alkylglycerylchitosan 
(CS-OXn) 
Ionotropic crosslinking with TPP 
Ionotropic crosslinking with DEX-S 
Coating of nanoparticles from PLA 
Alkylglyceryldextran 
(DEX-OXn) 
Mixing with CS 
Coating of nanoparticles from PLA 
Poly(lactic acid)-graft-alkylglyceryl dextran 
(PLA-DEX-OXn) 
Solvent displacement via dialysis 
Nanoprecipitation 
Electrospraying 
 
4.3.1.  Nanoparticles formulated from alkylglyceryl-modified chitosan
 derivatives 
Nanoparticles were formulated from alkylglyceryl-modified chitosans (CS-OX4, CS-
OX5 and CS-OX8) by crosslinking with either sodium tripolyphosphate (TPP) or dextran 
sulphate (DEX-S). These nanoparticles were studied for size, zeta potential, loading with dye 
Evans Blue and stability in various pH conditions. Furthermore, nanoparticles of poly(lactic 
acid) (PLA) were coated with CS-OX4 and the influence of surfactants upon the pH stability of 
the colloidal system was studied. 
 
 
 PREPARATION AND CHARACTERISATION OF POLYSACCHARIDE NANOPARTICLES 
95 
 
4.3.1.1. Nanoparticles formulated from alkylglyceryl modified chitosan  
by crosslinking with sodium tripolyphosphate 
 
Nanoparticles from alkylglyceryl-modified chitosans (CS-OX4, CS-OX5 and CS-OX8) 
were prepared by crosslinking with TPP following a method reported in the literature [111]. As 
prepared (pH 4; in 0.035 % acetic acid v/v), nanoparticles formulated from these chitosan 
derivatives exhibited submicron diameter and positive zeta potential (Table 4.3.), however 
noticeable aggregation was observed (sometimes into the micron range) when the pH was 
changed to neutral by redispersion in PBS (pH 7.4) (Table 4.3.). 
 
Table 4.3. Characteristics of nanoparticles formulated from chitosan and alkylglyceryl 
chitosans with different degree of substitution by crosslinking with TPP  (n=3). using different 
techniques (DLS – Dynamic Light Scattering; NTA – Nanoparticle Tracking Analysis, EPM - 
Electrophoretic Mobility Measurements, PDI – polydispersity, ZP – Zeta Potential). 
 
 
pH 4.0 pH 7.4  
 
DLS NTA EPM DLS 
 
Z-av. ± SD 
[nm] 
PDI 
 
Diam. ± SD 
[nm] 
ZP ±SD 
[mV] 
Z-av. ±SD 
[nm] 
CS 143± 2 0.308 153 ± 75 40.1 ± 1 963 ± 145 
CS-OX4 (15%) 133 ± 3 0.284 128 ± 54 36.0 ± 0 1555 ± 396 
CS-OX4 (95%) 151 ± 2 0.200 124 ± 55 36.9 ± 1 1101 ± 367 
CS-OX5 (67%) 100 ± 10 0.227 100 ± 20 39.0 ± 6 871 ± 325 
CS-OX8 (127%) 188 ± 50 0.367 125 ± 54 42.7 ± 3 1273 ± 290 
 
The macroscopic aggregation of the nanoparticles was observed during the purification 
of the nanoparticles by dialysis. The centrifugation, employed as second purification method, 
yielded pellets for further freeze-drying (Table 4.3.). The yields were calculated as a ratio of 
mass of material used in formulation and mass of the pellet after freeze drying (expressed in per 
cent). It was apparent that the alkylglyceryl substitution of chitosan had influenced the yields of 
nanoparticles as the highest yields were obtained from unmodified chitosan derivatives and the 
lowest from the CS-OX8. In some cases there was no pellet at all (Table 4.4.). 
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Table 4.4. Percentage recovery of polymeric materials used for crosslinking with TPP; pellet 
after centrifugation (n=3). 
 
 
The morphology of alkylglyceryl-chitosan nanoparticles. Scanning Electron 
Microscopy investigation of butylglycerolchitosan (CS-OX4) nanoparticles after lyophilisation 
revealed spherically shaped particles with a diameter in the micron range (an example of CS-
OX4 is given in Figure 4.3.). Such findings can confirm the studies using Dynamic Light 
Scattering on nanoparticles redispersed in neutral media conditions (Table 4.3.).  
 
Figure 4.3. SEM photograph of nanoparticles (ARROW) prepared from CS-OX4 crosslinked 
with TPP. 
 
4.3.1.2. Nanoparticles formulated from alkylglyceryl modified chitosan by 
 crosslinking with dextran sulphate 
 
Nanoparticles from butylglyceryl modified chitosan (CS-OX4) and dextran sulphate 
(DEX-S) were prepared by ionic crosslinking in two modifications: the DEX-S was dissolved 
either in water or in a diluted acetic acid (0.035 % v/v) while CS was dissolved in diluted acetic 
acid in all the cases. Nanoparticles were characterised by DLS and it was found that, when 
Material Yield of 
nanoparticles 
w/w [%] 
CS 6-30 
CS-OX4 0-14 
CS-OX5 0-19 
CS-OX8 0-8 
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acetic acid was used a solvent for both CS-OX4 and DEX-S, particle size was generally smaller 
and it was dependent on the ratio of CS-OX4 and DEX-S (Table 4.5.); no such a trend was 
observed when DEX-S was dissolved in water. The influence of the solvent on the diameter of 
nanoparticles was significant when the same concentrations were compared (ANOVA, p<0.05). 
Electrophoretic mobility measurements in acidic conditions (pH 3-4) revealed in all cases a 
negative zeta potential of about – 40 mV.  
 
Table 4.5. Nanoparticles of CS-OX4 crosslinked with DEX-S, influence of ratio (n=3; ±SD).  
DEX-S 
solvent 
CS-
OX4:DEX-S  
Ratio 
Average 
PDI 
Average Zeta Potential 
[mV] 
Average diameter  
DLS [nm] 
HPLC 
water 
1:5 0.54±0.22 - 47.0 ±3.0 505 ±12 
1:10 0.56 ±0.12 - 47.6 ±4.6 471 ±22 
1:20 0.60±0.15 - 35.1 ±3.1 547 ±17 
Acetic 
Acid 
1:5 0.41±0.18 - 40.3 ±1.1 224 ±16 
1:10 0.34±0.24 - 43.6 ±4.1 315 ±90 
1:20 0.53±0.20 - 47.2 ±4.4 434 ±33 
 
These results appear similar to those obtained by Chen et al. [177] for particles prepared 
from normal chitosan (CS) and dextran sulphate (DEX-S), when it was observed that an excess 
of CS led to larger particles. His research focused on investigation of ratios DEX-S to CS. In an 
excess of chitosan (the ratio CS: DEX-S was 5:3) the size of particles was found in micrometre 
range (2100 nm ± 400, PDI 0.86) and Zeta potential was positive (50 mV). On the other hand, 
the excess of DEX-S produced nanoparticles 250-350 nm with negative Zeta potential (-25 to -
47 mV). The influence of the ratio of the polysaccharides on the diameter was also found 
(Table 4.5.). The ratio 1:20 exhibited the largest diameters in each environment group 
(ANOVA, p<0.05). This would also support the previous findings that the size of nanoparticles 
was dependent on the total concentration of polymers in solution. That could be explained by 
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the fact that diluted solutions tend to create small coacervation nuclei, while highly concentrated 
solutions support complexation and coacervation of large nanoparticles [177].  
 
Morphology of nanoparticles of alkylglyceryl-chitosan crosslinked by dextran 
sulphate. SEM analysis of nanoparticles prepared from CS-OX4 crosslinked with DEX-S 
(prepared in acetic acid, ratio 1:5) and isolated by centrifugation revealed that these 
nanoparticles were compacted together during separation; it appears that the subsequent drying 
of the pellet collapsed the material and destroyed the structure of individual particles (Figure 
4.4.).  
 
Figure 4.4. SEM micrograph representing the collapsed nanoparticles (ARROW) prepared from 
CS-OX4 crosslinked with DEX-S. 
 
Stability of nanoparticles of alkylglyceryl-chitosan crosslinked by dextran 
sulphate. Nanoformulations prepared from butylglyceryl-modified chitosan (CS-OX4) 
crosslinked with either sodium tripolyphosphate (TPP) or dextran sulphate (DEX-S) were 
investigated for their stability in different pH conditions. Nanoparticle diameter and zeta 
potential were measured while varying the pH in the range of approx. pH 4 - 9 using a titration 
with NaOH solutions. The comparison of these results indicated an improved stability of CS-
 PREPARATION AND CHARACTERISATION OF POLYSACCHARIDE NANOPARTICLES 
99 
 
OX4 nanoparticles across a wide pH range when DEX-S was employed as a crosslinker 
compared to TPP (Figure 4. 5.).  
 
Figure 4.5. Variation of hydrodynamic diameter (column bars) and zeta potential (triangle) of 
nanoparticles prepared from CS-OX4 crosslinked with either TPP (green) or DEX-S (red) with 
increasing pH. (n=3, error bars represent standard deviation). 
 
Nanoparticles from CS-OX4 crosslinked with DEX-S exhibited an almost constant 
diameter of ca. 200 nm over the whole range of pH, and a negative zeta potential (-30 mV), 
while nanoparticles obtained from CS-OX4 crosslinked with TPP also exhibited a low diameter 
(ca. 140 nm) and a stable and positive zeta potential (ca. 40 mV) but only in acidic conditions. 
However, when TPP was employed as a crosslinker, and in stark contrast to the behaviour of the 
formulations obtained using DEX-S, a noticeable increase in diameter accompanied by a 
decrease of the zeta potential occurred above the pKa value of chitosan (ca. 6.5 [406]). As a 
result of the chitosan interactions with TPP being affected by the deprotonation of the amino 
groups, hydrodynamic diameter increased to 500 nm and zeta potential dropped to negative 
values, leading to gradual sample agglomeration. Interestingly, this behaviour was not observed 
when CS-OX4 was ionotropicaly crosslinked with DEX-S. The explanation may lie in a 
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different interaction of amino groups from chitosan with either sulphate groups of DEX-S or 
with phosphate groups of TPP [407]. 
Nanoparticles prepared from CS-OX4 crosslinked with either TPP or DEX-S were 
loaded with Evans Blue as a model fluorescent marker; although different properties as diameter 
and zeta potential, both types of systems showed similar loading capacity (3.67 ± 0.21 % and 
3.01± 0.13 % respectively, Table 4.6, determined from a calibration curve.. The loaded 
nanoparticles from CS-OX4 with TPP had slightly smaller diameter (and positive zeta 
potential)compared to those obtained from CS-OX4 crosslinked with DEX-S, that were 
negatively charged (Table 4.6.).  
 
Table 4.6. Characteristics of Evans Blue-loaded nanoparticles obtained from CS-OX4 
crosslinked with either TPP or DEX-S (pH 3.5; n=3; ±SD). 
 
 
4.3.1.3. Nanoparticles from poly(lactic acid) coated with akylglyceryl-modified 
 chitosan  
 In an attempt to improve the stability of nanoformulations based on alkylglyceryl 
chitosan at physiologically relevant pH values, butylglyceryl chitosan (CS-OX4) was coated on 
core nanoparticles of poly(lactic acid) (PLA), in the presence of various surfactants.  
Poly(lactic acid) nanoparticles were prepared by nanoprecipitation and were coated by 
butylglyceryl modified chitosan (CS-OX4), as in chapter 4.2.1.3. The hydrodynamic diameter, 
polydispersity index and zeta potential of poly(lactic acid) core nanoparticles are presented in 
Table 4.7. The PLA nanoparticles coated with CS-OX4 are similar to those PLA nanoparticles 
coated with chitosan reported in the literature [128, 243, 408]. Table 4.7. also presents the same 
characteristics of butylglyceryl chitosan-coated nanoparticles in the presence of various 
CS-OX4 
crosslinked with 
Z-ave diameter 
(DLS) [nm] 
Zeta potential 
[mV] 
Evans Blue loading 
capacity [% w/w] 
TPP 183 ± 12 43.6 ± 1.2 3.67 ± 0.21 
DEX-S 243 ± 22 -23 ± 3.3 3.01 ± 0.13 
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surfactants such as Poloxamer 407 (P407), Poloxamer 188 (P188) and polyvinylalcohol (PVA). 
Coating with CS-OX4 did not induce changes in the hydrodynamic diameter of PLA 
nanoparticles and led to a change of their global charge (zeta potential shifted from ca. -30 mV 
for uncoated nanoparticles to ca. +30 mV for coated ones), when measured in an acidic 
environment. However after purification (10 000 RPM, 10 min, Eppendorph MiniSpin 
centrifuge), when the nanoparticles were redispersed at neutral pH, CS-OX4 coating appeared to 
induce a significant increase in size in comparison to uncoated nanoparticles (ANOVA, p < 
0.05), while zeta potential changed back to negative. At neutral pH, PVA seemed to slightly 
increase the size and lower the zeta potential of coated nanoparticles compared to the other 
surfactants considered in this study, but no general trends could be observed.  
 
Table 4.7. Characteristics of CS-OX4-coated PLA core nanoparticles prepared in the presence 
of different surfactants,(P407 – Poloxamer 407; P188 – Poloxamer 188; PVA – 
polyvinylalcohol; n=3; ±SD). 
Surfactant Surfactant 
conc. 
[mg/mL] 
Z-ave diameter, mean 
[nm ± sd] 
Zeta potential, mean 
[mV ± sd] 
pH 4 pH 7 pH 4 pH 7 
- 0 173.2 ± 3.1 197.2 ± 3.7 -29.3 ± 3.4 -27.6 ± 3.3 
P407 1 176.4 ± 2.2 392.2 ± 2.5 26.2 ± 2.1 -30.9 ± 2.2 
10 171.7 ± 2.6 306.0 ± 2.9 46.7 ± 2.2 -38.5 ± 3.0 
P188 1 171.9 ± 2.7 366.3 ± 3.0 46.6 ± 4.1 -33.9 ± 2.1 
10 174.6 ± 2.6 303.2 ± 2.1 44.5 ± 2.1 -26.3 ± 3.2 
PVA 1 183.9 ± 2.8 1269.7 ± 65.1 22.5 ± 2.7 -17.3 ± 2.9 
10 163.6 ± 3.3 489.3 ± 13.4 49.9 ± 2.7 -25.2 ± 3.3 
 
4.3.2. Nanoparticles prepared from alkylglyceryl-modified dextran 
derivatives 
 Two techniques (complexation with chitosan oligomers and coating of nanoparticles 
from poly(lactic acid)) were employed to formulate butylglyceryl dextran (DEX-OX4) 
(prepared as described in chapter 4.2.2.) into nanoparticles. These were further characterised 
under simulated, physiologically relevant conditions in terms of, hydrodynamic diameter, zeta 
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potential and morphology. Nanoparticles prepared from poly(lactic acid)-graft-alkylglycerol-
modified dextran are described in 4.3.2.3. 
4.3.2.1. Nanoparticles formulated from alkylglyceryl-modified dextran  
 and chitosan oligomers 
Nanonoparticles based on DEX-OX4 and chitosan oligosaccharide (o-CS, MW approx. 
700 Da) were prepared in the presence of Poloxamer 407 (P407) following the method 
described in chapter 4.2.2.1. The formulation of nanoparticles was optimised by varying the 
amount of P 407. The nanoparticles were characterised for size and zeta potential in conditions 
of preparation and after redispersion in conditions of physiological pH. 
 
Figure 4.6. Size distribution of nanoparticles prepared from DEX-OX4 (1 mg/mL) and CS 
oligomer (0.02 mg/mL) in the presence of surfactant (P407, 1 mg/mL), represented as 
percentage intensity (Malvern Zetasizer Nano ZS).  
 
The formulation required only a small amount of surfactant (i.e. 1 mg/mL, for Z-av. 
diameter approx. 150 nm, Figure 4.6.) as nanoparticles were not forming in its absence; at the 
same time, an increased amount of P407 was found to lead to an increase in both size and 
polydispersity index (Figure 4.7.). 
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Figure 4.7. Variation of hydrodynamic diameter and polidispersity index with the concentration 
of surfactant for nanoparticles prepared from butylglyceryldextran and chitosan oligomer in the 
presence of Poloxamer P407 (n=3, ±SD). 
 
The mechanism of nanoparticle formation could possibly lie in hydrogen bonding; a 
similar effect was observed in concentrated dextran solutions [389] or van der Waals forces, 
observed in [181, 409]. When CS was replaced with polyethyleneimine there was no formation 
of nanoparticles observed (excluding possible electrostatic forces), however exclusion of CS 
from the formulation whilst keeping P407 did not result into formation of nanoparticles either.  
 Nanoparticles were further separated by ultracentrifugation (40 000 RPM, 30 min, 
20 °C, Rotor 70.1 Ti) and redispersed in PBS (pH 7.4, saline 0.9 %). The characteristics of 
nanoparticles after redispersion are presented in Table 4.8. 
Table 4.8. Characteristics of nanoparticles prepared from DEX-OX4 and CS oligomer in the 
presence of surfactant (P407), following separation and redispersion in PSB (pH 7.4;.n=3; 
±SD). 
Nanoparticle 
formulation 
Characteristics 
Diameter [nm] PDI 
Zeta pot. 
[mV] 
As prepared 
(pH 4) 
123.4 ± 35.5 0.22 ± 0.07 17.20 ± 2.65 
Redispersed in 
PBS (pH 7.4) 
222.3 ± 29.43 0.28 ± 0.12 0.68 ± 4.74 
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Results indicated that the redispersion of nanoparticles influenced both the diameter 
(size increased from ca. 120 nm to ca. 220 nm) and the zeta potential (decreased from 17.20 to 
0.68 mV) of these nanoparticles. However, the low zeta potential measured after redispersion 
did not induce and immediate agglomeration of the sample as it was noticed in the case of 
nanoparticles prepared from CS-OX4 (chapter 4.2.1.); the presence of P407 might provide a 
possible explanation for the stability observed in this case.  
 
Figure 4.8. The influence of pH on the characteristics of DEX-OX4 (5.0 mg/mL) complexes 
stabilised by CS (0.5 mg/mL) and P407 (1.0 mg/mL) (n = 3, ±SD). 
Automatic pH titrations (using 0.05 M NaOH, Figure 4.8.) of the formulations prepared 
from DEX-OX4 and CS and P407 (DEX-OX4 5.0 mg/mL, CS 0.5mg/mL, P407 1.0 mg/mL) 
also indicated these nanoparticles maintained (or had only a minimal increase in) their size (ca. 
200 ± 20 nm) when the environment turned neutral/alkaline despite the zeta potential turning 
negative, possibly an effect of the stabilisation likely induced by P407 providing steric repulsion 
[410]. 
Nanoparticles prepared from DEX-OX4 and CS and P407 (DEX-OX4 5 mg/mL, CS 
0.5mg/mL, P 407 1 mg/mL) were loaded with doxorubicin-the drug was incorporated into the 
nanoparticles at acidic pH (approx. 4). The amount of doxorubicin loaded was determined 
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indirectly by UV-Vis by measuring the drug content in supernatant after removing the 
nanoparticles by centrifugation (chapter 4.2.2.1.). The nanoparticles exhibited similar features to 
the unloaded ones (approx. 130 nm, zeta potential 15 mV). The content of doxorubicin loaded 
in the nanoparticles was found to be in the range 0.9 - 4.1 % w/w (compared to 12.7-55.8 % 
w/w) for other polysaccharide-based nanoparticles (CS and DEX) reported in the literature 
[182]. 
The morphology of nanoparticles prepared from DEX-OX4 and CS and P407 (DEX-
OX4 5.0 mg/mL, CS 0.5mg/mL, P407 1.0 mg/mL) was studied by Scanning Electron 
Microscopy (SEM) following their separation by centrifugation, freeze-drying  and coating with 
golden alloy. An example of a SEM image of freeze-dried nanoparticles is presented in Figure 
4.9. 
 
Figure 4.9. SEM micrograph of nanoparticles (ARROW) prepared from DEX-OX4 and CS and 
P407 (DEX-OX4-5.0 mg/mL, CS-0.5mg/mL, P407 1.0 mg/mL). 
 
4.3.2.2. Nanoparticles from poly(lactic acid) coated with akylglyceryl-
 modified dextran 
Nanoparticles were prepared by a dropwise addition of poly(lactic acid) (PLA) solution 
in acetone (5 mg/mL) to an aqueous solution of butylglyceryl dextran (DEX-OX4) (conc. range 
0.66 – 5.00 mg/mL) under magnetic stirring (chapter 4.2.2.2.). The diameter of nanoparticles, 
measured by DLS after purification by centrifugation, was in the range 100 - 150 nm; though no 
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trend associated with an increase in the DEX-OX4 amount could be observed (Figure 4.10.). 
These results would suggest that the ratio of DEX-OX4 / PLA does not influence much the size 
of nanoparticles (in accordance to previous literature report about modified dextran as a 
surfactant in PLA nanoparticles preparation [150]) and that DEX-OX4 was possibly adsorbed to 
a certain limit onto a poly(lactic acid) core, as Rouzes et al. found following studies on the 
influence of hydrophobic modified dextrans acting as surfactants during preparation of PLA 
nanoparticles [411]. Zeta potential was determined by electrophoretic mobility measurements in 
range -15 mV to -23 mV. 
 
Figure 4.10. The hydrodynamic diameter (Z-av.) of nanoparticles from PLA and DEX-OX4 
obtained using different DEX-OX4 concentrations (volume 15 ml, n=3; ± SD). 
 
The presence of both dextran and PLA nanoparticles core was confirmed by FT-IR 
spectroscopy. The nanoparticles were centrifuged and the pellets were freeze-dried and analysed 
in ATR mode. Both molecules were confirmed in the structure after preparation. The band at 
3500 cm
-1
 is indication for OH groups of modified dextran and band at the 1750 cm
-1
 indicates 
C=O group for poly(lactic acid). However the amount of DEX-OX decreased after further 
purification (via centrifugation 10 000 rpm, 15 min, Eppendorph Mini Spin) followed by 
redispersion in water by sonication, and appeared to be removed completely after three 
purification cycles (Figure 4.11.). This would point towards adsorption of DEX-OX4 on the 
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surface of the nanoparticles rather than its incorporation into the hydrophobic core of poly(lactic 
acid) nanoparticles during the nanoprecipitation process. 
 
Figure 4.11. FT-IR spectra (ATR) of nanoparticles prepared by nanoprecipitation of PLA into 
water containing DEX-OX4, bottom-one cycle of purification, top-three cycles of purification 
 
4.3.2.3. Nanoparticles formulated from poly(lactic acid)-graft-alkylglyceryl-
 modified dextran  
 Nanoparticles were formulated from poly(lactic acid)-graft-butylglyceryl-modified 
dextran (PLA-DEX-OX4) using three techniques: solvent displacement, nanoprecipitation and 
electrospraying. Nanoparticles were characterised in terms of dimension, stability, morphology, 
and loading/release of fluorescent markers such as Fluorescein, Rhodamine B or Doxorubicin.  
A) Solvent displacement. Nanoparticles were prepared by dialysing a DMSO solution 
of PLA-DEX-OX4 of different concentrations in deionised water for 2 days, freeze-dried and 
redispersed in HPLC water, affording 100 - 400 nm size nanoparticles (depending on 
concentration of polymer in DMSO) with PDI values in the range 0.20 - 0.45. The results 
presented in Figure 4.12. would suggest the nanoparticle diameter increased with an increase of 
the concentration of polymer in DMSO, however statistical treatment of data, apart from the 
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highest one, could not evidence a significant difference between other values  (ANOVA, 
p>0.05). Furthermore there was no statistical difference between various polymers (PLA-DEX, 
PLA-DEX-OX4, PLA-DEX-OX8) at conc. 1.0 mg/mL in DMSO. 
A)  
B)  
Figure 4.12. A) The influence of polymer concentration in DMSO on the hydrodynamic 
diameter of nanoparticles formulated from PLA-DEX-OX4 via solvent displacement, B) 
Comparison of PLA-DEX, PLA-DEX-OX4, PLA-DEX-OX8 at 1.0 mg/mL (n=3; ±SD). 
 
B) Nanoprecipitation. A dropwise addition of a PLA-DEX-OX4 in DMSO solution 
into water (as described in chapter 4.2.2.3.) produced nanoparticles in the range 100 - 300 nm 
(Figure 4.13. concentration dependent), similar to nanoparticles from poly(lactic acid) dextran 
copolymer (PLA-DEX) prepared via similar method (80 - 125 nm [252]; 50-200 nm [253]). As 
DMSO (a solvent for PLA-DEX-OX4) has a higher boiling point (189 °C at 1010 mbar) than 
the non-solvent (water) it needs to be removed from the preparation mixture by dialysis or 
alternatively, nanoparticles have to be separated by centrifugation.  
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Figure 4.13. The influence of concentration of polymer on the diameter of nanoparticles 
prepared from PLA-DEX-OX4 by nanoprecipitation (n=3, ±SD). 
 
C) Electrospraying. Poly(lactic acid)-graft-butylglyceryl dextran (PLA-DEX-OX4) 
nanoparticles were also prepared by electrostatic atomisation (electrospraying) of a solution of 
polymer dissolved in DMSO (as described in chapter 4.2.2.3.), which resulted in the formation 
of particles 100 - 200 nm in diameter having a negative zeta potential (-15 to -30 mV), Table 
4.9. The spray was collected into a circular dish containing water (as DMSO has low volatility 
during electrospraying) and nanoparticles were further purified by dialysis (10.0 L exchanged 3 
times a day for 48 hours) or by ultra-centrifugation (40 000 RPM, 30 min, 20 °C). 
The comparison of nanoparticles from PLA-DEX-OX4 prepared by all three methods 
(Table 4.9.) showed that products of each method exhibited hydrodynamic dimensions suitable 
for drug delivery at physiological pH, measured in PBS (pH 7.4; saline 0.9 %). In optimal 
preparation conditions for solvent displacement via dialysis (concentration 1.0 mg/mL of 
polymer in DMSO), nanoprecipitation (concentration 5.0 mg/mL of polymer in DMSO) or 
electrospraying (concentration 50 mg/mL of polymer in DMSO) the nanoparticles were in 100 - 
200 nm range bearing negative zeta potential -15 to -30 mV. Such a diameter is considered to be 
ideal for intravascular drug delivery system [412]. 
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Table 4.9. Characteristics of nanoparticles prepared from PLA-DEX-OX4 by various methods 
acquired by optimal conditions.  
PLA-DEX-OX4 
nanoparticles 
Diameter 
NTA 
nm [±SD] 
Diameter 
DLS 
nm [±SD] 
Zeta 
Potential 
mV [±SD] 
Yields (after purification) 
% [±SD] 
Dialysis Centrifugation 
Solvent 
displacement* 
123[±85] 161 [±61] -22 [±7] 71[±19] N/A 
Nanoprecipitation** 142[±53] 152 [±48] -23 [±7] 44 [±23] 15[±7] 
Electrospraying*** 155 [±63] 143 [±69] -25 [±8] 61[±16] 20 [±13] 
* concentration of PLA-DEX-OX4 in DMSO was 1 mg/mL 
** concentration of PLA-DEX-OX4 in DMSO was 5 mg/mL 
*** concentration of PLA-DEX-OX4 in DMSO was 50 mg/mL 
 
Zeta potential of nanoparticles prepared from PLA-DEX-OX4. The stability of PLA-
DEX-OX4 nanoparticles in different pH conditions was investigated by titration in ultrapure 
water while measuring their diameter and zeta potential. Figure 4.14. shows that both 
parameters were stable over a wide range of pH values, however an increase could be noticed 
(in particular for the zeta potential) around the isoelectric point (pKa 3.1 [413]); as expected, the 
acidic solution led, in time, to nanoparticles starting to agglomerate. 
 
Figure 4.14. Variation of PLA-DEX-OX4 nanoparticle characteristics (size and zeta potential) 
with pH,(1 mg/mL suspension; prepared by solvent displacement, automatic titration with 
NaOH 0.05 M, Malvern instrument). 
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Purification of PLA-DEX-OX4 nanopaticles. Generally, higher yields were obtained 
when nanoparticles were purified by dialysis followed by freeze drying rather than by 
redispersion followed by centrifugation (when there might be redispersion-related loss of 
material and when not all fine particles can be recovered, Table 4.10. Using a glycerol or 
trehalose bed (which can also act as a cryoprotectants during the freeze-drying step [414, 415]) 
at the bottom of the centrifugation tube can help with redispersion by lessening the degree to 
which the centrifugation pellet is being compacted, however neither of these two additives did 
influence positively the redispersion of samples of PLA-DEX-OX4 nanoparticles (produced by 
nanoprecipitation). In some cases authors recommend combination of purification methods as 
centrifugation and dialysis to ensure the high level of purity of the products [416]. 
Table 4.10. The purification methods of PLA-DEX-OX4 nanoparticles. 
PLA-DEX-OX4 
nanoparticles 
Yields (after purification) % 
[±SD] 
Dialysis Centrifugation 
Solvent 
displacement* 
71[±19] N/A 
Nanoprecipitation** 44 [±23] 15[±7] 
Electrospraying*** 61[±16] 20 [±13] 
 
* concentration of PLA-DEX-OX4 in DMSO was 1 mg/mL 
** concentration of PLA-DEX-OX4 in DMSO was 5 mg/mL 
*** concentration of PLA-DEX-OX4 in DMSO was 50 mg/mL 
 
 
Morphology of dry PLA-DEX-OX4 nanoparticles. Scanning Electron Microscopy has 
been employed to investigate the morphology of freeze-dried nanoparticles of poly(lactic acid)-
graft-alkylglyceryl dextran (PLA-DEX-OX4) prepared by dialysis as described in chapter 4.1. 
The nanoparticles exhibited micron/submicron diameter and spherical shape (Figure 4.15.). It 
was also shown that not all the polymer was converted into the nanoparticles. 
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Figure 4.15. SEM micrograph (LEFT) and AFM image (RIGHT) of freeze-dried PLA-DEX-OX4 
nanoparticles (prepared via solvent displacement by dialysis).  
 
AFM was also employed to investigate the shape of PLA-DEX-OX4 nanoparticles, 
which appear – when scanned in dried state, Figure 4.15. - as oval having a vertical diameter of 
ca. 15 nm and ca. 60 nm horizontal (see also Table 4.11.). The difference between vertical and 
horizontal dimensions may be explained by the deformation induced by the pressure exerted by 
the cantilever on the top of the nanoparticle. The difference observed when comparing these 
results to those presented in Table 4.9. for the same type of nanoparticles but measured in 
aqueous environment can be explained by the hydration of the outer layer of the nanoparticle 
and possibly by the different conformation of the polymeric chains present on the surface of the 
particles [182]. 
Table 4.11. AFM dimension of nanoparticles 
Nanoparticles 
Horizontal diameter/ 
SD [nm] 
Vertical diameter/ 
Standard deviation 
[nm] 
PLA-DEX-OX4 64.4 ± 11.7 15.4 ± 2.2 
PLA-DEX 52.5 ± 15.4 14.4 ± 4.5 
 
Loading and release of fluorescent molecules from PLA-DEX-OX4 nanoparticles. 
Fluorescein isothiocyanate (FITC), Rhodamine B base and Doxorubicin base, selected for their 
fluorescence characteristics such as good detection limits and limited photobleaching, were 
loaded into PLA-DEX-OX4 nanoparticles that were prepared by either solvent displacement or 
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by electrospraying. Typically, the dye was dissolved in the DMSO and added during the 
formulation as described in chapter 4.2.2.3. The amount of each type of dye loaded into PLA-
DEX-OX4 nanoparticles was determined using calibration curves in DMSO; the results are 
presented in Table 4.12. The results suggest that electrospraying provides a more efficient 
loading method compared to solvent displacement.  
Table 4.12. Loading fluorescent molecules into PLA-DEX-OX4 nanoparticles using various 
methods 
 
Percentage of drug loaded (w/w) using different techniques 
Solvent displacement via 
Dialysis 
Electrospraying 
Fluorescein 0.02 ± 0.01 % N/A 
Rhodamine B 0.32 ± 0.11 % 4.93 ± 0.76 % 
Doxorubicin 0.50 ± 0.23 % 12.57 ± 3.17 % 
 
Fluorescein isothiocyanate (FITC) was loaded into PLA-DEX-OX4 nanoparticles by 
solvent displacement method only, as the amount loaded was found to be minimal (Table 4.12.) 
and the release showed an instant burst effect that was complete within 30 min (which would 
indicate surface interaction of the dye with the nanoparticles). Rhodamine B base and especially 
Doxorubicin base showed better loading while their release also had an initial burst phase 
followed by a plateau (Figure 4.16.), which is in agreement with literature for fluorescent 
marker-loaded PLA and PLGA nanoparticles [250, 379] and can be explained by the (more 
leaky) porous structure resulting from freeze-drying [417]. The release of drug from 
Doxorubicin-loaded (3 – 6 % w/w) PLGA-DEX nanoparticles (size 90-200 nm) was also 
described by Choi as burst for the first day, and followed then by a plateau for another 5 days 
[379]. 
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A)  
B)  
C)  
Figure 4.16. Release of A) FITC, B) Rhodamine B, C) Doxorubicin from loaded PLA-DEX-OX4 
nanoparticles (1 mg/ml) in PBS (pH 7.4; saline 0.9 %) at 37 °C (n=3, ±SD).  
 
4.3. Conclusions  
Amongst other criteria, nanoparticulate systems employed for intravascular drug 
delivery purposes are expected to have submicron size (ideally between 100 and 200 nm) and to 
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show stability in physiological conditions furthermore, ease of purification and reconstitution of 
a colloidal system are important indicators of their practical potential.  
Nanoparticles formulated from alkylglyceryl-modified chitosan (CS-OXn, where n = 4, 
5, 8) were prepared by ionotropic gelation with sodium tripolyphosphate (TPP) in acidic 
environment, when their hydrodynamic diameter was found to be in the range of 100-200 nm 
(DLS). An increase in size (up to 800-1500 nm) was noticed when acidity decreased to pH 7 
(using an automatic titrator) or after purification by dialysis (against deionised water) followed 
by re-suspension in a physiologically relevant simulated medium such as PBS saline (pH 7.4; 
0.9 % salinity). Purification of nanoparticles by ultracentrifugation (144 000 g; 30 min) 
exhibited low yields (0 - 30 %); moreover, high speed centrifugation used for the separation of 
nanoparticles appeared to have a negative effect upon their subsequent redispersion in similar 
media, with sonication being of only marginal help. 
Employing larger counterions compared to TPP (such as dextran sulphate) was expected 
to influence the stability of the synthesised chitosan-based colloidal systems in neutral 
conditions, for sterical reasons. Indeed, nanoparticles prepared from butylglycerylchitosan (CS-
OX4) by ionotropic crosslinking with dextran sulphate (DEX-S) were in the range of 200-300 
nm in an acidic environment (pH 4), and the diameter remained unchanged during titration up to 
pH 7.4; moreover, the zeta potential of the nanoparticles remained constant (-30 mV) across the 
whole pH range studied (pH 4 to 7.4). However, partial agglomeration has been noticed 
following purification by dialysis (possibly due to partial removal of DEX-S in the process), and 
their resuspension following ultracentrifugation was still not complete. 
Butylglyceryl chitosan (CS-OX4) was also employed for coating nanoparticles prepared 
from poly(lactic acid) in the presence of different concentrations of surfactants (such as 
Poloxamer 407, Poloxamer 188 or Poly(vinyl alcohol)); employed as 1 mg/mL and 10 mg/mL 
conc.). The hydrodynamic diameter of normal PLA nanoparticles prepared by nanoprecipitation 
did not change after coating with CS-OX4 when measured in the preparation conditions (pH 4), 
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but the adsorption of CS-OX4 was evidenced by a major change of zeta potential (from ca. -29 
mV of uncoated PLA nanoparticles, to ca. 40 mV when coated with CS-OX4). However, the 
size of coated nanoparticles increased significantly when the pH was changed to neutral (from 
ca. 170 nm to 300-1300 nm). Using Poloxamer 407 in the coating process allowed for the 
preparation of smallest size particles compared to those obtained using other surfactants (ca. 300 
nm, at a Poloxamer 407 conc. of 10 mg/mL) while using Poly(vinyl alcohol) resulted in a 
significant increase in particle size (ca. 1270 nm. at a Poly(vinyl alcohol) conc. of 1 mg/mL). 
Generally, an increase in surfactant concentration resulted in smaller nanoparticles.  
Nanoparticles prepared from butylglyceryl-modified dextran (DEX-OX4) and chitosan 
oligosaccharide  in the presence of Poloxamer 407 exhibited size and zeta potential which were 
also found to vary with an increase in pH (size increased from 170 to 220 nm, while zeta 
potential decreased from +17 to -0.7 mV when pH was varied from 4 to 7.4). However the 
stabilising effect of P407 was not further reflected in the purification process (separation by 
centrifugation followed by redispersion led to significant agglomeration). Maximum loading of 
Doxorubicin was assessed by UV/VIS as 4.1 % w/w.  
An attempt to prepare nanoparticles from poly(lactic acid) and DEX-OX4 by 
nanoprecipitation led to submicron size nanoparticles (100-140 nm) with negative zeta 
potentials (-18 mV to -25 mV),  however  DEX-OX4 appeared to be easily washed away in the 
centrifugation / redispersion process (as evidenced by FT-IR analysis; likely due to weak 
interaction between hydrophobic poly(lactic acid) and DEX-OX4).  
In an attempt to study the influence of the preparation method on the characteristics of 
nanoformulations, solvent displacement, nanoprecipitation and electrospraying methods have 
been comparatively employed for obtaining nanoparticles based on polylactic acid-graft-dextran 
copolymer (PLA-DEX-OX4). It has been found that the size of the nanoparticles prepared using 
the three optimised methods were similar (in the range of 120-155 nm) and had a negative zeta 
potential (-20 mV to -25 mV). The stability of electrosprayed nanoparticles was observed across 
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a wide range of pH values (2.5 - 8.0); while the hydrodynamic diameter remained of ca. 120 
nm, the zeta potential dropped from -20 mV (pH 7.4) to 0 mV (pH 2.5). SEM and AFM analysis 
of freeze-dried nanoparticles from PLA-DEX-OX4 confirmed the spherical shape and low 
uniformity of nanoparticles. Though time consuming, dialysis seemed to afford better yields and 
a more facile redispersion when employed as a purification technique compared to 
centrifugation. When fluorescent molecules were employed as model actives, electrospraying 
provided also better loading capacity for Doxorubicin and Rhodamine B when compared to 
solvent displacement (4.9 % vs. 0.3 % w/w for Rhodamine B; 12.57 % vs. 0.5 % w/w for 
Doxorubicin). The loading of FITC in PLA-DEX-OX4 nanoparticles was extremely low; a burst 
release was observed in all cases, independent of the method of preparation (this was complete 
within 30 min for FITC while for Doxorubicin and Rhodamine B it seemed to be sustained for 
at least several hours).  
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5 
 STUDIES IN VITRO 
             
Cell cultures of mouse and human origin were employed to study the interactions 
between brain endothelial cells and the modified biopolymers and their corresponding 
nanoformulations described earlier. Aspects such as cytotoxicity, cell uptake, influence on the 
cell layer permeability and transendothelial electric resistance were investigated with a view to 
establish the influence of the alkylglyceryl modifications on the cell-nanoparticle interactions. 
 
5.1. Materials and instrumentation  
DMEM media, TrypLE Express, Hoechst Blue 33342, PBS, PrestoBlue assay were 
purchased from Invitrogen, Life technologies. Matrigel
 
was sourced from BD Biosciences and 
EGM-2 media was purchased from Lonza as an EGM-2 Bullet Kit. Recovery Medium, HBSS, 
and distilled water (cell culture quality) were purchased from Gibco. Trypan blue, FITC 
dextran, and L-cysteine were purchased from Sigma Aldrich. Cryo-vials Greiner bio-one, Nunc 
96 well-plates were purchased from Fisher Scientific. The Transwell system (24 well-plates) 
was sourced from Millipore (Millicell-24 Cell Culture Plate; polyethylene terephthalate 
membrane; 1.0 µm; filtration surface 0.33 cm2; pore density 2x106 per cm2), 8WE10 array for 
ECIS was sourced from Applied Biophysics, USA. The trimethyl-chitosan derivatives (TMC, 
TMC-OX4 and TMC-OX8) were gift from Dr. Molnár. 
The cells were cultured under humidified atmosphere (human cells hCMEC/D3 in a 
standard Mini Galaxy E incubator, mouse cells bEnd3 in a Nuaire DH AUTOFLOW Air-
Jacketed incubator) at 37 C and 5 % CO2 in small T25 culturing flasks (Fisher). Nunclon F 96-
well plates were sourced from Thermo Scientific. The analysis of the well-plates was performed 
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using a PolarStar Optima (BMG Labtech) fluorimeter. Cells were observed with an Olympus 
IX71 inverted phase microscope and images were taken using Olympus Soft Imaging System, 
UK. Images of cells were also obtained using an LSM 710 confocal microscope (ZEISS, 
fluorescence excitation at 405 nm, 488 nm and 633 nm; facilitated by a Twin Gate main beam 
splitter).  Cells were counted using either a Vi-CELL
 
XR Cell Viability Analyser (Beckman 
Coulter, UK) or a haemocytometer. Cell cultures were spun using a Beoco C28A centrifuge 
(Wolf Laboratories, UK). Electric Cell-substrate Impedance Sensing (ECIS) measurements 
were conducted using an ECIS Zθ instrument (Applied Biophysics) operating at a frequency 
range of 2 000-32 000 Hz and employing 8 well-arrays type 8W10E. 
 Butylglyceryl-modified dextran (DEX-OX4 DS 42 %), octylglyceryl-modified dextran 
(DEX-OX8 DS 17 %) were prepared as described earlier, dextran (MW 6 kDa) and chitosan 
(low MW) were sourced from Sigma Aldrich. Nanoparticles from poly(lactic acid)–graft-
butylglycerol dextran (PLA-DEX-OX4, DS 42-55%), poly(lactic acid)–graft-octylglycerol 
dextran (PLA-DEX-OX8, DS 31%) and poly(lactic acid)–graft-dextran (PLA-DEX) were 
obtained by solvent displacement method (via dialysis). Nanoparticles from chitosan (CS) and 
alkylglycerolchitosan derivatives (CS-OX4 DS 88 % and CS-OX8 18 %), and trimethylchitosan 
(TMC, TMC-OX4 DS 23 %, TMC-OX8 DS 43 %) were prepared by ionic gelation. 
 
5.2. Methods 
Mouse (bEnd3) and human (hCMEC/D3) endothelial cells have been cultured as 
described in section 5.2.1. The following sub-chapters present the setups and methods employed 
for toxicity assays, cell-uptake experiments, live cell monitoring of endothelial electrical 
resistance (TEER) studies and trans-epithelial transport investigations.  
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5.2.1. Cell cultures 
Mouse brain endothelial cells (bEnd3, Figure 5.4-A.) were sourced in-house (Molecular 
Medicine Laboratory; Prof. Górecki). The cells were kept in supplement-enriched DMEM 
media (Table 5.1.). For optimal growth, bEnd3 cells were seeded onto surfaces that have been 
previously coated with 1.5 mg/mL Matrigel
 
by incubating at 37 °C for 30 min. 
Table 5.1. The composition of media and conditions employed for cell culturing.  
 bEnd3 hCMEC/D3 
Cell type Mouse Endothelial cells Human endothelial cells 
Origin 
Health Protection Agency Culture 
Collections, UK 
Institut Cochin, INSERM, Paris, France 
Passage no 31-35 30-37 
Medium DMEM (Invitrogen) EGM-2 (Lonza) 
Culturing 
flask 
CORNING T25 
Medium 
volume 
3-5 ml 
Serum 10 % (v/v) FBS 2 % (v/v) HS or 2 % (v/v) FBS 
Supplements 
1 % (v/v) non-essential amino acids 
2 mM L-glutamine 
1 mM sodium pyruvate 
5 M -mercapthoethanol 
100 U/mL penicillin 
0.1 mg/mL streptomycin 
Single Quots (one dose per 500 mL 
medium), consisting of: 
Hydrocortisone 
VEGF 
hFGF‐B 
Gentamicin 
Amphotecerin‐B 
R3‐IGF‐1 
hEGF 
Ascorbic Acid 
Heparin 
Coating of 
flasks 
1.5 mg/mL Matrigel 1.5 mg/mL Matrigel/no coating 
 
Human cerebral microvascular endothelial cells (hCMEC/D3) that were immortalised 
with hTERT/SV40 Lagre T antigen were also sourced in-house (Cellular and Molecular Neuro- 
Oncology group Laboratory; Prof. Pilkington). The human brain endothelial hCMEC/D3 cells 
(Figure 5.4-B.) were kept in EGM-2 media that was enriched in supplements as presented in 
Table 5.1. For optimal growth, the cells were seeded onto surfaces that have been previously 
coated with 1.5 mg/mL Matrigel
 by incubation at 37 °C for 30 min; unless specified that no 
coating was applied.  
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The endothelial cells were grown in a incubator (standard Mini Galaxy E incubator for 
hCMEC/D3 and Nuaire DH AUTOFLOW for bEnd3) in the corresponding media (Table 5.1.) 
under a humidified atmosphere at 37 C and 5 % CO2 in small T25 culturing flasks. After first 
day the medium was removed and the cells were washed twice with PBS, which was then 
replaced with fresh medium. This process was repeated every 3 - 4 days until the cells became 
confluent (80 - 90 %; as verified by optical microscope Olympus IX71 inverted phase 
microscope), at which point the cells required sub-culturing. 
 
5.2.2. Cell passaging 
Cells that reached the confluent state and were surplus for immediate experiments were 
passaged as follows: cells were washed twice with PBS, trypsinised with TrypLE Express (1 
mL per T25 flask, equilibrated at 37 °C for 5 minutes to detach the cells from the flask; the 
TrypLE Express was deactivated by serum containing media, in a ratio of 1:1); cell dissociation 
was monitored using a microscope. The cell suspension was then centrifuged at 1 000 RPM for 
5 min using a Boeco C28A centrifuge and the supernatant was discarded. The pellet was 
resuspended in fresh media and split into fresh culture flasks, and the cultures to be used for 
immediate experiments were counted by methods relying on Trypan Blue.  
The classical haemocytometer method was employed for counting bEnd3 cells, as 
follows: 10.0 μL of cell suspension (normally, the pellet from one flask resuspended in 1.0 mL 
of fresh medium) was mixed with 90.0 μL of Trypan Blue solution. An aliquot of 10.0 μL 
(covered with a slide) was analysed by counting the living cells in the 5 visible squares (4 
corners and middle) under a microscope (Figure 5.3.); this was done in duplicate. The average 
count from one square was multiplied by 10
4
 (the volume of the counting device) and by 10 (the 
dilution factor) to express the number of the living cells in 1.0 mL.  
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A)  B)  
Figure 5.1. A) Structure of a haemocytometer B) counting area; image adopted from [418] 
 
hCMEC/D3 cells were counted using an automatic Cell Viability Analyser Vi-CELL
TM
 
XR after mixing a 100 μL aliquot of cell suspension with 500 μL of medium in the sample cup 
(giving a dilution factor of 6). 
 
Cryopreservation and resurrection of cell cultures. Cells were sub-cultured as 
described in the previous paragraph, and the pellet from one T25 culture flask was reconstituted 
in 1.0 mL of the Recovery Medium formulated with 10% DMSO (cold 2-8°C) inside the 
cryotube, which was then frozen at the rate of 1 °C / min, and stored overnight in a freezer at – 
80 °C and second day finally immersed in the liquid nitrogen tank for storage. 
To resurrect the cells, the cryotubes were removed from the nitrogen storing tank, 
placed into a plastic box for ca. 1 min and then transferred into a water bath (37 °C) to thaw the 
cell suspension. The content of each cryotube was then transferred into a T25 culture flask 
previously equilibrated with appropriate media (3.5 mL) at 37 °C. The flask was maintained in 
the incubator overnight and the medium was replaced the next day in order to remove the 
DMSO containing freezing medium. 
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5.2.3. Cytotoxicity assays of nanoparticles from alkylglyceryl-modified 
 polysacchariedes 
Nanoparticles were tested in various concentrations for toxicity against both mouse and 
human endothelial cells, at different time points (3 h and 24 h). A MTT assay [419] was 
employed for bEnd3 cells and a PrestoBlue assay [420] was used for hCMEC/D3 cells.  
 
Toxicity against mouse bEnd3 cells. Materials (such as chitosan, dextran and modified 
dextrans DEX-OX4 and DEX-OX8) and nanoparticles (PLA-DEX, PLA-DEX-OX4 and PLA-
DEX-OX8) were tested for toxicity against bEnd3 cells (seeding 10
4 
cells, APPENDIX X) using 
an MTT assay. The compounds were dissolved in modified DMEM (1 mg/mL) except for 
chitosan which was dispersed due to its insolubility at in the media at pH 7.4. The compounds 
were incubated for 24 hours with confluent bEnd3 cells. PBS (no nanoparticles) and Digitonin 
(dispersion in PBS, 10 mg/mL) were used as negative and positive control, respectively. (MTT 
method in APPENDIX XI) 
 
Toxicity against human hCMEC/D3 cells. Nanoparticles from dextran- based 
compounds (PLA-DEX-OX4 and PLA-DEX-OX8 and PLA-DEX) and chitosan-based 
compounds (CS, CS-OX4, CS-OX8, TMC, TMC-OX4 and TMC-OX8) were tested with 
hCMEC/D3 cells (seeding 10
4
) by PrestoBlue assay (APPENDIX XI). 
The nanoparticles (PLA-DEX-OX4 and PLA-DEX) were tested for toxicity in short 
time (3 hours, doses 1 mg/mL, 2 mg/mL and 4 mg/mL). The dose dependent toxicity (0.2 – 4.0 
mg/mL) of PLA-DEX-OX4 nanoparticles was studied for 24 hours. Nanoparticles from 
chitosan derivatives were tested in concentration 1 mg/mL in 24 hours incubation. PBS and 
dispersion of Digitonin served as a negative and a positive control, respectively (PrestoBlue 
method in APPENDIX X). 
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5.2.4. The uptake of nanoparticles from poly(lactic acid)-graft-
 butylglyceryldextran by mouse endothelial cells 
bEnd3 cells were employed for studying the nanoparticle-cell interactions. Cells (5.0 x 
10
4
) were seeded onto glass cover slips previously coated with Matrigel 1.5 mg/mL and 
incubated for 24 h in 2.0 mL of modified DMEM (composition given in Table 5.1.) in a 6 well 
plate. Media was then replaced with 2.0 mL of a nanoformulation (2 mg of PLA-DEX-OX4 
nanoparticles loaded with Rhodamine B (0.5 % w/w) dispersed in modified DMEM) and the 
slips were incubated with nanoparticles for further 3 h. As a control, cells were treated with 
Rhodamine B solution of the same concentration as that of the nanoformulation (2.0 mL of cell 
media containing 0.001 mg of Rhodamine B base prepared from stock solution 1 mg/mL), 
another control was provided by cells in media without addition of nanoparticles or dye. After 
incubation the cells were washed twice with PBS, fixed for 10 min in paraformaldehyde (4.0 % 
w/v) at 4 °C, permeabilised for 20min with Triton X-100 (0.1 % v/v), and incubated for 40 min 
with nuclear counter-stain Hoechst 33342 (5.0 μg/mL) at room temperature. The cells were then 
visualised using a confocal microscope (LSM 710, ZEISS, 405 nm for Hoechst, 543 nm for 
Rhodamine B). 
 
5.2.5. The effect of nanoparticles from poly(lactic acid)-graft-
 butylglyceryldextran on electrical resistance of endothelial cells 
Nanoparticles prepared from PLA-DEX and PLA-DEX-OX4 were studied for their 
effect on the transendothelial resistance (TEER) of confluent (either mouse bEnd3 or human 
hCMEC/D3) brain endothelial cells with Electric Cell Impedance Sensing (ECIS). A 
polycarbonate 8 well array (Applied Biophysics, USA; 8W10E) was employed for these 
experiments (Figure 5.2.). Each well has a surface area of 0.9 cm
2
 and a maximum capacity of 
600 μL (with a 400 μL recommended volume), and has 10 gold electrodes of 250 μm diameter 
that are capable of measuring altogether the signal arising from ca. 500 - 1000 cells. 
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Figure 5.2. ECIS array well plate (model 8W10E; Applied Biophysics). 
 
The wells were washed twice with HBSS prior to use and equilibrated with cell culture 
grade water. The electrodes were stabilised by incubation for 15 min with L-cysteine (10 mM), 
at room temperature. The wells were washed again with HBSS and coated with Matrigel 1.5 
mg/mL (incubation at 37 °C for 15 minutes). The wells were washed briefly with HBSS prior to 
seeding cells (hCMEC/D3; 2.5 x 10
5
 cells per well bEnd3; 3.0 x 10
5 
cells per well, one well was 
left empty serving as a no cell control), and the plate was incubated at 37 °C. After reaching 
confluency (indicated, after 40-50 h, by a plateau in resistance over time: ca. 1 500 Ω for 
hCMEC/D3 and ca. 800 Ω for bEnd3 cells) the media was replaced with a mix of fresh media 
(350 μl) and PBS-based nanoformulation (50 μl of PBS containing dispersed nanoparticles in 
various concentrations, final concentrations in range 1 – 4 mg/mL of PLA-DEX-OX4 and 4 
mg/mL of PLA-DEX).After incubation with nanoparticles (24 h), the nanoformulation was 
removed and replaced with fresh media and monitored for further 24 hours. ECIS readings were 
taken continuously for the whole duration of the experiment using an ECIS Zθ instrument at 
2 000 – 32 000 Hz frequency. 
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5.2.6. The effect of nanoparticles from poly(lactic acid)-graft-
 butylglyceryldextran on translocation of a fluorescent marker 
 through barriers of endothelial cells 
 
 
Figure. 5.3. Transwell setup used for translocation experiments.  
Nanoparticles prepared from PLA-DEX-OX4 were investigated for their effect on the 
paracellular transport of FITC-labelled detran (FITC-DEX, MW 150 kDa; employed as a 
fluorescent marker) using a Transwell-type BBB model based on confluent brain endothelial 
cells (Figure. 5.3.); both mouse and human endothelial cells were employed.. 24 well plates 
Millipore Millicell (PET membrane; 1 µm pore diameter; 600 μL max volume) were washed 
twice with HBBS (500 µL) and equilibrated with water for 15 min at 37 °C. After equilibration 
in water, filter membranes were coated with ice-cold 150 µL of Matrigel (1.5 mg/mL) and 
incubated for 15-30 min at 37 °C to promote better adhesion of the cells. After coating, filters 
were washed twice with HBBS, and cells were seeded (bEnd3, 3 x 10
5
 cells per well; 
hCMEC/D, 2 x 10
5
 cells per well) and maintained at 37 °C in incubator in appropriate media 
(Table 5.1.). Media were replaced every 2 days in both (apical and receiving) compartments. 
Meanwhile, cells were also seeded alongside in a standard 24 well plate to monitor the health 
and confluency of the cells (the filter in Transwell was opaque hindering cell inspection). The 
experiments were carried out after reaching confluency, usually 3-4 days from seeding. In case 
of bEnd3 cells, a specific cocktail of barrier enhancers (consisting of 250 µM cAMP, 20 µM 
RO-20-1724, and 550 µM hydrocortisone) was applied after 24 h of cells reaching confluency. 
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The nanoparticles (PLA-DEX-OX in range 1-4 mg/mL and PLA-DEX at concentration 4 
mg/mL, used as a control) were applied in media together with fluorescently-labelled dextran 
(FITC-DEX, 100 μg/mL) and the concentration of FITC-DEX in receiving compartment was 
investigated. The sampling was performed every 30 minutes, as follows: a sample (100 μL) was 
collected from the receiving compartment and the volume removed was replaced with fresh 
media. Samples (in triplicate) were collected into 96-well plates and analysed using a 
fluorescence plate reader Optima BMG (excitation 485 nm; emission 520 nm). The amount of 
FITC-DEX was determined using a calibration curve of FITC-DEX in cell media (APPENDIX 
XII) . 
The concentration of FITC-DEX in the receiving compartment was used to calculate the 
apparent permeability coefficient (Papp), as described by Arthursson [421]: 
    (    
  )   
  
  
 
  
       
 
dQ/dt   the flux of FITC-DEX transported across the membrane (g/sec);  
VR  the basolateral volume (600 μL); 
A  the surface area of the filter insert (0.33 cm
2
); 
C0  the initial mass concentration of FITC-DEX at the apical side (100 g/mL) 
60    a conversion factor (from minutes to seconds)  
 
Statistical analysis. The statistical analysis was performed using OriginPro 7 software 
from OriginLab, USA by one-way analysis of variance (ANOVA) followed by post hoc Tukey 
test (p values were set at level 0.05 unless stated otherwise). Measurements are presented as 
mean ± standard deviation unless stated otherwise. 
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5.3. Results and discussion 
The brain endothelial cells were chosen as a suitable model tissue for the studies 
relevant to drug delivery across the blood-brain barrier (BBB). Mouse brain endothelial cells 
(bEnd3, Figure 5.4-A.) were first characterised in the literature by Omidi et al. [422]. The 
bEnd3 cell line exhibits some favourable features (as expression of junctional and transport 
proteins) and were used as a model of the BBB in several cases: [423, 424, 129].  
The human endothelial hCMEC/D3 cell line (Figure 5.4-B.) was chosen as a suitable 
model for simulation of the BBB based on previous research: descriptive studies [425-427] or in 
vitro models development [49, 428].  
 
Figure 5.4. LEFT: Mouse brain endothelial cells (bEnd3) 4x magnification; RIGHT: human 
brain endothelial cells (hCMEC/D3) 10x magnification. Images taken by OLYMPUS IX71. 
 
5.3.1. Cytotoxicity studies  
 Alkylglyceryl-modified dextran and chitosan derivatives (DEX-OX and PLA-
DEX-OX derivatives and CS-OX derivatives) were investigated in terms of their toxicity 
towards either mouse or human endothelial cell cultures using MTT and PrestoBlue assays, at 
different exposure times and concentration. The MTT assay can determine toxicity by 
measuring the change of colour caused by the reduction of a yellow tetrazole (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan inside the living 
cells [419]. The Presto Blue assay is based on the reduction of a cell-permeable blue resazurin 
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compound (known also as Alamar Blue) inside the living cell to a fluorescent red [420]. This 
assay is supposed to be quicker and easier to run than MTT whilst providing accurate results 
[429]. 
5.3.1.1. Toxicity of materials 
Materials (such as chitosan, dextran and modified dextrans DEX-OX4 and DEX-OX8) 
were tested initially for toxicity against bEnd3 cells as a 1.0 mg/mL solution in PBS, pH 7.4 
(except chitosan derivatives, which did not dissolve and was used as dispersion) using an MTT 
assay (Figure. 5.5.). Blank treatment with PBS and digitonin (10 mg/mL, known to act as 
cytotoxic agent [430]) were used as negative and positive controls respectively. The results 
express relative viability to no-nanoparticle (PBS treatment, 100 %). It appeared that modifying 
dextran with alkylglyceryl chains did not induce an increase in toxicity when compared to 
native dextran (both modifications exhibited viability above 80 %). Interestingly, the lowest 
viability (below 60 %) for the bEnd3 cells was observed following incubation with chitosan 
(ANOVA, p < 0.05), possibly explained by the microparticulate form due to the insolubility of 
normal chitosan in PBS at neutral pH and by positive charge of the polysaccharide [199]. On 
contrary, nanoparticles from chitosan derivatives were found to be non-toxic [196]. It should be 
noted that both assays were conducted with various kinds of cells. 
 
Figure 5.5. Relative toxicity of compounds employed further for various nanoformulations;  
bEnd3 cells incubated with 1 mg/mL material for 24 h; MTT assay; digitonin and PBS blank 
treatment as controls (n =12; ±SD; CS- chitosan; DEX-dextran, DEX-OX4 – butylglyceryl-
modified dextran, DEX-OX8 – octylglyceryl-modified dextran, digitonin as a positive control). 
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5.3.1.2. Toxicity of poly(lactic acid)-graft-alkylglyceryl-modified dextran nanoparticles 
A cytotoxicity assay following incubation of mouse brain bEnd3 endothelial cells for 24 
h with poly(lactic acid)-graft-alkylglyceryldextran derivatives nanoparticles (1 mg/mL) revealed 
no significant toxicity induced by these nanoformulations compared to the PBS control (Figure 
5.6, ANOVA p < 0.05). As previously reported earlier for chitosans [129, 173], modifying 
dextran with alkylglyceryl pendant chains did not appear therefore to lower significantly the 
mouse brain endothelial cell viability. It appeared that the viability of cells for treatment with 
nanoparticles from PLA-DEX, PLA-DEX-OX4 and PLA-DEX-OX8 was about 90 % (when 
compared to PBS control).  
The non-toxicity finding was confirmed by experiments with human endothelial cells 
(hCMEC/D3) as no toxic effect of alkylglyceryl modification was observed in direct 
comparison of PLA-DEX with PLA-DEX-OX4 nanoparticles in concentrations 1 mg/mL, 2 
mg/mL and 4 mg/mL after 3 hours of incubation (Figure 5.7.), even doses as high as of 4 
mg/mL are well tolerated by human endothelial cells. It appeared that the alkylglyceryl 
modification exhibited even decreased toxicity when compared to PLA-DEX. This supports the 
original finding about non-toxic features of alkylglycerols [95].  
A dose response experiment of PLA-DEX-OX4 nanoparticles (range 1 – 4 mg/mL) 
employing hCMEC/D3 human brain endothelial cells for 24 h exhibited reduced viability (74 
%) at doses 2 mg/mL and higher (ANOVA, p < 0.05). The doses 0.2-1.0 mg/mL influenced the 
viability as well however not in a significant way (Figure 5.8.). 
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Figure 5.6. Relative toxicity of nanoparticles formulated from poly(lactic acid)-graft-
alkylglyceryldextran derivatives; MTT assay; bEnd3 cells incubated with 1 mg/mL of  
nanoparticles for 24 h; PSB and, digitonin as controls  (n=18, ±SD); (PLA-DEX-OX4 - 
poly(lactic acid)-graft-alkylglyceryldextran, PLA-DEX-OX8 - poly(lactic acid)-graft-
butylglyceryldextran, PLA-DEX - poly(lactic acid)-graft-dextran, PBS and digitonin is as a 
negative and positive cytotoxic control respectively 
 
 
Figure 5.7. Relative toxicity of nanoparticles formulated from poly(lactic acid)-graft-
alkylglyceryldextran derivatives; PrestoBlue assay; hCMEC/D3 cells incubated with 
nanoparticles for 3 h; PSB and, digitonin as controls (n=12, ±SD); (PLA-DEX-OX4 - 
poly(lactic acid)-graft-alkylglyceryldextran, PLA-DEX - poly(lactic acid)-graft-dextran, PBS as 
a control 
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Figure 5.8. Relative toxicity of nanoparticles formulated from poly(lactic acid)-graft-
alkylglyceryldextran derivatives (1 – 4 mg/mL); PrestoBlue assay; hCMEC/D3 cells incubated 
with nanoparticles for 24 h; PSB and, digitonin as controls  (n=12, ±SD); (PLA-DEX-OX4 - 
poly(lactic acid)-graft-alkylglyceryldextran, PBS as a control). 
 
5.3.1.3. Toxicity of alkylglyceryl-modified chitosan nanoparticles crosslinked with 
 TPP 
The cytotoxicity of nanoparticles prepared from alkylglyceryl-modified chitosan 
derivatives crosslinked with TPP was assessed on human endothelial cell cultures incubated for 
24 h and using a Presto Blue assay. While chitosan (CS) and trimethylchitosan (TMC) appear 
non-toxic, their alkylglyceryl-modified counterparts seem to reduce cell viability (Figure 5.9.). 
However, this conclusion is questionable as (despite a large number of repeats) standard 
deviations were rather large and differences were not statistically significant. Occasional 
reproducibility issues due to the reduced stability at neutral pH of these chitosan-based 
nanoformulations (also mentioned in the literature [111, 173, 174]) represent a likely 
explanation for the large standard deviation observed. 
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Figure 5.9. Relative toxicity of nanoparticles formulated from chitosan-derivatives; hCMEC/D3 
cells incubated with 1 mg/mL nanoparticles; PSB and digitonin as controls  (n=36, ±SD); 
PrestoBlue assay; (CS - chitosan; TMC – trimethylchitosan; CS-OX4 - butylglycerylchitosan, 
TMC-OX4 trimethylbutylglycerylchitosan, CS-OX8 – butylglycerylchitosan, TMC-OX8 - 
trimethyloctylglycerylchitosan).  
 
5.3.2. The uptake of nanoparticles from poly(lactic acid)-graft-
 butylglyceryl-dextran by mouse endothelial cell 
To investigate the uptake of the nanoparticles prepared from PLA-DEX-OX4 loaded 
with Rhodamine B (0.5 % w/w), bEnd3 mouse brain endothelial cells were incubated for 3 h 
with a 1 mg/mL of nanoformulation in modified DMEM (as described in chapter 5.2.4.); media 
was then removed and cells were washed with PBS twice (to remove nanoparticles and/or 
released Rhodamine that were not taken up) and observed using a confocal microscope. A 
Rhodamine B solution (5 x 10
-4
 mg/mL) was employed as a control. Images presented in Figure 
5.10. are indicative of nanoparticle uptake as they show the presence of Rhodamine B-loaded 
carriers in the cell cytoplasm around the peri-nuclear space, while no evidence of Rhodamine B 
administered as a control solution could be found inside cells. While there is no evidence of 
particular targeting the nuclei, the nanoparticles appear to have been localised in vesicles 
(possibly Golgi apparatus, as previously demonstrated for CS-OX4 nanoparticles [129]) inside 
the bEnd3 cells as displayed on Figure 5.11. which is a 3 dimensional  projection of z stack of a 
series of confocal sections.  
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   Hoechst         Rhodamine B         Merge  
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2a  2b  2c  
Figure 5.10. Confocal microscope images of bEnd3 cells following incubation with poly(lactic 
acid)-graft-butylglyceryldextran (PLA-DEX-OX4) nanoparticles for 3 h. Top (number 1)-
nanoparticles, bottom (number 2)- dye control, a)-image of cell nuclei (laser 405 nm), b)-image 
of the Rhodamine B labelled structures (laser 543nm), c)-merge. Rhodamine B –loaded 
nanoparticles are visualised in red, while Hoechst-counterstained nuclei appear in blue. 
 
Figure 5.11. Three dimensional Z stack projection of optical sections of bEnd3 cells containing 
nanoparticles from PLA-DEX-OX4 loaded with Rhodamine B (red arrow). Nuclei stained with 
Hoechst (blue arrow). 
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5.3.3. The effect of nanoparticles from poly(lactic acid)-graft-
 butylglyceryl-dextran  on electrical resistance of endothelial 
 cells 
The interactions of nanoparticles with brain endothelial cells were also studied by 
monitoring their Trans Endothelial Electrical Resistance (TEER) using Electrical Cell 
Impedance Sensing (ECIS). Both bEnd3 and hCMC/D3 cells were separately cultured on 
8W10E, 8 well golden electrode arrays, previously coated with Matrigel 1.5 mg/mL to support 
the endothelial cell growth [129] (there can be used also other kinds of the extracellular matrix 
as rat tail collagen 1 [341] or fibronectin [49]), as described in section 5.2.5. The mouse model 
reached ca. 800 Ω resistance, while the human model exhibited a resistance of ca. 1200 Ω when 
the cell cultures achieved confluency (at 48 h, data not shown). The cells were then incubated 
with nanoparticles (PLA-DEX-OX4 1-4 mg/mL or PLA-DEX 4 mg/mL) for 24 h, after which 
nanoparticles were replaced with fresh media; cell behaviour was continuously monitored by 
TEER measurements.  
The changes detected in the TEER of confluent cell layers both during incubation and 
following removal of nanoparticles are presented in Figure 5.12. (as relative value to PBS 
control with no nanoparticles). Mouse cells bEnd3 incubated with nanoparticles prepared from 
poly(lactic acid)-graft-butylglyceryldextran (PLA-DEX-OX4) showed a different behaviour 
compared to those incubated with poly(lactic acid)-graft-dextran (PLA-DEX) nanoparticles. A 
drop in TEER was observed during incubation with nanoparticles bearing the alkylglyceyl-
modification in all concentrations. Furthermore, following nanoparticle removal, TEER 
recovered for all the formulations except in the case of the highest dose of PLA-DEX-OX4 (at 
point 72 h a statistical difference, ANOVA, p<0.05, Figure 5.12.-A). This can be attributed to 
long term toxicity of high doses of PLA-DEX-OX4 nanoparticles. No significant dose response 
effect could be observed for human brain endothelial cells when repeating the experiment using 
hCMEC/D3 cell cultures (Figure 5.12.-B).  
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A) 
 
B) 
Figure 5.12. ECIS plot (relative resistance of. PBS treated control) of TEER development (2000 
Hz) on A) bEnd3, B) hCMEC/D3 endothelial monolayers cultured on 8W10E test plates, 
following exposure to and then removal of nanoparticles(orange arrows). Treatment with 
nanoparticles prepared from PLA-DEX and PLA-DEX-OX4 (dose-response experiment). 
Nanoformulations were added to the cells at 48 h and removed at 72 h, after which the cells 
were allowed to recover for a further 48 h. Data are presented as means of at least three wells 
(n = 3) for each condition of a representative measurement (±SE). Untreated cells (PBS, no 
nanoparticles added) were employed as control. 
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5.3.4. The effect of nanoparticles from poly(lactic acid)-graft-
 butylglyceryldextran on translocation of a fluorescent marker 
 through barriers of endothelial cells 
  
Permeation studies of PLA-DEX-OX4 nanoparticles through brain endothelial cell 
monolayers were performed using a translocation model system based on a Transwell setup, as 
described in chapter 5.2.6. Both mouse and human endothelial cells were employed in these 
studies; the permeability of each nanoformulation (PLA-DEX-OX4 1-4 mg/mL and PLA-DEX 
4 mg/mL) was assessed using FITC-labelled dextran (MW 150 kDa), employed as a marker to 
verify the possibility of poly(lactic acid)-graft-butylglycerol-modified dextran nanoparticles 
(PLA-DEX-OX4) to influence permeability of the models of the blood-brain barrier.  
 It was found that the model based on human cells allowed less marker to pass through 
the barrier (Figure 5.13.). The amount of transported FITC was used to calculate the apparent 
permeation coefficient. The apparent permeation coefficient (Papp) was determined by 
concentration of FITC-DEX in known volume transported across the barrier of known surface 
area (chapter 5.2.6.). The apparent permeability coefficient Papp was described by Arthursson 
[421] and has been used in numerous studies, e.g. by Gaillard [431], Ragnaill [432]. The 
formula can illustrate a translocating capacity of a cellular monolayer based on surface area of a 
population (given by the surface area of a filter membrane where the cells grow) of the cell 
culture and time.  
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A) 
 
B) 
Figure 5.13. FITC-dextran (150 KDa) translocation through an endothelial cell layer: A) 
bEnd3 cells, B) hCMEC/D3 cells. Treatment with nanoparticles prepared from poly(lactic 
acid)-graft-dextran (PLA-DEX) or poly(lactic acid)-graft-butylglyceroldextran (PLA-DEX-
OX4), at different doses. Variation in the percentage of FITC dextran transported across the 
barrier over time. FITC dextran only employed as a control (n = 5, ±SD).  
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Table 5.2. Papp coefficients for PLA-DEX and PLA-DEX-OX4 nanoparticles using human and 
mouse endothelial cells at 3 h incubation time (FITC-DEX only as control, n=3, ±SD). 
 
The results showed concentration dependent performance of PLA-DEX-OX4 
nanoparticles (significant only in dose 4 mg/mL at 3 hours using human cells model, ANOVA 
p<0.05). Lower values of Papp were obtained for the hCMEC/D3 cell model compared to the 
bEnd3 one which points towards better barrier properties of human cell model (Table 5.2.) The 
values for human model were different to cases reported previously in the literature, which is 
not unexpected though, considering the different conditions employed in each reported study (as 
a different tracer molecule and different pore size of the filter), and the relative high 
concentration of nanoparticles used in these experiments [432, 433]. However values obtained 
with mouse model were consistent with previous findings of Lien et al. [129], who studied 
modified-chitosan nanoparticles (0.25 mg/mL) using bEnd3 cells and obtained Papp values of ca. 
1 x 10
-7
 at 4 h of incubation of the cells with FITC-DEX, 150 kDa. As Lien discussed, a barrier 
enhancing formula was used to decrease the permeability of the Transwell cellular monolayer 
(though this has been previously debated in the literature as introducing a non-physiological 
feature into the system [86, 434]). Data presented in Table 5.2. suggest that PLA-DEX-OX4 
nanoparticles were more effective in influencing the permeability for the FITC-DEX through 
both bEnd3 and hCMEC/D3 cell monolayers compared to PLA-DEX nanoparticles (3 hours of 
application, dose 4 mg/mL, ANOVA, p<0.05). Previous toxicity experiments revealed that the 
alkylglyceryl modification does not induce additional toxicity to cells for short time up to 3 h 
(section 5.3.1); therefore the increased transport of FITC-DEX should be not attributed to cell 
death and consequent development of “leaky holes” in the cell monolayers. While PLA-DEX 
nanoparticles were also seen to increase the transport of FITC-DEX to certain extent (possibly 
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via non-specific nanoparticle-cell interaction [154]), results appear to support therefore the 
hypothesis that the alkylglyceryl modification could possibly increase this permeability via 
mediated opening of the tight junctions [129]. 
 
5.4. Conclusions  
The novel polymers (DEX-OX8 and DEX-OX4) and formulations of nanoparticles from 
chitosan based derivatives (CS-OX derivatives crosslinked with TPP), and novel dextran based 
derivatives (PLA-DEX-OX4 and PLA-DEX-OX8), were tested with both mouse (bEnd3) and 
human (hCMEC/D3) brain endothelial cells 
The toxicity of alkylglyceryl-modified dextrans (DEX-OX) was tested on mouse brain 
endothelial cells (bEnd3) using an MTT assay. Both modifications were compared to native 
dextran and chitosan. DEX-OX4 and DEX-OX8 exhibited similar toxicity as native dextran 
however both DEX-OX derivatives were less toxic than chitosan in 24 hour incubation for 
concentration1mg/mL (ANOVA, p<0.05).  
Toxicity of nanoformulations prepared from novel materials (poly(lactic acid)-graft-
alkylglyceryl-modified dextran derivatives) was investigated using human brain endothelial 
cells (hCMEC/D3) by employing a Presto Blue assay. The nanoparticles from PLA-DEX-OX4 
and PLA-DEX-OX8 were not found to be more toxic than nanoparticles without alkyglyceryl 
modification (PLA-DEX) in concentration 1 mg/mL after 24 h incubation. Furthermore, short 
time incubation (3 h) with a concentration range of 1 - 4 mg/mL revealed no significant 
differences in terms of toxicity between nanoparticles prepared from alkylglyceryl-modified 
polymer (PLA-DEX-OX4) and nanoparticles prepared from polymer without alkylglyceryl 
modification (PLA-DEX). When tested for long-term incubation (24 h), PLA-DEX-OX4 
nanoparticles appeared non-toxic at low concentrations, though cell viability was found to 
decrease (down to ca. 70 %) at higher concentrations (differences become statistically 
significant above 2 mg/mL; ANOVA, p=0.05). For comparative purposes nanoparticles 
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prepared from alkylglyceryl-modified chitosans were also investigated for toxicity; however 
reproducibility issues due to low stability of chitosan-based nanoformulations at pH 7.4 did not 
allow a reliable interpretation of the results obtained. 
Cell-nanoparticle interactions were studied on mouse brain endothelial cells (bEnd3) 
using PLA-DEX-OX4 nanoparticles loaded with Rhodamine B, employing confocal 
microscopy (cell nuclei were stained with Hoechst Blue while the dye was visualized in red). It 
was found that PLA-DEX-OX4 nanoparticles were rapidly taken up by the bEnd3 cells into 
vesicles that localized into the cytoplasm, around the nuclei. The Rhodmine B solution, 
employed as a control, was not detected inside the cells.  
Electric Cell Impedance Sensing (ECIS) was employed to monitor changes in the 
transendothelial electrical resistance (TEER) of brain endothelial cell layers that were induced 
by the incubation with PLA-DEX-OX4 nanoparticles. Both mouse and human endothelial cells 
were tested (in monocultures), and PLA-DEX nanoparticles were used as controls. With bEnd3 
cell cultures, PLA-DEX-OX4 nanoparticles were found to induce dose-dependent changes in 
TEER (concentration range 1 - 4 mg/mL, significant for highest concentration, ANOVA, 
p<0.05). TEER recovery was observed for all formulations except for the most concentrated one 
(4 mg/mL), that generated a significantly different behaviour compared to that observed for the 
other PLA-DEX-OX4 concentrations and also for the nanoparticles prepared from unmodified 
dextran-based material (PLA-DEX; 4 mg/ml). Interestingly, no significant differences could be 
observed in the cell behaviour induced by PLA-DEX or PLA-DEX-OX4 nanoformulations 
when they were tested in the same range of concentrations (1 - 4 mg/mL) using human brain 
endothelial cells (hCMEC/D3).   
A blood brain barrier model based on a Transwell system was employed to assess the 
influence of PLA-DEX-OX4 nanoparticles on the transport of fluorescein labelled dextran 
(FITC-DEX) through a confluent layer of either mouse (bEnd3) or human (hCMEC/D3) brain 
endothelial cells. It was found that the translocation of FITC labelled dextran through the human 
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hCMEC/D3 cell layer was enhanced by PLA-DEX-OX4 nanoparticles in a concentration 
dependent manner (1 - 4 mg/mL), while the application of PLA-DEX nanoparticles, employed 
as control (4 mg/mL), did not appear to have a similar effect. Under the conditions studied, the 
mouse model was found to be leaky to allow reliable differentiation of the FITC tracer flux 
between treatments.  
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PRELIMINARY STUDIES IN OVO 
             
This chapter investigates the interactions of nanoparticles from poly(lactic acid)-graft-
alkylglyceryl-modified-dextran with chicken embryos in ovo. The purpose of this preliminary 
study also was to outline the possibilities and limitations of using chicken embryos as 
an alternative to the employment of  mammalian models for the evaluation of drug delivery 
systems.  
 
6.1. Materials and instrumentation 
Embryos in their early stage of development (HH 19, day 2; eggs supplied from a local 
farm after fertilization) were employed for these studies. After delivery, eggs were stored prior 
use in a cold storing room (15 °C). Gentamycin and PBS were supplied from Gibco; fountain 
ink (India) was purchased from Pelikan. Fast green, Paraformaldehyde and Rhodamine B were 
obtained from Sigma, UK. A pumping device (Pneumatic PicoPump pv820, World Precise 
Instruments, USA) was used for intracardial administration via glass micro-needle (prepared in 
house). A vibratome Series 1000 (Section Vibratome System) was used for microscopy sample 
preparations, which were observed using a confocal microscope LSM 710, ZEISS, UK.. The 
nanoparticles from poly(lactic acid)-graft-alkylglyceryl-modified-dextran (PLA-DEX-OX4) 
were loaded with Rhodamine B (by electrospraying method, loading 0.5 % w/w). 
 
6.2. Methods  
Eggs (n = 6) were placed into an incubator (37 °C, 60-70 % humidity) 48 hours prior to 
nanoparticle injection. After 72 h in the incubator (Hamburger-Hamilton stage19-20), a needle 
  PRELIMINARY STUDIES IN OVO 
144 
inserted through the eggshell at the narrow apex was used to remove the excess of egg white. 
The adhesive tape was used to cover the egg on the top and a small oval window was cut into 
the shell through the tape (Figure 6.1.). The adhesive tape was able to keep the egg structure 
rigid without collapsing. 
 
Figure 6.1. Egg with a window cut in the shell, the adhesive tape supports the opened shell  
 
100 μL of gentamycin in PBS (10 % w/v) was instilled inside the egg as an antibiotic 
pre-treatment prior to any manipulation. Fountain pen ink was then injected under the embryo to 
provide a contrast background for easier orientation and manipulation. The vitelline membrane 
enveloping the embryo was then cut with a forceps to reach the heart area of the embryo. A thin 
glass micro-needle (diameter ca. 25 μm) connected to a pneumatic pumping device was used to 
inject the nanoformulation into the heart of the embryo, close to aorta. Rhodamine B-loaded 
PLA-DEX-OX4 nanoformulations (5 μL; 1 mg/mL; Rhodamine loading 1.5 % w/w) were 
employed for this study, with a Rhodamine B solution (5 μL; 0.015 mg/mL) used as a control. 
The examined solutions were stained by the Fast Green solution (1 % v/v) which was used to 
visualise the blood stream of the embryos. The egg cavity was instilled again with a dose of the 
antibiotic (as above), and the shell window was sealed with transparent adhesive tape. The eggs 
were then further incubated (37 °C, 60-70 % humidity) for 24 h before harvesting the embryos. 
The embryos were removed from the eggs and further purified by removing the rest of the 
vitelline membrane (by forceps), fixed for 15 minutes in paraformaldehyde solution in PBS 
(4 % w/v) and embedded in hot gelatine (60 °C). After 2 hours in fridge (4 °C) the embryos 
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were removed and cut using vibratome (50 μm thick slices). The analysis was performed by a 
confocal microscope (543 nm laser for Rhodamine B).  
6.3. Results and discussion 
1a  1b  1c  
           
2a 2b 2c  
 
3  
Figure 6.2. Confocal microscopy images of sections of somnites of chicken embryos: 1) 
nanoparticles loaded with Rhodamine B; 2)Rhodamine B solution (a-fluorescence at 543 nm, 
b-Differential Interference Contrast (Nomarski) image, c-merge), 3) illustration of the site of 
injection and a sample of somnites. 
  
 Nanoparticles prepared from PLA-DEX-OX4 and loaded with Rhodamine B (degree of 
loading 1.5 % w/w) were injected into the heart of chicken embryos as described in section 6.2. 
(Rhodamine B solution was used as control). Following injection, nanoparticles did not appear 
to aggregate in the circulation or to affect the viability of the embryos (100 % viability for both 
control and nanoparticles was recognised by the heart function of the embryos) for the duration 
of the experiment (min. 24 h following injections). No specific patterns could be observed in the 
INJECTION SECTION 
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biodistribution of Rhodamine B, which appeared to be circulated freely in the embryo as the 
blood-brain barrier is still leaky at this stage [376, 435]. The dye was taken up by the tissues, 
most of the fluorescence appeared around blood vessels. Also, no differences could be observed 
in the distribution of Rhodamine B between the two administration methods employed (i.e. as 
solution, or loaded into nanoparticles and later released during incubation), Figure 6.2; 
(APPENDIX XIII). 
6.4. Conclusions  
Results of in vitro studies (reported in Chapter 5) have indicated the potential of 
nanoparticles prepared from poly(lactic acid)-graft-butylglyceryldextran (PLA-DEX-OX4) as 
permeating vectors in brain drug delivery applications therefore justifying their further 
investigation. However in vivo studies based on mammalian models require a rather complex 
setup so a rapid, simple and inexpensive method employing chicken embryos was used to 
preliminarily check for biodistribution and simple organism toxicity. While an important 
disadvantage of using chicken embryos is the absence of fully developed barriers (including the 
blood-brain barrier) prior to the early postnatal period, and while such methods cannot replace 
rigorous studies based on adult animal models, living embryos are complex enough to provide 
useful information between in vitro experiments using cell cultures and full scale in vivo studies 
on adult animals.  
Nanoparticles prepared from PLA-DEX-OX4 loaded with Rhodamine B were applied 
via intracardiac microinjection (5 μl; 1 mg/mL), with free Rhodamine B solution injected in a 
control embryo. Transparency of embryos allowed direct observation of the distribution of the 
fluorescent hydrophilic dye (Rhodamine B) that has been loaded into the nanoparticles. The 
biodistribution was also studied by confocal microscope, and the vasculature appeared to be 
‘leaky’, indicating no barriers in tissues that could resist permeation of the dye. The dye was 
taken up by the tissues and there was no different pattern of distribution of Rhodamine B 
observed between the control and loaded nanoparticles.   
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Furthermore, it was possible to assess the toxicity of nanoparticles during the 
investigated period (24 h): no aggregation of nanoparticles was observed in the cardiovascular 
system, indicating no visible interaction with the blood components. All embryos were alive 
after 24 h of incubation, indicating no acute toxicity at the administered dose (5 μL; 1 mg/mL), 
and no damage to organs could be detected under the microscope 
.   
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7 
GENERAL CONCLUSIONS 
             
Being able to direct actives into the brain via non-invasive routes may be compared to 
seeking for the holy grail of drug delivery, and continues to pose challenges for current 
pharmaceutical research. The brain is well protected by the blood-brain barrier, which maintains 
specific conditions for neuronal signalling by regulating the traffic of metabolites and restricting 
non-invited compounds from entering the brain. Among a number of recent experimental 
approaches, the employment of short chain alkylglycerols was shown to improve permeation of 
co-administered drugs into the brain, as was the use of nanoparticulate drug delivery systems. 
This project was aimed at combining these two approaches by developing alkylglyceryl-
modified nanoparticles and testing the ability of such delivery systems to cross the BBB. 
Polysaccharides such as chitosan and dextran were selected for modification with 
alkylglyceryl pendent chains due to their biocompatibility, biodegradability and non-toxicity 
combined with good drug carrier properties. Following in-house preparation of the required 
oxiranes, alkylglyceryl-modified chitosan derivatives (CS-OXn; where n = butyl-, pentyl-, 
octyl-) were prepared with degrees of substitution varying from 14 to 88 % (calculated from 
1
H-
NMR spectra). Novel alkylglyceryl-modified dextran derivatives (DEX-OXn; where n = butyl, 
octyl) were prepared with degrees of substitution varying from 0.7 to 75.1 %.  
Butylglyceryl-dextran (DEX-OX4) and octylglyceryl-dextran (DEX-OX8) were grafted 
onto poly(lactic acid) using zero-length crosslinkers (CDI and DCC) to yield PLA-DEX-OX4 
and PLA-DEX-OX8 (degree of grafting 88-120 units of poly(lactic acid) per 100 units of DEX-
OXn, as determined by 
1
H-NMR). Attempts to modify poly(lactic acid) with maleic anhydride 
anchors via a radical reaction in order to ultimately increase the number of reactive groups for 
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further grafting with dextran afforded only a low degree of modification (0.8 - 2.2 %), and were 
not pursued further. 
Nanoparticles formulated from CS-OXn materials via ionotropic gelation with sodium 
tripolyphosphate (TPP) had acceptable features for drug delivery (size 100-150 nm; zeta 
potential 40-50 mV). However, they were difficult to redisperse following purification by either 
ultracentrifugation or dialysis against deionised water, and gradual particle agglomeration was 
observed at physiological pH values (pH 7.0 to 7.4). Crosslinking of CS-OX4 with dextran 
sulphate (DEX-S) resulted in nanoparticles (200 – 400 nm; zeta potential  - 30 mV; in acidic 
conditions, as prepared) with improved stability at neutral pH, however, redispersion following 
purification by centrifugation still showed stability problems.  
Coating poly(lactic acid) nanoparticles with CS-OX4 in the presence of surfactants such 
as poly(vinyl alcohol), poloxamer 188 or poloxamer 407 provided stable nanoparticles  at acidic 
pH (ca. 190 nm diameter; zeta potential 50 mV; pH 4). However, agglomeration was still 
observed when pH was changed to neutral (ca. 300-1200 nm; zeta potential ca. -10 mV; pH 7); 
best results were obtained when poloxamers in concentration 10 mg/mL were used. 
Overall, nanoformulations containing CS-OXn derivatives showed redispersion 
difficulties and limited stability at neutral pH. While the formulations studied here would not be 
ideal for drug delivery to the brain, they could make good candidates for applications that can 
tolerate acidic conditions, such as topical skin delivery. 
Complexation of butylglyceryl-dextran (DEX-OX4) with chitosan oligomers in the 
presence of poloxamer 407 as surfactant resulted in stable nanoparticles at neutral pH (ca. 200 
nm diameter; zeta potential ca. - 1 mV; at pH 7.4) and which could be successfully loaded with 
Doxorubicin (degree of loading 4.1 % w/w). However, purification using centrifugation induced 
redispersion problems as seen with the nanoformulations based on alkylglyceryl-modified 
chitosans.  
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Nanoprecipitation of poly(lactic acid) into solutions of buylglyceryl-dextran (DEX-
OX4) resulted into structures (100-200 nm diameter) that were stable at physiological 
conditions (pH 7.4; PBS buffer, 0.9 % saline), but further investigation using repeated 
centrifugation-redispersion cycles revealed that the layer of butylglyceryl-dextran coating the 
PLA core was unstable. 
Graft copolymers (PLA-DEX-OXn, n= butyl-, octyl-) were obtained by covalently 
linking poly(lactic acid) to alkylglyceryl-dextran by means of zero-length crosslinkers (CDI, 
DCC). These materials were then formulated into nanoparticles using different methods: solvent 
displacement (via dialysis), nanoprecipitation and electrospraying. All three methods produced 
nanoparticles with similar characteristics (size range 100-200 nm; zeta potential -25 mV) that 
were loaded with hydrophilic model drugs/markers such as Fluorescein, Rhodamine B or 
Doxorubicin. Electrospraying showed superior loading compared to solvent displacement for 
Rhodamine B and Doxorubicin (4.93 % and 12.57 % vs. 0.32 % and 0.50 % respectively - all % 
w/w). The release profiles of all hydrophilic drugs/markers employed showed an initial burst 
phase followed by a release that could be monitored for several hours.  
In vitro studies using brain endothelial cell cultures (mouse bEnd3 and human 
hCMEC/D3) revealed no toxicity for the nanoparticles prepared from dextran-based materials at 
doses below 2 mg/mL, although cell viability decreased to 80 % for 4 mg/mL. Nanoparticles 
prepared from PLA-DEX-OX4 exhibited different behaviour during electric cell substrate 
impedance sensing (ECIS) experiments compared to those obtained from PLA-DEX. The 
change in transendothelial electrical resistance (TEER) observed upon incubation of human or 
mouse endothelial cells with PLA-DEX-OX4 nanoparticles, which can be associated to changes 
in cell morphology that may indicate an effect at the tight junctions level, was more significant 
in the mouse model and was found to be concentration dependent.  
Compared to PLA-DEX at the same concentration (4 mg/mL), PLA-DEX-OX4 
nanoparticles were shown to enhance the FITC-labelled dextran flux through a Transwell-based 
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BBB model comprised of either mouse (bEnd3) or human (hCMEC/D3) brain endothelial cells. 
However, both mouse and human cell monoculture models were found to be leaky; they 
exhibited a significant flux of fluorescent tracer even for negative controls, with the mouse 
model being worse.  
In ovo experiments assessed the effect of PLA-DEX-OX4 nanoparticles on simple 
organisms of chicken embryos. All embryos (n = 6) were alive after 24 h of incubation, which 
supports in vitro data indicating the lack of acute toxicity for PLA-DEX-OX4 nanoparticles. 
The chicken embryo biodistribution of Rhodamine B marker loaded into nanoparticles was 
similar to that exhibited by the free Rhodamine B solution employed as a control. This is likely 
to be due to the release of dye from nanoparticles combined with the leaky barriers present in 
the embryo at this stage. Confocal microscopy observations did not show any accumulation in a 
specific organ.  
In comparison to nanoparticles prepared from alkylglyceryl-modified chitosan 
derivatives (CS-OX),which exhibited low stability at neutral pH and so make such formulations 
rather unsuitable for intravenous drug delivery, nanoparticles from poly(lactic acid)-graft-
butylglyceryl dextran (PLA-DEX-OX4) were found to have promising characteristics that can 
encourage further research in the direction of brain drug delivery. They were stable at 
physiological pH and relatively non-toxic for mouse and human endothelial cells and chicken 
embryos. PLA-DEX-OX4 based nanoparticles were also observed to induce a dose-dependent 
change in TEER – indicative of a modification of the integrity of the endothelial cell epithelium 
– and to enhance the transport of FITC dextran through endothelial cell monocultures.  
Employing a higher-level in vitro model of the blood brain barrier (e.g. one that 
simulates the support of endothelial cells by pericytes and astrocytes, the fluid flow, or the 
interaction of nanoparticles with plasma proteins) would be an important step in the further 
investigation of the potential of PLA-DEX-OX4 nanoparticles to act as permeating vectors that 
can transport a drug load through the BBB. As the preliminary in ovo study reported here could 
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not provide any information in terms of biodistribution, in vivo work employing a rodent model 
would be necessary in order to collect relevant data.  
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DEX-OX4 
Off white solid 
DMSO soluble, water soluble 
FT-IR (ATR; vmax; cm-
1
): 3227 (O-H str, OH pyranose ring); 2872 (C-H, str pyranose ring, CH2 
of butyl group); 1336 (C-O-H def, pyranose ring, alkylglycerol); 1111 (C-O-C, str, glycoside 
linkage); 1006 (C-O def, pyrnose ring, alkylglycerol); 913, 866 (C-C def, pyranose ring); 526 
(C-C-O def, alkylglycerol) 
1
H-NMR (400MHz; DMSO-d; δ; ppm): 0.9 (m, 3H, alkylglyceryl terminal-CH3); 1.3 (m, 2H, 
alkylglyceryl-3-CH2); 1.5 (m, 2H, alkylglyceryl-2CH2); 3.2 (m, 2H, dextran 2CH, 4CH); 3.4 (m, 
1H, dextran 3CH); 3.6 (m, 2H, dextran 5CH, 6CH’); 3.7 (s, 1H, dextran 6CH) 4.7 (s, 1H, 
dextran 1CH) 
13
C-NMR (100MHz; DMSO-d; δ; ppm): 14.29 (butylglycerol terminal CH3,); 19.40 
(butylglycerol-3CH2); 27.00 (butylglycerol-2CH2);31.36 (butylglycerol-1CH2);61.80 (dextran-
6CH2); 69.38 (dextran-2CH); 70.81 (dextran-4CH); 72.76 (dextran-5CH); 73.64 (dextran-
3CH); 98.77 (dextran anomeric-1CH) 
 
  
  APPENDICES 
179 
APPENDIX II    
1
H-and 
13
C-NMR spectra of DEX-OX8 
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DEX-OX8 
Beige solid 
DMSO soluble, water soluble 
FT-IR (ATR; vmax; cm-
1
): 3322 (O-H str, OH pyranose ring); 2922 (C-H, str pyranose ring, CH2 
of butyl group); 1346 (C-O-H def, pyranose ring, alkylglycerol); 1149 (C-O-C, str, glycoside 
linkage), 1000 (C-O def, pyrnose ring, alkylglycerol);915, 852 (C-C def, pyranose ring); 506 
(C-C-O def, alkylglycerol) 
1
H-NMR (400MHz; DMSO-d; δ; ppm): 0.8 (m, 3H, alkylglyceryl terminal-CH3); 1.2 (m, 12H, 
alkylglyceryl-2-7CH2); 1.4 (m, 2H, alkylglyceryl-1CH2); 3.2 (m, 2H, dextran 2CH, 4CH); 3.3 
(m, 1H, dextran 3CH); 3.6 (m, 2H, dextran 5CH, 6CH’); 3.7 (s, 1H, dextran 6CH) 4.7 (s, 1H, 
dextran 1CH) 
13
C-NMR (100MHz; DMSO-d; δ; ppm): 14.48 (octylglycerol terminal-CH3,); 22.66 
(octylglycerol-7CH2); 26.22 (octylglycerol-6CH2); 29.22 (octylglycerol-5CH2); 29.28 
(octylglycerol-4CH2); 29.45 (octylglycerol-3CH2); 29.78 (octylglycerol-2CH2); 31.86 
(octylglycerol-1CH2); 66.56 (dextran-6CH2); 70.74 (dextran-2CH); 71.164 (dextran-4CH); 
72.63 (dextran-5CH); 73.87 (dextran-3CH); 99.71 (dextran anomeric-1CH)  
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APPENDIX III   
1
H-and 
13
C-NMR spectrum of PLA- DEX-OX4 
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PLA-DEX-OX4 
Off white solid 
DMSO soluble, water soluble 
FT-IR (ATR; vmax; cm-
1
): 3387 (O-H str, OH pyranose ring); 2941 (C-H, str pyranose ring, CH2 
of butyl group); 1755 (C=O str, poly(lactc acid)); 1451 (C-O-H def, pyranose ring, 
alkylglycerol); 1148 (C-O-C, str, glycoside linkage), 1001 (C-O def, pyrnose ring, 
alkylglycerol); 915, 852 (C-C def, pyranose ring); 506 (C-C-O def, alkylglycerol) 
1
H-NMR (400MHz; DMSO-d; δ; ppm): 0.9 (m, 3H, alkylglyceryl terminal-CH3); 1.3 (m, 2H, 
alkylglyceryl-3-CH2); 1.4 (s, 3H, poly(lactic acid)CH3); 3.2 (m, 2H, dextran 2CH, 4CH); 3.4 
(m, 1H, dextran 3CH); 3.6 (m, 2H, dextran 5CH, 6CH’); 3.7 (s, 1H, dextran 6CH); 4.7 (s, 1H, 
dextran 1CH); 5.2 (m, 1H, poly(lactic acid) CH) 
13
C-NMR (100MHz; DMSO-d; δ; ppm): 14.38 (butylglycerol terminal CH3,);16.99 (poly(lactic 
acid)CH3); 19.40 (butylglycerol-3-CH2); 20.09 (butylglycerol-2CH2);31.88 (butylglycerol-
1CH2); 66.62 (poly(lactic acid)CH); 69.24 (dextran -6CH2); 70.71 (dextran -2CH); 70.82 
(dextran -4CH); 72.74 (dextran -5CH); 73.88 (dextran -3CH); 98.76 (dextran anomeric -1CH) 
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APPENDIX IV   
1
H-and 
13
C-NMR spectrum of PLA- DEX-OX8  
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PLA-DEX-OX8 
Off white solid 
DMSO soluble, water soluble 
FT-IR (ATR; vmax; cm-
1
): 3360 (O-H str, OH pyranose ring); 2933 (C-H, str pyranose ring, CH2 
of butyl group); 1754(C=O str, poly(lactc acid)); 1452(C-O-H def, pyranose ring, 
alkylglycerol); 1184 (C-O-C, str, glycoside linkage), 1008 (C-O def, pyrnose ring, 
alkylglycerol); 905, 852 (C-C def, pyranose ring); 539 (C-C-O def, alkylglycerol) 
1
H-NMR (400MHz; DMSO-d; δ; ppm): 0.8 (m, 3H, alkylglyceryl terminal-CH3); 1.2 (s, 12H, 
alkylglyceryl-2-7CH2); 1.5 (s, 3H, poly(lactic acid)CH3); 3.2 (m, 2H, dextran 2CH, 4CH); 3.3 
(m, 1H, dextran 3CH); 3.6 (m, 2H, dextran 5CH, 6CH’); 3.7 (s, 1H, dextran 6CH) 4.8 (s, 1H, 
dextran 1CH); 5.2 (m, 1H, poly(lactic acid) CH) 
13
C-NMR (100MHz; DMSO-d; δ; ppm): 14.51 (octylglycerol terminal-CH3,); 17.01 (poly(lactic 
acid)CH3); 22.69 (octylglycerol-7CH2); 26.08 (octylglycerol-6CH2); 29.22 (octylglycerol-
5CH2); 29.28 (octylglycerol-4CH2); 29.45 (octylglycerol-3CH2); 29.78 (octylglycerol-2CH2); 
31.86 (octylglycerol-1CH2); 66.62 (poly(lactic acid)CH); 69.24 (dextran-6CH2); 70.68 
(dextran-2CH); 71.15 (dextran-4CH); 72.45 (dextran-5CH); 73.75 (dextran-3CH); 98.76 
(dextran anomeric-1CH) 
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APPENDIX V    GPC  spectra  of DEX-OX4 and DEX-OX8 
 
GPC: Calibration of pullulan standards of  range of MW: 0.6 × 104, 1 × 104, 2.17 × 104, 
4.88 × 104 and 11.3 × 104, 21 × 104, 36.6 × 104, 80.5 × 104 g/mol.  
Narrow standard curve: y= 51.17 - 5.693x + 0.2389x
2
 - 0.00349x
3
 
 
DEX-OX4 
 
DEX-OX8 
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APPENDIX VI   Calibration curve of Evans Blue in acetic acid 
  
 
UV-Vis calibration curve of Evans Blue in acetic acid (55 %) 
 
APPENDIX VII   Calibration curve of Doxorubicin in water  
 
 
Fluorescence calibration curve of Doxorubicin in water, excitation 480 nm, emission 
590 nm 
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APPENDIX VIII Calibration curve of FITC, Rhodamine B     
   and Doxorubicin in DMSO      
 
UV-Vis calibration curve of absorbance at 493 nm Fluorescein Isothiocyanate in DMSO. 
 
 UV-Vis calibration curve of absorbance at 318 nm, Rhodamine B in DMSO. 
 
UV-Vis calibration curve of absorbance at 478 nm, Doxorubicin in DMSO.  
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APPENDIX IX  Calibration curve of FITC, Rhodamine B    
    and Doxorubicin in PBS     
  
 
Fluorescence calibration curve -  Doxorubicin  in PBS (excitation/emission 475 nm/ 570 nm, 
respectively) 
Fluorescence calibration curve - Rhodamine B in PBS (excitation/emission 540/625 nm, 
respectively) 
 
Fluorescence calibration curve - fluorescein isothiocyanate in PBS (excitation/emission 
485/525 nm, respectively)   
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APPENDIX X  Calibration of cell seeding density      
 
 
Calibration hCMEC/D3, PrestoBlue assay, intensity vs. seeding numbers of cells, 
PrestoBlue Assay. 
 
Calibration bEnd3, MTT assay, intensity vs. seeding numbers of cells, MTT assay. 
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APPENDIX XI   Cytotoxicity protocols 
 
MTT assay  
A solution of3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) in serum-free DMEM (5 mg/mL; kept in dark at 2 - 8 °C until use) was 
equilibrated at 37 °C and then diluted (1:4) with serum-free DMEM to create the 
working solution. bEnd3 mouse endothelial cells were seeded onto 96 well-plates (at a 
density of 10
4
 cells per well) which were incubated in 200 μL media (DMEM with 10 % 
FBS added) for 24 h. The wells on the edge of the plate were filled with PBS to prevent 
uneven evaporation of the media under the plate cover. In each well, 50 μL of media 
was then removed and replaced with 50 μL of PBS-based nanoformulation containing a 
specific concentration of nanoparticles (obtained by redispersing by sonication for 5 
min, a known mass of ultracentrifugation pellet or lyophilisate). After incubation, 
medium was removed from the wells and replaced with 100 μL of the MTT working 
solution (prepared as described above). The plate was incubated at 37 °C in dark for 1 
hour, then the media was removed and replaced with 100 μL of DMSO, to dissolve the 
formazan crystals. After an additional 1 hour of dissolution process in dark at on the 
bench room temperature (25 °C), the plate was inserted into the plate reader PolarStar 
Optima (BMG Labtech), shaken horizontally for 30 seconds and the absorbance of the 
plates was read at 570 nm. The viability of the cells was displayed as per cent relative to 
PBS treatment. PBS was used as a negative control for toxicity, Digitonin (10 mg/mL) 
was used as a positive control, and average value for empty wells with media was 
subtracted as a background signal. 
 
Presto Blue assay  
hCMEC/D3 human endothelial cells were seeded onto 96 well-plates (10
4
 cells 
per well), which were incubated in 200 μL of EGM-2 medium (containing FBS 2 % 
v/v) for 24 hours. The wells on the edge of the plate were filled with PBS to prevent 
uneven evaporation of the media under the plate cover during. After 24 h, 50 μL of 
media was removed and replaced with 50 μL of PBS-based nanoformulation containing 
a specific concentration of nanoparticles (obtained by redispersing by sonication for 5 
min, a known mass of ultracentrifugation pellet or lyophilisate). After incubation for 30 
minutes, the medium (110.0 μL)  was removed from each well and replaced with 10.0 
μl of the Presto Blue solution (to allow dilution factor 10 between cell media and Presto 
Blue), followed by incubation for 30.0 min at 37.0 °C in darkness. The fluorescence 
(excitation 540 nm / emission 590 nm) was then read using a PolarStar Optima (BMG 
Labtech) plate reader. 
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APPENDIX XII  Transwell: FITC-DEX calibration    
 
 
 
 
Calibration line representing fluorescence vs. concentration of FITC-labelled dextran (FITC-
DEX) in EGM-2 media  
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APPENDIX XIII  Microscopic images of sections of chicken embryos 
   1 1’   
   2 2’   
   3 3’   
Chicken embryos, following 24 hours incubated with Rhodamine B labelled nanoparticles or free dye 
as a control. DIC (Nomarski) normalised and fluorescent image merge, vibratome sections 50 µm 
thick. 
Nanoparticles from PLA-DEX-OX4    Rhodamine B solution - control 
1 Olfactory region     1’ Trunk section   
 2 Trunk section      2’ Somnites (trunk)   
 3 Neuroepithelium     3’ Neuroepithelium   
